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Abstract 
Descending facilitation of nociceptive processing via the rostral ventromedial 
medulla (RVM) has been shown to contribute to behavioural hypersensitivity in a 
number of models of pain. Pain arising from the joints is a significant clinical 
problem, and studies to date have focused largely on the underlying peripheral 
causes. The aim of this study was to investigate the contribution of central 
mechanisms of descending facilitation to pain in a model of joint inflammation. 
To determine if the RVM is activated following ankle injection of Complete Freund’s 
adjuvant (CFA), a model of joint inflammation, pERK immunohistochemistry and 
labelling of active GABAergic synapses were carried out. At 6h post CFA, pERK 
labelling was increased, predominantly within 5-HT expressing neurons. Later, at 3d 
post CFA a decrease in GABAergic transmission was identified. This suggests time 
dependent changes in neuronal function occur within the RVM following joint 
inflammation. Selective lesion of descending 5-HT fibres and mu opioid receptor 
expressing (MOR+) cells of the RVM combined with behavioural studies indicated 
that both descending pathways contribute to mechanical hypersensitivity of the 
ipsilateral hindpaw. As the dorsal horn mechanisms underlying descending 
facilitation are not well understood, microarray analysis was carried out to identify 
changes in dorsal horn gene expression associated with descending facilitation. This 
led to the identification of a number of immune system related genes, including the 
chemokine Cxcl10 and its receptor Cxcr3 suggesting descending facilitation is 
mediated in part by neuronal - immune system interactions. 
These findings demonstrate for the first time that behavioural hypersensitivity in 
joint pain is dependent in part on descending facilitation via the RVM. In addition to 
peripheral pathology and spinal cord sensitisation, brainstem contributions should 
also be taken into account in the study and treatment of joint pain. 
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1.  Introduction 
Pain has an important protective role as it alerts the individual to harmful or 
potentially harmful external stimuli, and provokes prompt behavioural 
responses to minimise injury. The essential role of pain perception for 
survival is most apparent in individuals suffering from a congenital inability 
to feel pain. The absence of this important protective mechanism leads to 
failure to respond to harmful stimuli which can result in severe injuries 
throughout life. Although the sensation of pain is unpleasant, these cases 
illustrate the importance of an intact pain system for the wellbeing of the 
individual (Cox et al., 2006; Goldberg et al., 2007; Verpoorten et al., 2006). 
In contrast to these rare cases of insensitivity to pain, a more widespread 
clinical problem is chronic pain. This is pain which persists after the injury 
has healed or for periods beyond it being useful as a warning signal. Chronic 
pain, lasting for longer than 3 months, is highly prevalent with reports of up 
to 20% incidence in the general population (Breivik et al., 2006; Reid et al., 
2011). Chronic pain is a symptom of many underlying pathologies, including 
arthritis, nerve injury, and cancer. Despite its prevalence, many patients 
suffering from chronic pain receive inadequate relief from existing therapies. 
This has a negative impact on quality of life for the affected individual, and is 
a considerable economic burden for society due to the costs of healthcare 
management and the inability of some chronic pain patients to work (Reid et 
al., 2011). For this reason basic research on the neurobiology of pain and 
identification of potential pharmacological targets remains an important 
goal. 
1.1  Classification of pain 
Pain is defined as an unpleasant sensory and emotional experience 
associated with actual or potential tissue damage, or described in terms of 
such damage (International Association for the Study of Pain, 2011). This 
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precise definition illustrates some important points about the nature of pain. 
Importantly, pain is an experience with both sensory and affective 
components and cannot be considered only in terms of sensory input. In 
addition pain can occur even in the absence of tissue damaging stimuli. It 
has been proposed that there are three main types of pain which differ in 
terms of cause, duration and function (Scholz and Woolf, 2002). 
1. Nociceptive pain occurs in the presence of an acute noxious stimulus. 
This form of pain serves an important protective role in that it alerts the 
individual to tissue damaging stimuli (Basbaum et al., 2009). Nociceptive 
pain is typically of short duration and stops once the noxious stimulus is 
removed.  
2. Pathological pain does not serve a useful biological function. Conditions 
in this category often lead to pain in the absence of noxious input, and 
can be chronic. One widely studied example of a pathological pain 
condition is neuropathic pain, caused by direct lesion of the nervous 
system (Costigan et al., 2009b). A range of other conditions also come 
under this category, which produce the sensation of pain without 
obvious noxious input, such as irritable bowel syndrome and 
fibromyalgia (Woolf, 2010).  
3. Inflammatory pain is caused by inflammation associated with tissue 
damage and has some characteristics in common with both nociceptive 
and pathological pain. Inflammatory pain arises as a direct result of 
tissue injury and therefore like nociceptive pain has a protective role, 
alerting the individual to a physical injury and preventing further 
damage. However it is also problematic for patients, as it can be chronic, 
like many of the pathological pain states. 
Chronic pain conditions are characterised by hyperalgesia, allodynia, and 
spontaneous pain. Hyperalgesia is defined as increased pain from a stimulus 
that normally provokes pain, and allodynia is defined as pain due to a 
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stimulus that does not normally provoke pain (International Association for 
the Study of Pain, 2011). These symptoms arise due to sensitisation of the 
nociceptive system. This is defined as a reduction in the threshold and an 
increase in the magnitude of a response to noxious stimulation, and is driven 
by both peripheral and central mechanisms (Gold and Gebhart, 2010). Table 
1.1 summarises the characteristics of the three forms of pain. 
 Nociceptive Inflammatory Pathological 
Cause Acute noxious stimuli: 
heat, cold, mechanical 
Inflammation caused by 
tissue injury 
Neuropathic: nervous 
system injury 
Others idiopathic, e.g. 
irritable bowel syndrome 
Function Protective function: reflex 
withdrawal 
Protective function: 
reduce further injury, 
promotes repair 
Dysfunctional, serves no 
protective role 
Duration Acute Variable: can be acute or 
chronic 
Chronic 
Sensations Intense heat, cold or 
mechanical pain 
Hyperalgesia 
Allodynia 
Spontaneous pain  
Hyperalgesia 
Allodynia 
Spontaneous pain 
Treatment Not always necessary Reduce peripheral 
inflammation, e.g. non-
steroidal anti-
inflammatories 
Disease modification e.g. 
joint replacement or 
immunosuppression in 
arthritis 
Poor treatment options 
available 
Table 1.1 Characteristics of nociceptive, inflammatory and pathological pain.  
Adapted from Scholz and Woolf, 2002. 
1.2  Overview of the nociceptive system 
Nociceptive stimuli are detected by nociceptors innervating peripheral 
tissues, and are relayed to the dorsal horn of the spinal cord which forms the 
first synapse of the pathway (Hunt and Mantyh, 2001). From here the signal 
is conveyed to the brain which leads to the perception of pain. 
Chapter 1 
24 
 
Understanding the normal function of these peripheral, spinal and 
supraspinal mechanisms is crucial to understanding maladaptations that 
occur in chronic pain states. 
1.2.1 Nociceptors 
The concept of a sensory fibre specific to the detection of tissue damaging 
stimuli was first proposed by Sherrington in 1903 (Sherrington, 1903), 
however the existence of nociceptive specific sensory fibres was only 
demonstrated in the mid-1960s. A subset of thinly myelinated Aδ-fibres 
were identified which responded exclusively to noxious mechanical 
stimulation (Burgess and Perl, 1967). Unmyelinated C-fibres were also 
discovered which were either polymodal nociceptors, responding to a 
variety of noxious stimuli such as heat, cold, chemical and mechanical 
stimulation, or high threshold mechanoreceptors (Bessou and Perl, 1969).  
Aδ-fibres conduct more rapidly than C-fibres, and for this reason the Aδ-
fibres are thought to be responsible for rapid, sharp pain and C-fibres for the 
slow, dull pain that occurs upon noxious stimulation. Aβ-fibres are also 
myelinated and are the largest diameter sensory fibres in the DRG, however 
these do not act as nociceptors, and instead conduct rapidly in response to 
low intensity mechanical stimulation (Julius and Basbaum, 2001; Woolf and 
Ma, 2007). The cell bodies of nociceptors are located in the dorsal root 
ganglion (DRG) or trigeminal ganglion in the case of head and neck areas.   
As with all sensory afferents, nociceptors innervate various peripheral 
tissues including the skin, joints and viscera. The transduction of noxious 
stimuli into an action potential is achieved by the activation of transducer 
molecules on the nociceptor endings by high intensity, tissue damaging 
stimuli. This distinguishes nociceptors from other sensory fibres, which 
express low threshold transducers. Among the nociceptor transducers that 
have been identified are the transient receptor potential (TRP) family of ion 
channels. This includes TRPV1 which is responsible for the transduction of 
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noxious heat, and contributes to inflammatory pain and thermal 
hyperalgesia (Caterina et al., 1999). TRPA1 is activated by noxious cold and 
can also respond to chemical irritants such as formalin and mustard oil, and 
may play a role in mediating mechanical nociception (Vay et al., 2012). 
Another important family of noxious stimuli transducers are the acid sensing 
ion channels (ASICs). These are activated by protons in the extracellular 
environment, which are increased during tissue acidosis and so contribute to 
inflammatory pain (Deval et al., 2010). Recently, a mechanosensitive ion 
channel Piezo has been identified which may contribute to the transduction 
of noxious mechanical stimuli (Kim et al., 2012).  
Activation of these transducer channels leads to depolarisation of the 
membrane, producing a generator potential which is converted into an 
action potential if the stimulus is of large enough magnitude or spread 
(Raouf et al., 2010). Action potentials are propagated along the axon by 
voltage gated sodium channels (Nav). The subtypes Nav 1.7, 1.8, 1.9 are 
present in nociceptors and local anaesthetics act by inhibiting these 
channels (Eijkelkamp et al., 2012). Nav 1.7 plays an important role in 
inflammatory pain (Nassar et al., 2004). Nav 1.8 contributes to transmission 
of noxious heat and mechanical stimuli, and also contributes to cold pain 
sensitivity (Zimmermann et al., 2007).  
Glutamate is the major excitatory neurotransmitter released by nociceptors 
at their terminals in the dorsal horn. However other transmitters are also 
present in nociceptors, allowing them to be classified neurochemically. 
Nociceptors can be divided into a  subpopulation that contain peptides such 
as substance P and calcitonin gene related peptide (CGRP) and those that do 
not (Hunt and Rossi, 1985; Nagy and Hunt, 1982). Non-peptidergic C-fibres 
are associated with the epidermis of the skin whereas peptidergic C-fibres 
are associated with deeper parts of the skin as well as other tissues such as 
the joints and viscera (Todd, 2010). These non-peptidergic C-fibres can be 
Chapter 1 
26 
 
identified histochemically by their ability to bind isolectin B4 (IB4) 
(Plenderleith and Snow, 1993). Figure 1.1 summarises the mechanisms of 
noxious stimuli detection by nociceptors. 
 
Figure 1.1 Detection of noxious stimuli by the nociceptor. 
 1). Specialised ion channels (noxious signal transducers) on the peripheral terminal of the 
nociceptor are activated by noxious stimuli, leading to the generation of a local potential. 
2). Action potentials are generated and propagated along the axon by voltage gated Na+ 
channels and the membrane returns to resting potential via opening of voltage gated K+  
channels. 3). Arrival of the action potential at the central terminal triggers influx of Ca2+ 
which leads to neurotransmitter release in the dorsal horn. The green box and arrows 
highlight the basic mechanisms of peripheral sensitisation (discussed below in section 
1.4.1).  Both the transducer channels and voltage gated Na+ channels can be modulated by 
various peripheral mediators such as cytokines and neurotrophins via their target receptors 
(G protein-coupled receptors and receptor tyrosine kinases) on the peripheral terminals. 
Adapted from Raouf et al., 2010. 
1.2.2 Dorsal horn of the spinal cord and projections to the brain 
Primary afferent fibres terminate in the dorsal horn of the spinal cord, 
forming the first synapse of the pain pathway. Within the dorsal horn is a 
complex circuitry of excitatory and inhibitory interneurons which modulate 
the nociceptive signal before it is relayed to the brain. The gray matter of the 
spinal cord has a precise laminar organisation which was first described by 
Rexed (Rexed, 1952). Nociceptive fibres terminate in the outer laminae of 
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the dorsal horn, within lamina I and II. Peptidergic C-fibres terminate in both 
lamina I and IIo, while non-peptidergic C-fibres terminate mainly in lamina 
IIi. Non-nociceptive Aβ-fibres terminate in deeper layers, from lamina IIi– V 
(Todd, 2010, 2002). Figure 1.2 outlines the distribution of primary afferent 
terminals in the laminae of the dorsal horn. 
Electrophysiological recordings can be used to classify dorsal horn neurons 
on the basis of their responses to peripheral stimulation. Proprioceptive 
dorsal horn neurons respond only to Aα-fibre input. Nociceptive specific (NS) 
neurons respond only to noxious stimulation and are found largely within 
lamina I and II. Wide dynamic range neurons (WDRs) can respond to all 
types of afferent input, both nociceptive and non-nociceptive. These are 
located in the deeper laminae of the dorsal horn (lamina V) (D’Mello and 
Dickenson, 2008). The majority of the neurons within the dorsal horn are 
locally projecting interneurons which play an important role in modulating 
the output of the dorsal horn in response to nociceptive input. Both 
inhibitory and excitatory interneurons are present, with GABA and glycine as 
the main inhibitory transmitters and glutamate as the main excitatory 
transmitter (Todd, 2010). 
Projection neurons in the dorsal horn relay nociceptive information to the 
brain. These are located largely in lamina I (Spike et al., 2003). There are two 
main targets of the lamina I projection neurons. The lateral parabrachial 
area (PB) receives input from lamina I, and from here projects to brain areas 
responsible for the affective components of the pain experience such as the 
central nucleus of the amygdala and the hypothalamus (Gauriau and 
Bernard, 2002). The lateral thalamus (ventroposterior lateral nucleus, VPL, 
and ventroposterior medial nucleus, VPM) also receives input from lamina I 
and from there projects to areas such as the insular (IC) and somatosensory 
(SS) cortices, involved in the sensory-discriminative aspects of pain (Gauriau 
and Bernard, 2004). Other target structures of lamina I projection neurons 
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include the caudal ventrolateral medulla (CVLM), nucleus tractus solitarus 
(NTS) and periaqueductal gray (PAG) (Todd, 2010). Many lamina I projection 
neurons have collateral projections to more than one brain area (Al-Khater 
and Todd, 2009).  
Some projection neurons are also found within the deeper laminae of III – V. 
The projections from the deeper laminae terminate in the medial thalamus 
(central lateral nucleus, CL), which projects to areas such as the anterior 
cingulate cortex (ACC) (Van der Werf et al., 2002). This pathway is implicated 
in the attentional and motivational aspects of the pain experience. Some 
deep projection neurons also terminate in the reticular nuclei, which may 
mediate motor responses associated with pain (Gauriau and Bernard, 2002). 
A summary of the main ascending projection pathways is shown below in 
figure 1.3. This figure indicates ascending pathways that have been 
characterised for the rat, and it is important to note that there may be some 
species differences in the relative importance of these pathways. For 
example, there are fewer direct projections from lamina I to the thalamus in 
the lumbar spinal cord segment in the rat (Al-Khater and Todd, 2009) than in 
the primate (Zhang and Craig, 1997), and the rat has greater numbers of 
projections to the PAG and Pb (Todd, 2010). 
Many projection neurons express the neurokinin 1 (NK1) receptor, which 
binds substance P. These neurons are nociceptive specific (Salter and Henry, 
1991). Depletion of these neurons selectively by the neurotoxin substance P-
saporin prevents the development of behavioural hypersensitivity in models 
of inflammatory and neuropathic pain in the rat (Mantyh et al., 1997; 
Nichols et al., 1999). Furthermore it has been shown that these projection 
neurons are critical to the activation of descending controls in chronic pain 
states (Géranton et al., 2010; Suzuki et al., 2002). 
Dorsal horn projection neurons allow the nociceptive signal to reach the 
brain, where pain is perceived. There are many brain areas activated during 
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acute noxious stimulation. Data from human brain imaging experiments 
during noxious stimulation has shown that some of the most common areas 
activated during painful stimulation are the primary and secondary 
somatosensory, insular, anterior cingulate, and prefrontal cortices and the 
thalamus (Apkarian et al., 2005). In addition to these core regions other 
areas are also activated, depending on the circumstances, including the 
amygdala, hippocampus, basal ganglia (Tracey and Mantyh, 2007). 
Importantly, there is no one brain area that is uniquely activated by painful 
stimulation, and indeed many of these brain areas have also been shown to 
be involved in the detection of non-noxious, novel sensory stimuli. Therefore 
these regions may not form a pain specific network, but rather function in 
the detection of any novel sensory information (Iannetti and Mouraux, 
2010). 
 
Figure 1.2 Termination of primary afferents in the dorsal horn. 
Nociceptors innervate the periphery, and terminate in a structured manner in the dorsal 
horn of the spinal cord. Aδ-fibres terminate largely in lamina I and to a lesser extent in 
lamina II outer (IIo). Peptidergic C-fibres terminate in both lamina I and lamina IIo and non-
peptidergic C-fibres terminate in lamina II inner (IIi). Non-nociceptive Aβ-fibres terminate in 
the deeper laminae (Iii to V), and Aδ hair-follicle fibres terminate on the border of lamina II-
III. Image from Todd, 2010.  
1.2.3 Descending modulation of pain 
The relationship between nociceptive input and pain perception is not 
always linear. Under conditions of danger or stress, pain perception may be 
blunted, or completely abolished even under conditions of extensive noxious 
input (Fields, 2004). One example is that of injured soldiers in battle, many 
of whom do not report feelings of pain until some time after the injury 
(Melzack et al., 1982). Emotional state also has a large effect on pain 
perception, for example it is known that anxiety can increase pain 
perception (Ossipov et al., 2010). These examples demonstrate that 
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nociceptive signalling is subject to top-down modulation by the brain, and 
this provides a mechanism by which the brain can increase or decrease pain 
processing in the dorsal horn depending on the context.  
Early evidence from animals to suggest the existence of a descending 
modulatory system came from studies of spinal cord transection. This 
procedure was found to increase nociceptive reflexes, suggesting the 
presence of a tonic descending inhibitory system (Sherrington, 1906). Later 
it was found that electrical stimulation of the periaqueductal gray (PAG) 
produced analgesia in the unanaesthetised animal (Reynolds, 1969) and 
transection of the spinal cord prevents the inhibitory effects of PAG 
stimulation (Basbaum et al., 1977). This endogenous descending inhibitory 
system is activated in situations of fear or stress when intensely noxious 
input does not produce pain (Siegfried et al., 1990; Terman et al., 1984). The 
PAG is an important site of action of many analgesic drugs such as opiates 
(Herz et al., 1970; Yaksh et al., 1976). 
Information from the PAG is relayed indirectly to the dorsal horn via the 
rostral ventromedial medulla (RVM) to the dorsal horn (Ossipov et al., 2010). 
The RVM consist of two structures, the midline nucleus raphe magnus 
(NRM) and the more dorsal and lateral nucleus reticularis gigantocelluaris 
(GiA) (Fields and Heinricher, 1985). The RVM can exert both inhibitory and 
excitatory effects on spinal nociception. This bidirectional role of the RVM in 
pain processing can be explained in part by the heterogeneity of cells within 
the region. In vivo electrophysiological experiments have allowed for the 
classification of three cell types in the RVM depending on their firing 
properties immediately prior to the tail flick reflex in response to heat (Fields 
et al., 1983). ON cells show a brief burst in firing prior to the reflex, OFF cells 
show a decrease in firing and NEUTRAL cells show no alteration in their firing 
pattern. It has therefore been suggested that the ON cells are facilitatory 
and OFF cells are inhibitory in the modulation of the nociceptive reflex 
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(Heinricher et al., 2009). The role, if any, of NEUTRAL cells in the nociceptive 
reflex is unclear.  However interestingly it has been suggested that these 
cells may change phenotype under certain conditions such as during an 
inflammatory pain state, becoming either ON-cells or OFF-cells (Miki et al., 
2002). This suggests that cells defined as NEUTRAL during an acute 
nociceptive reflex in the naïve animal may contribute to descending 
modulation in chronic pain states. 
The different RVM cell types also have different responses to morphine. OFF 
cells increase firing and ON cells decrease firing in response to morphine 
microinjection (Barbaro et al., 1986). Microinjection of morphine to the PAG, 
a region which has projections to the RVM and is an important site in 
morphine mediated analgesia, also led to an increase in OFF cell firing and a 
decrease in ON cell firing at the time of a nociceptive reflex. NEUTRAL cells 
did not change firing properties (Cheng et al., 1986).  
Initially studies suggested that electrical stimulation of the RVM region 
always resulted in inhibition of spinal neuronal responses (Fields and 
Heinricher, 1989). Later it was demonstrated that electrical stimulation of 
the RVM could also lead to increased excitability of neurons in the dorsal 
horn (Light et al., 1986). This work highlighted the bidirectional nature of 
RVM modulation of nociception, with both inhibition and facilitation 
possible arising from the same site. It was found that low intensity 
stimulation of the RVM either electrically, of by administration of a low dose 
of glutamate has excitatory effects on spinal neurons, while higher intensity 
stimulation leads to inhibitory effects. This  further illustrated that the RVM 
is capable of both inhibition and facilitation (Zhuo and Gebhart, 1992a, 
1992b). This facilitation is also evident at the behavioural level as these 
procedures can enhance the tail flick reflex in the lightly anaesthetised 
animal (Zhuo and Gebhart, 1997). Therefore in the acute nociceptive reflex, 
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it is clear that both descending inhibition and facilitation are possible 
through the same brainstem region. 
Importantly physiologically defined ON, OFF and NEUTRAL cell types cannot 
be separated anatomically within the RVM itself  (Fields and Heinricher, 
1985; Fields et al., 1983) and neurochemically it is not known which 
transmitters are involved in ON and OFF cell signalling. The RVM contains 
many 5-HT neurons and initially it was thought that only NEUTRAL cells 
contain 5-HT (Potrebic et al., 1994) however it has since been shown that a 
subset of all three physiologically defined cell types contain 5-HT (Marinelli 
et al., 2002). To date the role of RVM 5-HT in descending modulation 
remains controversial, but it now appears that 5-HT can play a 
pronociceptive or antinociceptive role in the dorsal horn, depending on the 
receptor subtype activated (Bardin, 2011).  
GABA is another prominent transmitter in the RVM and these cells are also 
heterogeneous in their physiology (Kalyuzhny and Wessendorf, 1998). 
Although many RVM neurons project directly to the dorsal horn, some may 
also form local connections within the RVM region itself. In the case of OFF 
cells, these could form inhibitory projections onto projecting ON cells. For 
locally projecting ON cells, these could act to inhibit OFF cell output (Fields 
et al., 1991).  In addition there are a number of spinally projecting 
GABAergic neurons within the RVM, and recently these have been shown to 
coexpress glycine, presumably forming an important inhibitory pathway to 
the dorsal horn (Hossaini et al., 2012).  
 
Figure 1.3 Ascending and descending pathways.  
Projection neurons are located in lamina I and laminae III-V of the dorsal horn. Lamina I 
projection neurons (shown in black) convey information to the lateral thalamic nuclei 
(including the ventroposterior medial nucleus (VPM) and ventroposterior lateral nucleus 
(VPL)), and from there to the insular (IC) and somatosensory cortices (SS). Lamina I 
Chapter 1 
33 
 
projection neurons also project to the lateral parabrachial nucleus (PB), and from there 
neurons project to limbic structures such as the central nucleus of the amygdala (Ce) and 
hypothalamus (VMH). Other structures targeted by the lamina I projection neurons are the 
caudal ventrolateral medulla (CVLM), nucleus tractus solitarus (NTS) and periaqueductal 
gray (PAG). Projection neurons from the deeper laminae III-V (shown in red) convey 
information primarily to the medial thalamus (CL, central lateral nucleus), and from there 
information is conveyed to cortical areas such as the anterior cingulate cortex (ACC). 
Descending modulation of pain is relayed from cortical areas such as the ACC, as well as 
limbic structures such as the Ce and VMH (shown in blue). This descending information is 
relayed to the PAG. The PAG does not project directly to the dorsal horn. Instead 
information is conveyed indirectly via the rostral ventromedial medulla (RVM). The numbers 
on the left hand side of the image indicate the approximate distance of the coronal section 
from Bregma (mm). Adapted from Todd 2010, and Paxinos and Watson, 1998. These 
pathways are based on data from the rat literature, and some species differences may exist 
in the ascending pathways of the rodent and the primate. 
1.3  Animal models of pain 
1.3.1 Measuring pain hypersensitivity in animals 
To understand how animal models relate to human pain conditions, a 
behavioural outcome measure of the pain experience is needed. By 
definition pain is a subjective and individual experience. In studying pain in a 
human subject it is possible to ask questions about the pain to determine its 
severity however in animal models this is not possible. Therefore most 
studies using animal models do not measure pain directly, and instead use 
hypersensitivity to noxious stimuli as a surrogate measure of pain.  
Pain hypersensitivity can be measured in animals by studying the spinal 
reflex withdrawal from a noxious stimulus (Mogil, 2009). A number of 
measures have been developed to address hypersensitivity to noxious 
thermal (Hargreaves et al., 1988), cold, chemical and mechanical (Chaplan et 
al., 1994) stimuli and to deep pressure (Randall and Selitto, 1957). Thermal 
sensitivity is measured using the Hargreaves apparatus, which involves 
placing the animal in a box with a plastic floor, and applying radiant heat to 
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the individual paws. The time taken to withdraw the paw is the latency and 
is the measure used to assess thermal sensitivity, the more time taken the 
less the sensitive the animal. Mechanical thresholds are widely studied using 
von Frey hairs. These are a set of graded plastic filaments with a blunt end, 
applied to skin until the filament bends. At this point a calibrated force is 
exerted. In most cases the hairs are applied from lowest to highest force, 
and the lowest force at which paw withdrawal is observed is deemed the 
paw withdrawal threshold.  
Although difficult to measure, spontaneous pain is also important clinically 
and attempts are being made to address this in animal models. For example 
paradigms have been established to study tonic pain in animal models by 
using conditioned place preference with analgesic drugs (King et al., 2009; 
Sufka, 1994). Other attempts to measure spontaneous pain include 
monitoring innate behaviour such as vocalisation, scratching, biting and 
burrowing (Mogil, 2009), which may be altered when the animal is in pain. In 
addition attempts have been made to study comorbidities such as anxiety in 
animal models of pain, using paradigms that measure these complex 
behaviours such as the elevated plus maze and open field tests (Wallace et 
al., 2008). To date however measures of hypersensitivity using reflex 
withdrawal from a noxious stimulus remain the most widely used in pain 
research. 
1.3.2 Inflammatory pain models 
Tissue injury leads to an inflammatory response which aims to clear 
pathogens and aid repair of the damaged area. Inflammation also results in 
pain, which in some cases can persist beyond the time of healing. Common 
causes of inflammatory pain are surgical procedures, diseases of the joint 
and autoimmune disorders (Ren and Dubner, 2010). Various substances are 
used to model inflammation and pain in animals. Most commonly these are 
injected subcutaneously to induce localised inflammation and thermal and 
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mechanical hypersensitivity. Formalin injection can be considered a short 
term model of inflammatory pain (Dubuisson and Dennis, 1977). Longer 
lasting inflammatory compounds include carrageenan and Complete 
Freund’s adjuvant (CFA), which are more useful in modelling long term 
aspects of inflammatory pain. 
Clinically, joint inflammation is a leading cause of pain (Breivik et al., 2006) 
and a variety of methods are used to cause joint injury and inflammation in 
animals. Osteoarthritis is the most common cause of joint pain, and arises 
due to structural changes to the affected joint including loss of cartilage, 
synovial inflammation and destruction of the bone.  
In animals this can be modelled by injection of monosodium iodoacetate 
(MIA) to the joint (Fernihough et al., 2004). This is a NADPH inhibitor, which 
inhibits chondrocyte metabolism and leads to rapid destruction of the joints, 
which mimics that seen in osteoarthritis patients. High doses of MIA may 
also induce some primary afferent injury, which could contribute to 
neuropathic-like symptoms in the animal (Thakur et al., 2012). An alternative 
surgical method of inducing OA in the animal is to destabilise the medial 
meniscus, a cartilaginous component of the knee joint, by transecting the 
medial meniscotibial ligament (Inglis et al., 2008). 
Rheumatoid arthritis (RA) is an autoimmune disorder which causes 
inflammation of the joints, and  is another common cause of pain (Lee et al., 
2011a). RA can be modelled in animals by inducing systemic inflammation, 
for example by injecting CFA or a collagen and CFA emulsion into the tail 
(Clark et al., 2012; Neugebauer et al., 2007). This adjuvant-induced arthritis 
results in pathology at a number of joints, with an initial acute phase of 
inflammation up to 5d post injection, and a chronic phase which can last for 
weeks or months. At later stages joint destruction is  observed which is 
similar to that seen in RA patients (Neugebauer et al., 2007). Adjuvant 
induced polyarthritis is used to model the chronic and systemic nature of RA 
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in humans and is helpful in the study of potential disease modifying or 
analgesic therapies (Neugebauer et al., 2007). 
Importantly however systemic inflammation results in other adverse effects, 
such as skin lesions and weight loss, in addition to the joint pathology. This 
may affect the overall wellbeing of the animal, and confound the assessment 
of pain (Neugebauer et al., 2007). To address this problem, models of 
inflammatory monoarthritis have also been developed, including injection of 
CFA to the ankle joint (Butler et al., 1992). Although not a model of human 
RA per se, this method produces a reliable, localised inflammation of the 
ankle joint and results in stable behavioural hypersensitivity lasting up to 2 
weeks post inflammation. It can be considered an experimental model of 
inflammatory joint pain, and has been useful in characterising sensitisation 
that occurs during prolonged nociceptive input from the joint. For example 
our group has previously characterised dorsal horn gene expression changes 
that occur in this model (Géranton et al., 2007). 
Cutaneous inflammatory pain is often assessed by measuring thermal and 
mechanical hypersensitivity of the targeted hindpaw. In models of joint 
inflammation, it is more difficult to measure hypersensitivity of the affected 
area directly, however some measures such as withdrawal or vocalisation 
following compression of the joint have been developed (Neugebauer et al., 
2007). Indirect measures of joint hypersensitivity are also widely used 
including weight bearing and gait analysis, which are disrupted following 
inflammation or injury to the joint (Neugebauer et al., 2007). In addition, 
many studies use thermal or mechanical hypersensitivity of the hindpaw of 
the affected limb as outcome measures in models of joint pain (Fernihough 
et al., 2004; Sagar et al., 2011; Thakur et al., 2012). As these measure 
cutaneous hypersensitivity away from the affected joint, it is considered to 
be a reflection of secondary hyperalgesia or allodynia (Neugebauer et al., 
2007).  
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1.3.3 Primary and secondary hyperalgesia 
There are two forms of stimulus evoked hypersensitivity described in 
humans. Allodynia is defined as pain due to a stimulus that does not 
normally provoke pain. Hyperalgesia is defined as increased pain from a 
stimulus that normally provokes pain. A distinction can be made between 
primary and secondary hyperalgesia. Primary hyperalgesia refers to 
increased pain sensitivity that occurs at the site of injury while secondary 
hyperalgesia occurs at sites adjacent to but not at the site of injury (Hardy et 
al., 1950; Treede et al., 1992). Importantly it has been demonstrated in 
human studies that primary hyperalgesia is associated with both thermal 
and mechanical modalities, while secondary hyperalgesia is only associated 
with mechanical hypersensitivity (Ilkjaer et al., 1996; Treede et al., 1992). 
Primary and secondary hyperalgesia are also believed to have different 
neurobiological mechanisms. Primary hyperalgesia is thought to be driven 
largely by peripheral sensitisation, whereas secondary hyperalgesia is driven 
by central sensitisation (Treede et al., 1992).  
Although hyperalgesia is a term that can only be correctly used in human 
studies this distinction is important to consider when using animal models of 
pain hypersensitivity. In the context of joint inflammation, this suggests that 
sensitivity of the joint (primary hyperalgesia) is driven largely by peripheral 
mechanisms, while sensitivity of the ipsilateral hindpaw (secondary 
hyperalgesia) is driven largely by central mechanisms. In models of plantar 
inflammation however it is not clear if hindpaw sensitivity reflects primary 
or secondary hyperalgesia, and may be a combination of both.  
1.4  Sensitisation in pain states 
1.4.1 Peripheral sensitisation 
Under normal circumstances, nociceptors respond only to high intensity 
stimulation. However in conditions of injury or inflammation nociceptor 
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sensitivity is increased such that normally innocuous stimuli produce pain 
and noxious stimuli produce a greater pain response. These changes are 
produced in part by sensitisation of the peripheral nociceptor, which refers 
to a decrease in threshold and increase in magnitude of response to noxious 
stimulation (Gold and Gebhart, 2010). 
Tissue damage causes a local inflammatory response which leads to release 
of a variety of mediators from immune cells which can increase the 
sensitivity of the nociceptor terminals. These include GPCR activators (for 
example 5-HT, prostaglandins, and bradykinin), ion channel activators (ATP 
and H+), growth factors (NGF and GDNF) and cytokines (TNFα and 
interleukins) (Woolf and Ma, 2007). Peripheral sensitisation occurs by 
binding of these substances to their target receptors on the peripheral 
terminals and subsequent activation of intracellular signalling cascades that 
drive functional plasticity of the nociceptor (see figure 1.1). This allows the 
nociceptor to become sensitive to normally non-noxious stimuli as well as 
increasing the magnitude of responses to noxious stimuli. 
There are a number of ways in which the excitability of the peripheral 
nociceptor terminal can be increased. One is via modulation of the sensory 
transducer molecules directly. Modifications which increase the numbers or 
availability of transducer molecules at the nociceptor terminal will increase 
the ability of the nociceptor to convert noxious stimuli to a pain signal. One 
established example of this is the increased expression of the TRPV1 channel 
at the nociceptor membrane during inflammation. TRPV1 is a transducer of 
noxious heat (Caterina et al., 1999). Growth factors such as NGF acting at 
receptors on the nociceptor terminals lead to the activation of intracellular 
signalling pathways which result in TRPV1 phosphorylation. This leads to 
increased trafficking of the channel and insertion to the membrane, 
therefore increasing nociceptor excitability (Zhang et al., 2005). Other 
inflammatory mediators, including bradykinin, PGE₂ and ATP, can also 
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contribute to increased TRVP1 phosphorylation. This provides a direct 
mechanism by which inflammatory mediators can increase transduction of a 
pain signal (Schaible et al., 2011).  
Another mechanism by which nociceptor sensitivity can be increased in pain 
states is via the mediators of signal propagation. In the sensory axon these 
are primarily the voltage gated Na+ channels Nav1.7, Nav1.8 and Nav1.9. 
These channels are sensitised by exposure to inflammatory mediators 
including the cytokines TNF-α and IL-1β  (Linley et al., 2010).  
Direct modulation of ion channels explains the relatively rapid onset of 
sensitisation which occurs during acute injury and local inflammation. More 
long term changes in nociceptor function involve transcriptional changes, 
within the cell bodies of the DRG (Woolf and Costigan, 1999). Among the 
genes that are increased during inflammation include transducers such as 
TRPV1, and the peptides CGRP and substance P. In the non peptidergic, IB4 
expressing population, other transcriptional changes occur such as 
upregulation of the protein Reg-2, a survival factor for motoneurons 
(Nishimune et al., 2000), following plantar inflammation (Averill et al., 2008). 
Peripheral sensitisation is an important mechanism underlying nociception 
during acute tissue injury and inflammation, and indeed many common 
analgesics act through decreasing the availability of sensitising mediators at 
the peripheral terminal, for example the non-steroidal anti-inflammatory 
agents (NSAIDs) which inhibit the production of prostaglandins. However 
some aspects of chronic pain symptoms such as secondary hyperalgesia at 
non-injured sites cannot be accounted for by peripheral drive alone. 
1.4.2 Central sensitisation 
In addition to peripheral sensitisation it is known that plasticity within the 
dorsal horn can contribute to pain hypersensitivity. This was first 
demonstrated in animals by using repeated high intensity noxious input, 
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which was found to cause increased excitability of dorsal horn neurons 
which persisted even after the conditioning stimulus has ceased. This is 
termed central sensitisation (Woolf, 1983) and is a mechanism by which an 
initial noxious input can enhance later responses to further noxious 
stimulation. Central sensitisation also results in the ability of nociceptive 
dorsal horn neurons to be activated by low threshold stimuli that would not 
normally be able to do so, such as that from Aβ-fibres. Central sensitisation 
requires repeated activation of C-fibres and cannot be activated by Aδ 
nociceptors or Aβ-fibres. Following nerve injury or peripheral inflammation 
increased nociceptor input to the dorsal horn can also induce central 
sensitisation and it is now well established that central sensitisation is a 
common feature of models of chronic pain (Latremoliere and Woolf, 2009). 
Central sensitisation accounts for secondary hyperalgesia, which is pain 
beyond the site of injury (Woolf and Salter, 2000). 
1.4.2.1  Mechanisms of central sensitisation 
Since its discovery there have been many developments in understanding 
the molecular and cellular basis underlying central sensitisation. Increased 
neurotransmitter release by primary afferent fibres is a trigger for central 
sensitisation, and activation of the NMDA receptor is crucial to its induction 
(Woolf and Thompson, 1991). Under conditions of persistent noxious input 
the release of transmitters such as glutamate, substance P and CGRP occurs, 
and leads to depolarisation of the post-synaptic membrane and the removal 
of the Mg2+ ion block in the pore of the NMDA receptor (Mayer et al., 1984). 
This enhances the membrane depolarisation by glutamate, and allows rapid 
entry of Ca2+ to the post-synaptic neuron. Increased intracellular Ca2+ 
mediated by the NMDA receptor, as well as other mechanisms such as 
activation of Ca2+ permeable AMPA channels, voltage gated Ca2+ channels, 
and release from intracellular stores (Latremoliere and Woolf, 2009) is 
important in central sensitisation.  
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Elevated intracellular Ca2+ leads to the activation of Ca2+ dependent kinases, 
including protein kinase C (PKC) and calcium-calmodulin dependent protein 
kinase II (CaMKII) (Kuner, 2010). These kinases can influence neuronal 
excitability in a number of ways. One is by direct phosphorylation of ion 
channels, such as the NMDA and AMPA. This increases trafficking of the 
channels to the membrane and therefore increases postsynaptic excitability 
(Latremoliere and Woolf, 2009).  Another aspect of Ca2+ mediated plasticity 
is the activation of the extracellular signal related kinase (ERK) cascade by 
upstream activation of PKA (Kawasaki et al., 2004). This leads to 
transcriptional changes downstream of ERK. Other enzymes activated by 
increased intracellular Ca2+ include cyclooxygenase 2 (COX-2) and neuronal 
nitric oxide synthase (nNOS). These produce prostaglandin E2 (PGE2) and 
nitric oxide, respectively, both of which contribute to increased excitability 
in the dorsal horn (Samad et al., 2001; Wu et al., 2001). 
1.4.2.2  Contribution of non-neuronal cells to central sensitisation 
Non-neuronal cells contribute to plasticity in a number of CNS structures 
(Ben Achour and Pascual, 2010), including the dorsal horn in chronic pain 
states. Microglia are the resident immune cells of the CNS and in the normal 
resting state are involved in surveillance of the environment. During CNS 
infection or trauma they become active (Aguzzi et al., 2013). This is reflected 
in morphological changes of the microglia and in the chemical mediators 
released. Among these mediators are neuroactive molecules such as 
glutamate, ATP, nitric oxide (NO), cytokines and chemokines, all of which 
may interact with dorsal horn neurons (Palygin et al., 2010). Microglial 
activation occurs following peripheral nerve injury. The injured afferents 
release the chemokines fractalkine (CX3CL1) and CCL2, which attract 
microglia to the dorsal horn. This contributes to increased dorsal horn 
excitability (Calvo et al., 2012). One of the established mechanisms by which 
microglia increase spinal excitability in neuropathic pain states is through 
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the release of BDNF, which activates TrkB receptors on neurons of the dorsal 
horn and disrupts chloride homeostasis, which reduces the inhibitory effects 
of GABA and glycine on these neurons (Coull et al., 2005). The release of 
cytokines such as IL-1β, IL-16 and TNF-α from microglia may also contribute 
directly to increased excitability in the dorsal horn (Kawasaki et al., 2008). 
Inhibition of microglial activation within the spinal cord by administration of 
agents such as minocycline has been shown to reverse behavioural 
hypersensitivity in models of neuropathic pain (Raghavendra et al., 2003). 
Although the contribution of microglia has been more widely examined in 
neuropathic pain states, studies have demonstrated that microglial 
activation also contributes to behavioural hypersensitivity in models of joint 
(Clark et al., 2012; Sagar et al., 2011; Shan et al., 2007), visceral (Cho et al., 
2012) and inflammatory (Raghavendra et al., 2004) pain. 
Astrocytes are another important cell type within the CNS, providing 
homeostatic support for neurons. Astrocytes are more abundant than 
microglia, and have structural connections with synapses and blood vessels. 
Astrocytes contribute to synaptic plasticity by releasing neuroactive 
substances and by taking in released neurotransmitters from the synapse 
(Barres, 2008). Astrocyte activation within the dorsal horn has been 
reported in a number of pain models, including neuropathic and 
inflammatory pain states (Gao et al., 2010). As with microglial activation, 
activated astrocytes produce pro-inflammatory cytokines, such as IL-1β, 
which may increase neuronal excitability. Interestingly astrocyte activation 
occurs later than microglial activation in models of neuropathic pain, 
suggesting that astrocytes may play a role in the maintenance of behavioural 
hypersensitivity (Gao and Ji, 2010).  
1.4.3 Plasticity of descending controls 
In addition to modulation by peripheral input, dorsal horn excitability is 
subject to descending modulation from the brain. As discussed above 
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(section 1.2.3) the RVM is the main relay site involved in conveying 
information from the brain to the spinal cord, and can have both inhibitory 
and facilitatory effects on spinal processing of acute nociception (Ossipov et 
al., 2010). In models of persistent pain however evidence suggests that a 
shift towards increased descending facilitation occurs, contributing to 
increased behavioural responses (Pertovaara, 2000; Vanegas and Schaible, 
2004). 
1.4.3.1  Sensitisation of RVM neurons in models of pain 
Although not as extensively studied as central sensitisation within the spinal 
cord, a number of studies have demonstrated that RVM neurons alter their 
firing properties during chronic pain. In models of neuropathic pain, both ON 
and OFF cells in the RVM become responsive to normally innocuous stimuli, 
and develop longer responses to noxious stimuli prior to the tail flick reflex 
(Carlson et al., 2007; Gonçalves et al., 2007). Similar changes in RVM neuron 
physiology have been reported in a model of cutaneous inflammation 
(Kincaid et al., 2006) and in visceral pain (Sanoja et al., 2010). These studies 
suggest that as with neurons in the dorsal horn, RVM neurons can be 
sensitised in persistent pain models, and this may contribute to behavioural 
sensitivity.  
1.4.3.2  Behavioural studies following RVM lesion 
The role of the RVM in behavioural hypersensitivity in chronic pain models 
has also been studied using a number of approaches. For example, in a 
model of opioid-withdrawal induced hypersensitivity the behavioural 
response was found to be attenuated by RVM microinjection of lidocaine 
suggesting that in this model, suggesting descending facilitation contributes 
to behavioural hypersensitivity (Kaplan and Fields, 1991). Injection of 
lidocaine to the RVM also attenuated mechanical hypersensitivity in rats 
with neuropathic pain (Pertovaara et al., 1996).  
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Spinalisation of an animal removes descending modulation, and this 
technique has been used to investigate the role of descending modulation in 
a number of pain models. This manipulation attenuates secondary 
hyperalgesia associated with mustard oil application to the skin (Mansikka 
and Pertovaara, 1997). In the carrageenan model of inflammation, and the 
spinal nerve ligation model of neuropathy, spinalisation has also been shown 
to attenuate mechanical hypersensitivity (Kauppila et al., 1998). 
Other studies addressing the role of descending facilitation in behavioural 
hypersensitivity have used an electrolytic lesion to non-selectively destroy 
neurons of the RVM region. In one such study cutaneous application of 
mustard oil, which normally results in a robust secondary hyperalgesia of the 
surrounding region, had a lesser effect in animals with prior lesion of the 
region (Urban et al., 1996). Silencing of the RVM has also been shown to 
prevent mechanical hyperalgesia associated with muscle injection of 
hypotonic saline, a model strongly associated with central sensitisation (Tillu 
et al., 2008). 
While much information on the role of the RVM has been elucidated from 
such studies, the complicated heterogeneous nature of the region requires a 
more selective approach to address individual components of the system. 
One method of achieving this is to selectively target cells based on receptor 
expression. The ON cell population are believed to be the only RVM neurons 
which respond directly to morphine, and therefore express the mu opioid 
receptor (Heinricher et al., 1994; Marinelli et al., 2002). This characteristic 
has been exploited by using a toxin which targets cells expressing the mu 
opioid receptor (MOR+ cells). Saporin is a cytotoxin which needs to be 
internalised in order to have its effects. Conjugating saporin to an agonist for 
a particular receptor allows it to be taken in to those cells expressing the 
receptor and results in cell death within that population. Dermorphin-
saporin, which selectively ablates MOR+ neurons, has been used within the 
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RVM to characterise the role of these cells in chronic pain states. It has been 
shown repeatedly that these cells are required for the maintenance of 
mechanical hypersensitivity in models of neuropathic pain, but not in the 
induction phase (Bee and Dickenson, 2008; Burgess et al., 2002; Porreca et 
al., 2001; Zhang et al., 2009). This indicates a crucial role for descending 
facilitation in the maintenance of neuropathic pain. These cells have also 
been shown to contribute to visceral pain behaviour (Sikandar et al., 2012; 
Vera-Portocarrero et al., 2006)  
An alternative strategy to study the role of a particular subset of RVM 
neurons in a chronic pain state is to address the role of a particular 
neurotransmitter. 5-HT has been the most widely studied in this regard. The 
RVM is the major source of 5-HT within the dorsal horn (Kwiat and Basbaum, 
1992), and 5-HT can have either inhibitory or facilitatory effects on spinal 
processing of pain, depending on the receptor type activated (Bardin, 2011). 
The ionotropic 5-HT₃ receptor is the most widely implicated in mediating the 
pro-nociceptive actions of 5-HT in the dorsal horn (Millan, 2002). Lesion of 
the descending 5-HT pathway by the selective toxin 5,7-dihydroxtryptamine 
has been used to demonstrate a facilitatory role for this system in  pain 
behaviour following both neuropathic injury (Rahman et al., 2006) and 
cutaneous inflammation (Géranton et al., 2008). Recently, silencing of the 
tryptophan hydroxylase (TPH) enzyme (responsible for 5-HT synthesis) 
within the RVM has confirmed the facilitatory role of descending 5-HT in 
these pain states (Wei et al., 2010). 
1.4.3.3  Molecular changes in the RVM 
In addition to behavioural evidence for alterations in RVM activity, 
molecular changes have also been shown to occur in persistent pain states. 
For example, upregulation of NMDA receptor gene expression (Miki et al., 
2002), and AMPA receptor expression (Guan et al., 2003) and 
phosphorylation (Guan et al., 2004) has been shown to occur following 
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peripheral inflammation. Recently it has been demonstrated that a 
pentraxin protein, involved in recruiting AMPA receptors to the synapse, is 
upregulated in the RVM during neuropathic pain and contributes to 
hyperalgesia (Zapata et al., 2012). These molecular changes in the RVM 
during peripheral inflammation may contribute to enhanced excitability in 
the region, and in some ways mimic aspects of dorsal horn changes that 
occur in chronic pain states (Latremoliere and Woolf, 2009). 
1.4.3.4  The role of immune cells in the RVM 
As with central sensitisation in the dorsal horn, it has recently emerged that 
glial cells within the RVM may contribute to behavioural hypersensitivity in 
neuropathic pain. Activation of microglia occurs within days, and a more 
prolonged activation of astrocytes occurs in the later phases. Using selective 
inhibitors of microglia and astrocytes within the RVM regions, it has been 
demonstrated that microglia contribute to hypersensitivity in the early 
induction phase, and astrocytes contribute to the maintenance of the pain 
state (Wei et al., 2008). Microglia are also activated in the RVM after plantar 
inflammation, and local inhibition of microglia in the region attenuates 
behavioural hypersensitivity (Roberts et al., 2009).  
1.4.3.5  The role of the RVM in primary and secondary hyperalgesia  
It has been argued that the RVM plays different roles in primary and 
secondary hyperalgesia. This is most apparent in models of cutaneous and 
joint inflammation (Vanegas and Schaible, 2004; Vanegas, 2004). For 
example initial evidence suggested that in cutaneous inflammation 
increased descending inhibition from the RVM occurs, which suppresses 
central sensitisation. This was shown by measuring thermal hypersensitivity 
following plantar injection of CFA in animals with prior lesion of the 
dorsolateral funiculus, the main pathway from the RVM to the dorsal horn 
(Ren and Dubner, 1996). A later study addressed both primary and 
secondary hyperalgesia following cutaneous inflammation. Secondary 
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hyperalgesia was assessed by measuring thermal sensitivity of the hindpaw 
following knee injection of carrageenan or application of mustard oil to the 
skin, while primary hyperalgesia was assessed by injection of carrageenan to 
the hindpaw. This study illustrated that lesion of the RVM by ibotenic acid 
resulted in attenuation of secondary thermal hyperalgesia, but not primary 
thermal hyperalgesia (Urban et al., 1999). These studies suggest descending 
modulation of secondary hyperalgesia is facilitatory, while descending 
inhibition may predominate in primary hyperalgesia. Notably however these 
studies used thermal hyperalgesia as an outcome measure, and as discussed 
in section 1.3.3, secondary hyperalgesia is not generally thought to be 
associated with thermal sensitivity (Treede et al., 1992). 
1.5  Joint Pain 
1.5.1 Clinical features of joint pain 
Among the most common causes of pain in the general population is that 
arising from the joints (Breivik et al., 2006). The term arthritis refers to 
inflammatory diseases of the joint, and there are many forms and causes 
(Kidd et al., 2007). Pain of the affected joint and surrounding areas is a 
common feature to all arthritic diseases. Osteoarthritis (OA) is a leading 
cause of chronic pain and disability particularly among the elderly (Bennell 
et al., 2012). This is caused by structural changes to the affected joint 
including loss of cartilage, synovial inflammation and destruction of the 
bone. Interestingly the extent of joint destruction is not always correlated 
with the degree of pain in OA (Bedson and Croft, 2008). In addition joint 
replacement, which is a common procedure in patients with advanced OA, is 
not always successful in the relief of pain. Severe persistent pain after joint 
replacement is reported to be a problem in 15% of patients (Wylde et al., 
2011). Together these observations suggest that although joint destruction 
and inflammation are the initial cause of pain in OA, chronic pain may be 
due in part to changes within the nociceptive system. 
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Rheumatoid arthritis (RA) is another common cause of pain affecting about 
1% of the general population (Lee and Weinblatt, 2001). It differs from OA in  
that patients have systemic inflammation due to autoimmune processes, 
rather than physical destruction of the joint (Lee et al., 2011a). Although less 
common than OA, RA generally has an earlier age of onset and therefore can 
have a greater impact on quality of life for the patient. As with OA, pain 
associated with RA is not always directly correlated to the extent of joint 
pathology, as many patients have persistent pain despite treatment with 
disease-modifying, anti-inflammatory agents (Wolfe and Michaud, 2007). In 
addition it is known that patients have increased pain sensitivity at sites 
away from the inflamed joints (Edwards et al., 2009). Application of 
capsaicin to the skin results in mechanical hyperalgesia in normal individuals, 
and in patients with RA this effect is more pronounced. This reflects 
increased central sensitisation within the dorsal horn of these patients (Kidd 
et al., 2007; Morris et al., 1997) and implies central sensitisation may be an 
important component of chronic pain in joint diseases (Lee et al., 2011a). 
1.5.2 Differences in joint and cutaneous pain processing 
It has long been noted that pain from the deep tissue and viscera tends to 
be more dull and aching, rather than sharp, and poorly localised in 
comparison to cutaneous pain (Lewis, 1938; Schaible et al., 2009). This 
suggests that there are differences in the processing of nociceptive 
information from the skin and the joints. As in cutaneous tissue joints are 
innervated by Aβ-, Aδ- and C-fibres, however there are some differences in 
their roles within the joint. In cutaneous tissue activation of Aβ-fibres relays 
the sensation of innocuous pressure, but this does not occur in the joint 
under normal circumstances. Indeed the only sensations known to arise 
from the healthy joint occur in response to noxious input for example 
following a twisted ankle (Schaible et al., 2009). Increased pressure in the 
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joint capsule during inflammation is one mechanism by which nociceptors 
are activated during arthritis.  
Another difference between cutaneous and joint innervation is the unique 
localisation of C-fibre low threshold mechanoreceptors in the cutaneous 
tissue, and not in other tissues such as the joint. In the human these have 
been shown to play a role in pleasant touch (Löken et al., 2009). These 
cutaneous fibres can be identified in the rodent by their expression of the 
vesicular glutamate transporter VGLUT3, and they contribute to the 
development of mechanical hypersensitivity to previously innocuous stimuli, 
following inflammation and nerve injury (Seal et al., 2009). 
The content of the C-fibres also differs between cutaneous tissue and the 
joint. In the skin, both peptidergic and non-peptidergic fibres are present. In 
the joints there is no evidence of a non-peptidergic C-fibre population, 
identified by IB4 labelling (Ivanavicius et al., 2004; Jimenez-Andrade et al., 
2010; Nakajima et al., 2008). Recently it has been demonstrated that 
cutaneous C-fibres expressing the G-protein coupled receptor Mgrpd, which 
correspond to the IB4+ (non-peptidergic) population, are required for the 
development of cutaneous mechanical hyperalgesia in the mouse 
(Cavanaugh et al., 2009). However, the bone and joints are sensitive to 
noxious mechanical stimulation, despite the absence of these non-
peptidergic C-fibres. This indicates that mechanical hypersensitivity in the 
joint may be mediated solely by the peptidergic population, unlike 
cutaneous inflammation (Jimenez-Andrade et al., 2010). Interestingly this 
implies that treatments targeting the peptidergic population of afferents 
may be more effective in joint pain than cutaneous pain, and highlights the 
importance of studying the joint as a separate entity to the skin (Jimenez-
Andrade et al., 2010). 
IB4+ C-fibres terminate largely within lamina II of the dorsal horn (Hunt and 
Mantyh, 2001; Zylka et al., 2005). In contrast, it is known that joint fibres 
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terminate preferentially in lamina I (Doyle and Hunt, 1999; Mense and 
Prabhakar, 1986; Neugebauer et al., 1994). Therefore joint and cutaneous 
nociceptors have different patterns of termination in the dorsal horn, which 
suggests that cutaneous nociceptors are better able to induce changes in 
excitability of lamina II dorsal horn neurons, than those from the joint. 
Lamina II consists of interneurons, which modulate nociceptive input (Todd, 
2010). The absence of significant input from the joint to lamina II may lead 
to reduced recruitment of these interneurons in joint pain states.   
1.5.3 Peripheral sensitisation during joint inflammation 
As discussed in section 1.3.2, a variety of animal models of joint pain have 
been developed which address aspects of OA and RA. Models of 
inflammatory monoarthritis have also been very useful in establishing the 
basic mechanisms of peripheral and central sensitisation following joint 
inflammation (Neugebauer et al., 2007). During joint inflammation, 
sensitisation of the primary afferents occurs. Aβ-fibres show an increase in 
responses to mechanical stimulation of the knee, which may result from 
swelling and increased pressure within the joint (Schaible and Schmidt, 
1988). Low threshold Aδ-fibres have increased responses to both noxious 
and innocuous mechanical stimulation, and high threshold Aδ- and C-fibre 
nociceptors develop a lower threshold of activation (Guilbaud et al., 1985). 
Joint inflammation also leads to activation of ‘silent nociceptors’, C-fibres 
which do not respond to noxious stimulation under normal circumstances 
(Schaible and Grubb, 1993). Increased spontaneous firing of nociceptors has 
also been shown to occur which may contribute to spontaneous pain at rest 
during joint inflammation (Schaible and Schmidt, 1988).  
In arthritic disorders inflammation of the joint is the source of pain and 
therefore peripheral sensitisation plays an important role in these 
conditions. The dominant feature of joint pain is mechanical hyperalgesia, 
which contrasts with cutaneous inflammation in which thermal hyperalgesia 
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is more prominent. Although extensive work has been carried out regarding 
the mechanisms of peripheral sensitisation in cutaneous nociceptors, 
including the contribution of TRPV1 sensitisation to thermal hyperalgesia 
(Woolf and Ma, 2007), less is known regarding the molecular mechanisms of 
sensitisation of the joint afferents. Some of the modulators proposed 
include prostaglandins, bradykinin, and 5-HT suggesting that peripheral 
sensitisation in joint afferents may share at least some of the same 
mediators as cutaneous inflammation (Gold and Gebhart, 2010) 
Immune cell infiltration to the joint is a key feature of RA, and these act as a 
source of inflammatory mediators. In addition to contributing to the 
pathogenesis of the disease state, these mediators can act directly on joint 
afferents to induce sensitisation. DRG neurons express the IL-6 receptor 
(Obreja et al., 2005; von Banchet et al., 2005) and intra-articular injection of 
Il-6 increases C-fibre responses to noxious mechanical stimuli (Brenn et al., 
2007). Another cytokine implicated in joint afferent sensitisation is tumour 
necrosis factor alpha (TNF-α). TNF-α is important in regulating B and T cell 
infiltration in RA, however it also acts as a mediator of peripheral 
sensitisation. Primary afferents express the TNF-α receptor, and direct 
injection of  TNF-α injection to the joint increases afferent excitability 
(Boettger et al., 2008; Sommer and Kress, 2004). Administration of a TNF-α 
neutralising antibody in animal models of RA had both disease-modifying 
and analgesic effects (Boettger et al., 2008; Inglis et al., 2007). The 
humanised anti-TNFα antibody Etanercept is now widely used in the 
treatment of RA to reduce the inflammatory component of the disease. 
These recent discoveries suggest that the benefits of these drugs may be 
due in part to direct inhibition of peripheral sensitisation at the nociceptor. 
1.5.4 Central sensitisation during joint inflammation 
As described above central sensitisation is an important factor in chronic 
pain following nerve injury and cutaneous inflammation (Latremoliere and 
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Woolf, 2009). Increased excitability also contributes to hyperalgesia in 
animal models of joint pain. Following joint inflammation, dorsal horn 
neurons shown an increased responsiveness to noxious and non-noxious 
stimuli (Grubb et al., 1993; Neugebauer et al., 1993; Schaible et al., 1987). 
Behaviourally, in the MIA model of knee OA, mechanical hypersensitivity of 
the ipsilateral hindpaw develops which is indicative of central sensitisation 
(Fernihough et al., 2004). Interestingly it has been suggested that primary 
afferents from deep tissue such as the joints and muscle are better able to 
induce central sensitisation than those from cutaneous tissue (Sluka, 2002; 
Woolf and Wall, 1986). This implies that pain in arthritis is heavily 
dependent on dorsal horn adaptations however less is known about the 
mechanisms underlying central sensitisation following in joint pain than in 
neuropathic and cutaneous conditions.  
Many mechanisms are likely to be common to neuropathic and cutaneous 
injury. For example increased release of glutamate (Sluka and Westlund, 
1992), activation of NMDA receptors (Neugebauer et al., 1993) and 
metabotropic glutamate receptors (Zhang et al., 2002) are required for 
central sensitisation following joint injury. Increased release of peptides by 
primary afferents (Naeini et al., 2005; Neugebauer et al., 1994), activation of 
voltage gated calcium channels (Neugebauer et al., 1996) and production of 
prostaglandins (Bär et al., 2004) have also been implicated. Protective 
mechanisms may also be in place, as it has been demonstrated that the 
induction of OA increases expression of endocannabinoids in the dorsal 
horn, which may serve to counteract increased spinal excitability in arthritis 
(Sagar et al., 2010). 
Activation of dorsal horn immune cells is also important in central 
sensitisation in joint pain. Inhibition of microglial activation attenuates 
behavioural hypersensitivity in the MIA model of OA (Sagar et al., 2011).  
Similarly the collagen-CFA induced model of RA is associated with increased 
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microglial and astrocytic activation in the dorsal horn, and inhibition of 
fractalkine signalling attenuates mechanical hypersensitivity of the hindpaw 
(Clark et al., 2012).  
1.5.5 Molecular changes in the dorsal horn during joint inflammation 
As in other forms of long term plasticity (Bailey et al., 1996) changes in 
dorsal horn gene expression are important in central sensitisation (Kim et 
al., 1998). Gene expression changes in the dorsal horn have been 
characterised at various time points following ankle joint inflammation using 
microarray analysis (Géranton et al., 2007a). This study revealed that 
upregulation of a number of genes occurs in the acute stage of inflammatory 
pain (up to 24h post inflammation). In contrast at a later time point (7d), 
when mechanical hypersensitivity is still present, downregulation of a 
separate set of genes was observed. This suggests that different programs of 
gene expression mediate the development and maintenance of 
inflammatory joint pain (Géranton et al., 2007). The transcriptional 
repressor MeCP2 was found to play a role in mediating some of these early 
gene changes. Phosphorylation of MeCP2 relieves its repression of target 
genes and accordingly it was shown that phosphorylation of MeCP2 goes up 
in the early time points after inflammatory insults, enhancing activation of 
its target genes. Recently it has also been shown that upregulation of MeCP2 
levels occurs in the maintenance phase following ankle joint inflammation 
which would be reflected by a decrease in expression of MeCP2 target genes 
(Tochiki et al., 2012). Interestingly the opposite occurs in neuropathic injury 
in which downregulation of MeCP2 occurs, which would cause upregulation 
of target genes. This study suggests that the dorsal horn gene expression 
programs involved in joint and neuropathic pain are different.  
1.5.6 Descending modulation in joint pain 
Increased descending inhibition has been demonstrated following joint 
inflammation. Spinalisation of the animal results in increased responses of 
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dorsal horn neurons to noxious stimulation of knee joint afferents, and this 
is more pronounced in animals with prior inflammation (Cervero et al., 1991; 
Schaible et al., 1991) suggesting that tonic inhibition from supraspinal 
regions is increased in the acute phase of joint inflammation (1-3h). 
However similar experiments in a model of ankle joint inflammation 
indicated that this increased inhibition of spinal excitability occurs only in 
the acute and not in the chronic phase of inflammation (Danziger et al., 
2001). 
Descending facilitation has been shown to be an important factor in a 
number of animal models of chronic pain (Ossipov et al., 2010). Descending 
facilitation via the RVM is required for the maintenance phase of 
neuropathic pain behaviour (Bee and Dickenson, 2008; Porreca et al., 2001; 
Rahman et al., 2009). Behavioural hypersensitivity following cutaneous 
inflammation is also enhanced by descending facilitation via the RVM 
(Géranton et al., 2008; Wei et al., 2010), as is that arising from muscle injury 
(Tillu et al., 2008). Less is known regarding descending facilitation via the 
RVM in animal models of joint pain. One electrophysiological study has 
demonstrated that descending 5-HT has contributes to enhanced spinal 
excitability in the MIA model of osteoarthritis (Rahman et al., 2009), but to 
date no behavioural studies have investigated the role of descending 
facilitation in animal models of joint pain. 
1.6  Hypotheses 
The RVM is an important site in the relay of descending information from 
the brain to the spinal cord. The aim of this thesis was to investigate the role 
of descending facilitation in a rat model of inflammatory joint pain. My 
experiments were designed to test the following hypotheses: 
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 RVM neurons are activated following ankle injection of CFA, which 
may be reflected in increased ERK phosphorylation and decreased 
GABAergic inhibition. 
 Descending facilitation contributes to behavioural hypersensitivity 
associated with ankle joint inflammation, via both 5-HT and mu 
opioid receptor expressing neurons of the RVM.  
 Gene expression changes within the dorsal horn following joint 
inflammation are regulated in part by descending facilitation.
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2. Methods 
This chapter describes methods used in more than one chapter of this thesis, 
with specific experimental details provided in the individual chapters. 
Techniques used only in one chapter are described in the methods section of 
that chapter. 
2.1  Animals and surgical procedures 
2.1.1 Animals 
All studies presented in this thesis were carried out using male Sprague-
Dawley rats which were bred and supplied by the Biological Services Unit at 
University College London. Rats were housed in cages in groups of 1 – 4 
animals with a 12h light dark cycle (lights on at 8.00am). Access to food and 
water was ad libitum. Animals weighed between 180-250g at the start of the 
experiment, depending on the protocol. For the intrathecal injection 
experiments described in chapter 4, rats weighed 180-200g at the time of 
injection. For intra-RVM injections, described in chapter 3 and chapter 5, 
animals weighed 200-250g at the time of injection to ensure accuracy of the 
stereotaxic coordinates based on the rat brain atlas (George Paxinos, 1998). 
In all other experiments animals weighing 200-250g at the induction of the 
pain state were used. 
2.1.2 Microinjection to the RVM 
Isoflurane anaesthesia (5% for induction and 1.5-2% for maintenance 
combined with 100% O₂ (1l/min)) was used during the surgical procedures. 
Animals were secured using in a stereotaxic frame (Kopf instruments) and 
anaesthesia maintained via a facemask. The head was shaved and sterilised 
using 70% EtOH. A skin incision was made from the front to the back of the 
head and the skull was exposed. A dental drill was used to form a single hole 
at the site of microinjections. For the dermorphin-saporin lesion experiment 
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(chapter 5), two microinjections were carried out using a 5μl Hamilton 
syringe with 30 gauge needle at the following coordinates: anterior-
posterior -10.5mm from Bregma, lateral: ± 0.6mm, and dorso-ventral -9mm 
from the surface of the brain. The toxin was dispensed slowly over the 
course of 5 minutes and the needle was held in place for 1 min after the 
injection to minimise the back flow of toxin. The needle was then removed 
gradually. VGAT-C antibody injections (chapter 3) were carried as above but 
only one lateral injection was made, on the left hand side of the animal. 
Following RVM microinjections the skin covering the skull was sutured using 
5-0 Mersilk. Local anaesthetic cream (EMLA) was applied to the wound to 
reduce irritation. Following surgery animals were observed closely for 
weight loss, neurological impairments or general distress. 
2.2  Inflammatory pain model and behavioural testing 
2.2.1 Model of ankle joint inflammation 
Joint inflammation was carried out using a modified version of the protocol 
first described by Butler et al. (Butler et al., 1992). Although not a direct 
model of human rheumatoid arthritis, as it does not involve systemic 
inflammation, this method produces a reliable, localised inflammation of the 
ankle joint. This results in stable behavioural hypersensitivity which mimics 
many aspects of joint pain and localised tenderness in RA patients 
(Neugebauer et al., 2007). 
Inflammation of the left ankle joint was carried out by injection of 10μl of 
Complete Freund’s adjuvant (CFA, Sigma) while the animals were under 
isoflurane anaesthesia (see above, section 2.1.2). The skin covering the area 
was sterilised, and the foot was flexed to allow access the joint capsule. A 
disposable needle on a 100µl Hamilton syringe was inserted to the inta-
articular space.  The needle was pushed until a loss of resistance was felt 
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and CFA was then injected. Sham animals were exposed to the same 
anaesthesia as the CFA treated group but received no injection.   
Following CFA injection, the ankle became swollen and red. CFA treated rats 
were less mobile, with a visible reduction in weight bearing on the affected 
paw. These symptoms began within hours, and consistently peaked in 
severity at day 1 post injection. By day 7, some resolution of the swelling, 
redness and reduced weight bearing was observed. The adjacent cutaneous 
tissue of the hindpaw also became red and swollen, however this was less 
severe than in the immediate vicinity of the ankle joint. Signs of the 
cutaneous inflammation also resolved more rapidly, by day 1 post injection. 
The quantity of CFA used in the experiments described in this thesis is 
considerably lower than the 50µl used by others (for example, Uematsu et 
al., 2011; Yao et al., 2011) and as expected produced milder symptoms of 
inflammation which resolved more rapidly than described by these 
investigators. In all behavioural experiments, peak mechanical 
hypersensitivity of the ipsilateral hindpaw was reached by 6h post injection. 
By the 24h time point, a stable level of hypersensitivity was reached which 
was maintained for up 7 days post CFA injection. 
2.2.2 Measuring mechanical paw withdrawal thresholds 
On the day of testing, animals were transported to the testing room in their 
home cages, and placed in clear plastic containers on a wire mesh floor. The 
animals were allowed to settle for a minimum of 15min prior to testing. 
Habituation to the testing environment was achieved by taking a series of 
baseline measures, once daily for at least 3 days, prior to the initial 
experimental manipulation. 
The mechanical paw withdrawal threshold was obtained for the ipsilateral 
and contralateral hindpaw of the animal. A series of calibrated von Frey 
hairs were applied to the centre of plantar surface of the hindpaw, between 
the footpads.  The hairs were applied in ascending order, with 0.07g as the 
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minimum and 60g as the maximum cut off points. Each von Frey hair was 
applied until bending occurred. The hair was held in place for approximately 
4s. For each hair the stimulus was applied five times at 5s intervals. The paw 
withdrawal threshold was defined as the lowest weight von Frey hair at 
which a brisk withdrawal was observed at least once out of the five repeated 
stimuli. When a withdrawal response was observed to a given hair, no 
further hairs were applied.  
Both the ipsilateral and contralateral hindpaw thresholds were measured for 
each animal. The ipsilateral paw withdrawal thresholds for each animal were 
obtained first, followed by repetition of the procedure on the contralateral 
paw. Testing was carried out blind to treatment, except in pilot experiments 
(ondansetron experiment, figure 4.4 and dermorphin-saporin experiments 1 
and 2, figures 5.2 and 5.4). 
This method of analysis of manual von Frey thresholds has been described 
by our group and others previously for use in models of neuropathic pain 
(Bourquin et al., 2006; Géranton et al., 2009; Obara et al., 2011). Another 
widely used approach is the up-down method (Chaplan et al., 1994). This is 
used to calculate the 50% paw withdrawal threshold, a value which indicates 
the von Frey hair weight at which a brisk withdrawal response would be 
expected to occur 50% of the time (Mills et al., 2012). This method involves 
the sequential application of the von Frey hairs, in either ascending or 
descending order depending on whether a negative or positive response is 
obtained to the first hair applied. This up-down procedure is carried out at 
least 4 times following the first change in response, and so requires 
repeated withdrawals by the animal. In the ankle joint inflammatory model, 
obtaining repeated brisk withdrawals can be difficult on the ipsilateral 
hindpaw. In some instances the animal will produce a brisk withdrawal only 
once. This may be due to the pain within the joint itself, which would be 
exacerbated by the repeated withdrawal of the hindpaw. For this reason, 
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the up-down method of analysis was not deemed suitable for our study. 
Another alternative method is the use of electronic von-Frey apparatus, 
which has been used previously with this pain model (Géranton et al., 2007). 
However as with the up-down method this requires repeated withdrawals 
which can be difficult to obtain due to the ankle joint inflammation.  
2.2.3 Statistical analysis of behavioural data 
For all behavioural experiments data was analysed using SPSS (PASW) 18 
(IBM). Logarithmic transformation (log2) was carried out on the paw 
withdrawal thresholds (g) before statistical analysis as Levene’s test for 
equality of variance was significant (Bourquin et al., 2006; Géranton et al., 
2009). Appendix A3 includes a table listing paw withdrawal threshold values 
in grams and corresponding log2 transformed values.  
Analysis of variance (ANOVA) with repeated measures was used for all time 
course experiments. To proceed to further post hoc testing at least one main 
effect (CFA treatment or drug/toxin manipulation) or interaction was 
required to be statistically significant (p < 0.05). Post hoc analysis varied 
depending on the nature of the comparisons. Where appropriate a 
subsequent two-way ANOVA with repeated measures was carried out to 
determine if there was an overall effect of CFA or drug/toxin across a 
specific time window. Where this was not possible one-way ANOVA with LSD 
or Bonferroni post hoc test was carried out at individual time points. 
2.3  Tissue collection 
2.3.1 Perfusion 
At the end of behavioural testing, animals for perfusion were deeply 
anaesthetised with pentobarbital (Euthatal, 0.5 – 1ml per animal, i.p.) and 
the ribs were sectioned to allow access the heart. A small incision was made 
in the left ventricle. A cannula, attached to a pump, was connected and 
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inserted into the ventricle and up through the aorta. This was held in place 
with a clamp, and saline containing 5000 IU/ml heparin was pumped 
through the animal at a rate of 30ml per min, for 4min. This was followed by 
4% paraformaldehyde (PFA) in 0.1M phosphate buffer for 8min. Brains and 
spinal cords were dissected and post fixed in 4% PFA for 2 h.  Tissue was 
then cryoprotected in 30% sucrose (in 0.1M PB) and stored at 4°C until 
sectioning. 
2.3.2 Fresh tissue 
To obtain fresh tissue for western blot and RNA analysis, animals were culled 
by CO₂ asphyxiation. Rats were placed in a chamber with a slow steady flow 
of CO₂ to allow the concentration to rise slowly. When the rat had stopped 
breathing, death was confirmed by cervical dislocation. The spinal cord 
segment corresponding to the lumbar L4-L6 region was rapidly dissected on 
ice, and the ipsilateral and contralateral quadrants of the dorsal horn 
separated using a blade. These were frozen rapidly on dry ice. Samples were 
stored at -80°C until further use for protein or RNA extraction. 
2.4  Immunohistochemistry 
Immunohistochemistry was carried out to enable visualisation of specific 
target antigens within fixed tissue. This process involves application of a 
primary antibody which has been generated to target the antigen of interest 
followed by detection by a secondary antibody. In this thesis three different 
detection methods were used: direct fluorescence labelling, tyramide signal 
amplification and fluorescence labelling, or avidin-biotin chromogenic 
labelling. An overview of the process involved in these three types of 
detection is given below, in figure 2.1. The details of primary antibodies used 
are given in the individual chapters. Details of laboratory solutions used in 
immunohistochemistry protocols are given in appendix A1. 
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2.4.1 Sectioning 
40μm sections were obtained for the brainstem or spinal cord using a 
freezing microtome (Leica). These sections were stored in 5% sucrose (in 
0.1M PB) at 4°C until staining was carried out. Tissue was sectioned in series 
across 4 or 6 wells on a plate depending on the experiment (see individual 
chapters). All immunohistochemistry was carried out on freely floating 
sections, in 1ml tubes placed on a rocker.  
2.4.2 Direct fluorescence immunohistochemistry 
To begin immunohistochemistry, the sections were transferred from 5% 
sucrose to 0.1M PB using a small paintbrush. The PB was removed and 
sections were blocked for one hour in 1ml 0.1MPB, 30μl serum (Goat, 
Chicken or Horse, depending on the host of the primary antibody, Vector) 
and 30ul 10% Triton X (Sigma). The blocking solution was removed with a 
pipette and the sections were incubated with the primary antibody diluted 
as required in Tris-Triton buffered saline (TTBS , 30ml 10% Triton, 50ml Tris 
Solution and 8g NaCl in 920ml 0.1M PB) overnight at room temperature. 
Following primary antibody incubation, and between additions of all other 
reagents, the sections were washed three times for ten minutes in 0.1MPB. 
The sections were incubated in the dark with the appropriate secondary 
Alexa Fluor antibody (Invitrogen) for 2h. Sections were mounted on gelatin 
coated slides in 0.1MPB, followed by drying at room temperature and 
coverslipping with fluoromount (Sigma), or used for detection of a second 
antigen.  
2.4.3 Tyramide signal amplification fluorescence immunohistochemistry 
Sections were blocked and incubated with the primary antibody as above. 
The appropriate biotinylated secondary antibody (Vector, 1:400) was added 
for 90min. The secondary antibody was removed sections washed. An 
avidin-biotinylated horseradish peroxidase solution was prepared using the 
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Vectastain Elite ABC kit using 4ul solution A (avidin)+ 4ul solution B 
(horseradish peroxidase) (Vector) in 1ml TTBS and allowed to conjugate for 
at least 30min. This solution was added to the sections for 30mins followed 
by washing. 13.3µl of biotinylated tyramide in 1ml diluent (Perkin Elmer) 
was prepared and added to the sections for exactly 7min. The reaction was 
stopped rapidly by saturating with 0.1MPB and two washes followed. 
Sections were then incubated in the dark with fluorescein (FITC) conjugated 
avidin D (1:600, Vector), or cyanine 3 conjugated Streptavidin (Cy3, 1:4000, 
Jackson Laboratories) in TTBS for 2h or used for detection of a second 
antigen. 
2.4.4 Chromogenic immunohistochemistry  
Sections were blocked as described above, with the addition of 2% H₂O₂ to 
the blocking solution. Incubation with primary antibody was as described 
above. Biotinylated secondary antibody was added for 2h at a concentration 
of 1:500. An avidin-biotinylated horseradish peroxidase solution was 
prepared using the Vectastain Elite ABC kit using 1ul solution A (avidin) + 1ul 
solution B (horseradish peroxidase) (Vector) in 1ml TTBS was prepared and 
allowed to conjugate for at least 30min. Sections were incubated in this 
solution, following washes, for 1h. Sections were washed, and then the 
chromogenic substrate was developed using a 3,3’-diaminobenzidine  (DAB) 
substrate kit (Vector). DAB is a chromogenic electron donor, which produces 
a brown colour in the presence of H₂O₂ and the enzyme horseradish 
peroxidase (HRP). A solution containing DAB, H₂O₂ and the buffer (supplied 
in the kit) was prepared. pERK labelled sections were incubated in this 
solution for 7min, and the reaction was stopped rapidly by transferring 
sections into fresh wells containing distilled H₂O. Sections were then placed 
in 0.01M PB solution, and mounted on gelatin coated slides. These were left 
to dry at room temperature overnight, before dehydration in EtOH of 
decreasing increasing strength (10s in distilled H₂O, followed by 70% EtOH 
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for 1min, 95% EtOH for 1min, 100% EtOH for 1min), followed by placing in 
Histoclear (2 x 1min, National Diagnostics) and application of DPX mounting 
medium (VWR laboratories) and coverslipping. 
 
Figure 2.1 Immunohistochemistry detection methods. 
2.4.5 Controls for antibody specificity 
Control tubes of sections were prepared to ensure there was no non-specific 
binding of the antibodies. Control tubes were processed in parallel with the 
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experimental tubes, and underwent all steps of the staining protocol, except 
at the control step. At this point the tissue was placed in TTBS lacking the 
appropriate antibody. Four types of control were carried out, lacking either 
the first primary antibody, the first secondary antibody, the second primary 
antibody (for double labelling experiments) or the second secondary 
antibody (also for double labelling experiments). 
2.4.6 Fluorescence and chromogenic imaging 
Fluorescence labelled sections were viewed using a Leica DMR microscope 
(Leica Microsystems) and fluorescently tagged antigens were viewed using 
the appropriate excitation filter from a 50 W mercury lamp. Images were 
acquired using a Hamamatsu CCD digital camera (C5985, Hammamatsu 
Photonics) using Openlab 4.0.4 software (Improvision). Confocal imaging 
was carried out when required for double labelling studies using a laser 
scanning Leica TCS NT SP microscope (see below section 2.4.6).  
Chromogenically labelled sections were viewed using bright-field conditions 
on a Nikon Eclispe E800 microscope (Nikon) and images acquired using a 
Nikon Coolpix 4500 digital camera (Nikon). 
2.4.7 Confocal microscopy 
A laser scanning confocal microscope (Leica TCS SPE) was used to acquire 
images of fluorescence immunohistochemistry with double labelling. 
Sequential laser channel acquisition was used to prevent bleed through. The 
z-plane thickness was 0.5-0.7µm. Following acquisition, the series of z-plane 
images was viewed using Leica LAS lite software to determine if colabelling 
of the two channels could be observed.  Where confocal images are 
presented in this thesis, they indicate single z-planes from each channel, and 
a merged image of both channels.   
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2.4.8 Photoshop and image presentation 
Images were prepared for presentation using Adobe Photoshop CS4 
software (Adobe Systems). The only adjustments made were the individual 
curves for each colour channel, to improve the clarity of the image. Image 
sizes were adjusted as necessary while maintaining the original ratio of 
dimensions. 
2.4.9 Cell counts and statistical analysis 
Positively labelled neurons in the RVM were counted manually, using a 
Nikon Eclispe E800 microscope for DAB immunoreactivity, and Leica DMR 
microscope for fluorescence immunoreactivity. The RVM was defined by the 
boundaries of the NRM and GiA, from approximately -10.3mm to -11.3mm 
from Bregma, according to the rat brain atlas (George Paxinos, 1998). 
Counts were carried out while blind to treatment group. All sections per 
animal were counted, and the top 5 scoring RVM sections per animal were 
used for analysis. These were summed to generate a total number of 
positive cells per animal, and data is plotted as the mean ± SEM per group. 
 Statistical analysis was carried out in SPSS. Two-way analysis of variance was 
used when comparing two variables (e.g. CFA treatment, and time point). A 
significant main effect or interaction of the variables was a prerequisite for 
subsequent one-way ANOVA, or post hoc testing as appropriate. In cases in 
which there was only one variable but more than one group, one-way 
ANOVA with LSD or Bonferroni post hoc testing was used. In cases where 
only two groups were compared, independent samples t-tests were used.  
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3. Increased ERK activation and decreased 
GABAergic signalling in the RVM following joint 
inflammation 
3.1  Introduction 
Changes in neuronal activity in the rostral ventromedial medulla (RVM) has 
been demonstrated in a number of models of cutaneous inflammation and 
neuropathic injury (Géranton et al., 2010; Imbe et al., 2005; Terayama et al., 
2000).  These changes are believed to correlate with increased descending 
facilitation from the RVM and contribute to behavioural hypersensitivity in 
these pain states (Porreca et al., 2001; Wei et al., 2010). This chapter 
describes two experiments which aimed to determine if the RVM is 
activated following joint inflammation.  
3.1.1 Phosphorylation of extracellular signal related kinase (ERK): a 
marker of neuronal activity 
The mitogen activated protein kinase (MAPK) cascades are signalling 
pathways which convey information from cell surface receptors to 
intracellular compartments and lead to changes in gene transcription and 
protein translation. One example of a mammalian MAPK cascade is the 
extracellular signal related kinase (ERK) cascade, which plays a role in cell 
growth, differentiation and survival as well as in neuronal activation and 
plasticity (Impey et al., 1999; Sweatt, 2004). A well characterised role of the 
ERK signalling pathway is in growth factor signalling (Widmann et al., 1999). 
Binding of growth factors to their corresponding receptor tyrosine kinases 
leads to activation of the canonical ERK signalling cascade, resulting in the 
phosphorylation of ERK on threonine 202 and tyrosine 204 residues (see 
figure 3.1).  
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There are three levels of kinases involved in this cascade. The small GTP-ase 
Ras phosphorylates the MAPK kinase kinase (MAPKK) Raf, followed by 
activation of the MAPK kinase (MAPKK) MEK, which phosphorylates ERK. 
This sequential activation of multiple kinases allows for interaction with 
other signalling pathways, in addition to the activation of growth factor 
receptors (see figure 3.1). Within the CNS many different intracellular 
signalling mechanisms can converge upon ERK activation, including Ca2+ 
influx which activates protein kinase C (PKC), and increased cAMP levels 
which activates protein kinase A (PKA) (Ji et al., 2009). Phosphorylated ERK 
(pERK) then phosphorylates and activates downstream protein targets. Short 
term responses mediated by ERK include the phosphorylation of cell surface 
receptors and channels, leading to increased neuronal excitability. Long 
term cellular effects mediated by ERK include the activation of transcription 
factors such as CREB, or components of the translational machinery such as 
MNK (Impey et al., 1999) 
 
Figure 3.1  The ERK pathway.  
The classical mitogen activated protein kinase (MAPK) pathway involves activation of a cell 
surface receptor, followed by sequential activation of a MAPK kinase kinase kinase 
(MAPKKK), MAPK kinase kinase (MEKK), and MAPK kinase (MAPKK). This general pathway is 
outlined in red. One well studied example of a MAPK pathway is the activation of growth 
factor receptors, which leads to activation of the MAPPKKK Ras, the MEKK Raf, the MAPKK 
MEK, and ERK (outlined in blue). Other intracellular signalling pathways can also converge 
on this pathway, for example Ca2+ influx can trigger the protein kinase C (PKC) – ERK 
pathway, and cAMP can trigger the protein kinase A (PKA) – ERK pathway. Adapted from Ji 
et al. 1999. 
In the CNS, ERK activation is as a hallmark of neuronal activation and 
plasticity. Activation of ERK occurs in the hippocampus in a variety of 
learning and memory tasks, and inhibition of ERK activation can prevent 
memory formation (Impey et al., 1999). ERK activation also occurs within the 
CNS during nociceptive processing. Following noxious stimulation ERK is 
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activated within dorsal horn neurons. This has been demonstrated in a 
number of models of peripheral inflammation, including plantar injection of 
the irritant capsaicin (Ji et al., 1999) and Complete Freund’s adjuvant (CFA) 
(Ji et al., 2002). Movement of an inflamed joint can also induce ERK 
activation in the dorsal horn (Cruz et al., 2005). Activation of ERK in dorsal 
horn neurons correlates with pain in these models, as inhibition of ERK 
phosphorylation by intrathecal administration of a MEK inhibitor attenuates 
behavioural hypersensitivity (Cruz et al., 2005; Ji et al., 1999). 
3.1.2 ERK activation in the RVM 
pERK has also been used as a marker of neuronal activation in the RVM in a 
number of pain models. Intraplantar injection of CFA leads to increased ERK 
phosphorylation in the RVM which peaks at 7h post CFA injection, but 
remains elevated for 1d. Approximately 60% of the pERK neurons contained 
5-HT, as indicated by colabelling with tryptophan hydroxylase (TPH), the 
enzyme responsible for 5-HT synthesis (Imbe et al., 2005). Administration of 
an ERK inhibitor to the RVM attenuated thermal hyperalgesia in this model 
(Imbe et al., 2008). In a model of neuropathic pain ERK activation also 
occurs, largely within 5-HT neurons, with 60% of pERK+ neurons expressing 
TPH (Géranton et al., 2010). These studies suggest that ERK activation in the 
5-HT population of RVM neurons correlates with the development of 
behavioural hypersensitivity following cutaneous inflammation or nerve 
injury. 
3.1.3 GABAergic signalling in the RVM 
GABA is the other major neurotransmitter found in RVM neurons, and GABA 
containing neurons are distinct from those expressing 5-HT (Jones et al., 
1991; Reichling and Basbaum, 1990). Recently it has been demonstrated 
that 45% of retrogradely labelled spinally projecting RVM neurons are 
GABAergic (Hossaini et al., 2012) indicating a direct inhibitory role for these 
neurons within the dorsal horn. However these projection neurons 
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represent a relatively small proportion of the GABA containing neurons 
within the RVM overall, and it is thought that the majority of GABAergic 
neurons in the region act as local inhibitory interneurons (Jones et al., 1991). 
In support of this many spinally projecting RVM neurons have GABAergic 
synaptic input (Jones et al., 1991) and most of these GABAergic terminals 
arise from intrinsic RVM neurons with little input from other brain regions 
(Cho and Basbaum, 1991). GABAergic inhibition of RVM projection neurons 
is therefore likely to play an important role in modulating output during 
nociception. 
Injection of GABAA receptor antagonists to the RVM has an antinociceptive 
effect, while the injection of GABAA agonists is pronociceptive (Gilbert and 
Franklin, 2001; Heinricher and Kaplan, 1991). In addition, the analgesic 
effects of morphine are thought to occur at least in part by direct inhibition 
of GABAergic neurons in the RVM (Pan et al., 1997).  This indicates that in 
the normal animal, the net effect of GABAergic signalling within the RVM is 
to enhance acute nociception.  
3.1.4 Changes in GABAergic transmission associated with persistent pain 
It has been proposed that during persistent pain states changes to 
neurotransmitter synthesis and release may occur in a maladaptive manner. 
Recently it has been shown that inhibitory GABAergic signalling in the 
amygdala is decreased early in the induction of the kaolin-carrageenan 
model of arthritis (Ren and Neugebauer, 2010). Within the RVM changes to 
GABAergic transmission have also been reported. A decrease in presynaptic 
GABA release was found within the RVM at 3 days following plantar injection 
of CFA, but not at earlier stages (Zhang et al., 2011). In addition 
microinjection of the GABAA agonist muscimol, which in the naive animal has 
a pronociceptive effect, led to attenuation of thermal hyperalgesia in the 
inflammatory pain state. These authors also described studies indicating that 
epigenetic suppression of the Gad65 gene (which encodes the enzyme 
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responsible for GABA synthesis) by decreased histone acetylation at the 
promoter region, could underlie these changes (Zhang et al., 2011). This 
study provides important evidence that GABA synthesis and release may be 
altered within the RVM during inflammation, and could contribute to the 
enhancement of descending facilitation observed in these conditions. 
Therefore in addition to increased activation of 5-HT neurons, decreased 
GABAergic signalling may be an important mechanism underlying 
descending facilitation in persistent pain states.  
3.1.5 Hypothesis 
In this chapter I have tested two hypotheses concerned with the activation 
of the RVM following ankle inflammation: 
 That ERK phosphorylation, a widely used marker of neuronal 
activation, is increased in RVM neurons following ankle injection of 
CFA. 
 That Inhibitory GABAergic transmission within the RVM is decreased 
following ankle injection of CFA. 
3.2  Methods 
3.2.1 pERK expression in the RVM 
3.2.1.1  Immunohistochemistry 
Animals were divided into two groups, receiving either CFA injection (10µl) 
to the left ankle or undergoing a sham procedure (see section 2.1.1). These 
were then subdivided into groups and perfused at one of three time points, 
at 6h, 3d or 7d following CFA injection. 40µm sections were taken in series 
across four wells therefore sections in each well were at least 160µm apart. 
Two wells were used for each animal to carry out separate pERK 
immunohistochemistry protocols. 3,-3’diaminobenzidine (DAB) detection 
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was carried out to quantify pERK+ cell numbers in the RVM. Fluorescence 
immunohistochemistry with tyramide signal amplification was carried out 
for colabelling of pERK and tryptophan hydroxylase, a marker of 5-HT 
expressing neurons (see section 2.4 for full immunohistochemistry 
methods). Controls were included to ensure that the secondary antibodies 
were specific to their primary antibody targets. This was carried out by 
removing either the pERK primary antibody or the TPH primary antibody 
from the procedure, to ensure no non-specific labelling by the secondary 
antibodies. Table 3.1 lists the antibodies and detection methods used in this 
chapter. 
3.2.1.2  Cell counting and image acquisition 
Cells expressing pERK were counted manually using a Leica bright field 
microscope. Counts were carried out while blind to the treatment (CFA or 
sham) for that animal. For counting, the RVM was defined as the regions 
containing the NRM and GiA at approximately -10.3 to -11.3 mm from 
Bregma. Sections were deemed caudal of the RVM if the nucleus ambiguus 
was present (-11.6mm from Bregma). The number of pERK positive cell 
bodies per section was recorded. The five sections with the highest number 
of pERK+ neurons per animal were used for analysis. The total number of 
pERK+ cells across the five sections was calculated and the data is presented 
as the mean ± SEM per group. Representative images of DAB staining were 
acquired using a Nikon E4500 MDC digital camera. 
Fluorescence immunohistochemistry was used to quantify the number of 
pERK+ neurons colabelled with tryptophan hydroxylase (TPH) at the 6h time 
point. Slides were viewed using a Leica DMR immunofluorescence 
microscope. The total number of pERK labelled neurons and double labelled 
neurons were recorded for each section. The five sections with the highest 
number of pERK+ neurons per animal were used for analysis. The numbers 
of pERK+/TPH+, pERK+/TPH- and total pERK+ neurons, and percentage of 
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pERK+/TPH+ cells as a proportion of total pERK+ cells was calculated for each 
animal (n = 3 - 4). Data is presented as the mean ± SEM per group. 
Representative images of fluorescence staining at 6h post CFA were 
captured using a Hamamatsu digital camera and using Openlab 4.0.4 
software from Improvision. 
3.2.2 Labelling of GABAergic synapses in vivo 
3.2.2.1  Microinjection of a luminal domain specific VGAT antibody 
to the RVM 
To label active GABAergic synapses in vivo, a rabbit polyclonal antibody 
raised against the luminal domain (C terminus) of the vesicular GABA 
transporter (VGAT) (from Synaptic Systems) was microinjected to the RVM. 
The VGAT transporter is expressed in all synaptic vesicles at GABAergic 
synapses however the luminal domain is only exposed to the cell surface 
during synaptic release and vesicle recycling. Therefore when applied 
extracellularly the VGAT-C specific antibody is incorporated only into active 
synapses (see figure 3.2). This antibody has been used by others to label 
active GABAergic synapses in the hippocampus (Martens et al., 2008). The 
same technique was used here to label GABAergic synapses in the RVM in 
naive, CFA or sham treated animals. 
Microinjection was carried out as described in section 2.1.2, with a single 
unilateral injection of antibody (1.5µg in 1.5µl) made to the left side of the 
RVM (+0.6mm laterally). This concentration was chosen based on previous 
published work within the hippocampus, which described the use of 4μg/2μl 
injections to the hippocampi (Martens et al., 2008). An initial pilot 
experiment was carried out in naïve animals, and following confirmation of 
injection site and antibody specificity animals were microinjected at 3d 
following CFA or sham treatment.  
Chapter 3 
74 
 
Animals were perfused 24h after the microinjection. 40µm sections were 
taken in series across six wells therefore sections in each well were at least 
240µm apart. Although the VGAT-C antibody is tagged with a fluorescent 
label (Oyster-550) the raw signal was found to be weak, and fluorescence 
immunohistochemistry using tyramide signal amplification with Cy3 as 
fluorophore was carried out to detect the VGAT-C antibody within the tissue 
(see section 2.4 for immunohistochemistry methods). Double labelling with 
glutamate decarboxylase (GAD65/67), the enzyme responsible for GABA 
synthesis at synapses, was also carried out to identify GABAergic terminals. 
Controls were carried out to ensure that the detection of GAD65/67 was not 
affecting the VGAT-C signal, by removing the GAD65/67 primary antibody. 
 
Figure 3.2  Labelling of active GABAergic synapses. 
This schematic outlines the structure of the VGAT transporter, with N-terminus located in 
the cytoplasm, a number of transmembrane segments and the C-terminus located inside 
the lumen of the synaptic vesicle. At the inactive GABAergic synapse, the C-terminus of the 
VGAT transporter is located inside the lumen of the synaptic vesicle and not accessible to 
the VGAT-C specific antibody. During active synaptic release and vesicle recycling the lumen 
of the vesicle is exposed extracellularly and accessible to the VGAT-C specific antibody. 
Adapted from Martens et al., 2008. 
3.2.2.2  Imaging and analysis 
Confirmation of injection site and the spread of the antibody in naive 
animals was carried out using a Leica DMR immunofluorescence microscope. 
For quantification of VGAT-C and GAD65/67 labelling, sequential images of 
the green and red channels were obtained using a Leica SPE confocal 
microscope, with a step size of approximately 0.5µm. Images were captured 
contralateral to the microinjection, immediately above the pyramidal tracts, 
and next to midline (see figure 3.5). All sections used for analysis were 
within the region of -10.8mm to -11mm from Bregma.  
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The image analysis program Fiji (an open source image processing package 
based on ImageJ, with plugins included) was used to quantify the extent of 
VGAT-C and GAD65/67 double labelled punctae in these sections. Manual 
thresholding was carried out to define VGAT-C and GAD65/67 labelled 
punctae for each animal, across the entire z stack of images. Thresholding 
was carried out while blind to treatment group of the section. Three sections 
were analysed per animal with the same threshold settings used for each 
section in that animal. Particle analysis was used to count the number of 
defined red punctae (VGAT-C) and green punctae (GAD65/67) throughout 
the z-stack of images. The image calculator function was then used to create 
an overlay of the two thresholded channels followed by the particle analysis 
function which allowed the quantification of VGAT-C and GAD65/67 
colabelled punctae per stack. The number of colabelled punctae was 
expressed as a percentage of total GAD65/67 to control for the number of 
GABAergic synapses. Data is presented as mean ± SEM of all 9 sections 
imaged per treatment group. 
Antigen Host Company Concentration Method Fluorophore 
pERK  Rabbit Cell Signalling 1:250 TSA FITC 
pERK  Rabbit Cell Signalling 1:500 DAB Brown DAB 
TPH  Mouse Sigma 1:200 Direct  Alexa 594 
GAD65/67 Rabbit Millipore 1:1000 Direct  Alexa 488 
VGAT-C Rabbit Synaptic systems 1.5μg in 1.5μl  TSA Cy3 
Table 3.1 Primary antibodies, concentrations and detection methods. 
3.3  Results 
3.3.1 ERK activation in the RVM: general observations 
To determine the effect of ankle inflammation on ERK activation within the 
RVM rats were divided into groups and perfused at three time points 
following CFA or sham treatment. pERK DAB immunohistochemistry was 
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performed on 40µm RVM sections. The RVM was defined as consisting of 
the nucleus raphe magnus (NRM) and nucleus gigantocelluaris pars alpha 
(GiA) (figure 3.3a). In all groups, including shams, a high number of pERK 
positive (pERK+) neurons were observed. These were distributed mainly in 
the NRM and in the ventrolateral regions of the GiA (figure 3.3). Examples of 
pERK+ cells from the GiA and NRM are shown in figure 3.3b. Very few cells 
were identified in the more dorsal regions of the GiA. All sections falling 
within the rostral-caudal distribution of the RVM (approximately – 10.3 to - 
11.3mm from Bregma) were counted, however for analysis only the five 
sections with the highest number of pERK+ cells per animal were used. 
Positive cells were counted based on cell body labelling however extensive 
dendritic pERK immunoreactivity was also observed (figure 3.3b). 
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Figure 3.3 Increase in pERK+ neurons at 6h post CFA.  
A). Representative section of the RVM corresponding to approximately -11mm from 
Bregma. The boundaries of the nucleus raphe magnus (NRM) and nucleus reticularis 
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gigantocelluaris pars alpha (GiA) are outlined by the dashed lines. The pyramidal tracts (Py) 
are also shown. Scale bar indicates 250μm. B). Examples of pERK+ cells from the lateral GiA 
and midline NRM. Intense labelling of both cell bodies and dendrites was observed. Scale 
bars indicate 100µm. C). Numbers of pERK+ neurons in the RVM region at 6h, 3d and 7d 
following ankle injection of CFA (black bars) or sham treatment (white bars). Counts for the 
top 5 pERK+ RVM sections were summed and are presented as mean ± SEM. n = 3 – 8, * p < 
0.05, two-way ANOVA and Bonferroni post hoc test. 
3.3.2 Increase in ERK phosphorylation in the RVM at 6h post CFA 
injection 
The number of pERK+ neurons in CFA and sham treated animals at all three 
time points were compared (figure 3.3c). For each animal the five sections 
with the highest number of pERK+ neurons were summed to give a total 
number of pERK+ neurons per animal (n = 3 – 8 per group). Two-way 
analysis of variance (ANOVA) was carried out on the cell counts with 
treatment (CFA or sham) and time point (6h, 3d and 7d post CFA) as the 
between-subjects factors. There was no main effect of time or treatment (p 
> 0.1) however there was a significant time x treatment interaction (p = 
0.029).  A subsequent one-way ANOVA indicated there was an overall 
difference between all 6 groups (p = 0.027) and Bonferroni post-hoc analysis 
indicated the variation was due to a significant increase in pERK labelling in 
the CFA group compared to sham at 6h post injection (p = 0.018). The mean 
number of pERK+ neurons in the 6h CFA group was 176.4 ± 10.8 compared 
with 127.7 ± 8.3 in the 6h sham group, an increase of approximately 38%. No 
significant differences were found between CFA and sham groups at 3d or 
7d (p > 0.1). 
3.3.3 Proportion of pERK+ neurons double labelled with tryptophan 
hydroxylase 
To characterise the population of pERK+ RVM neurons double fluorescence 
immunohistochemistry was carried out to determine the proportion of 
pERK+ neurons which colabelled with tryptophan hydroxylase (TPH), a 
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marker of 5-HT neurons, at 6h post CFA injection (figure 3.4a). Cell counts 
were carried out as for the DAB experiment, however in this case the 
number of pERK+ neurons double labelling with TPH (pERK+/TPH+) and not 
double labelling with TPH (pERK+/TPH-) were also recorded (n = 3 – 4). A 
high proportion of pERK+ neurons colabelled with TPH in (84.6% ± 5 in the 
CFA group, and 78% ± 2.8 in the sham group) however there was no 
significant increase in the percentage of pERK neurons expressing TPH in the 
CFA treated group and sham animals (p = 0.2743, independent samples t-
test).  
Nonetheless, by comparing the numbers of pERK+/TPH+ and pERK+/TPH- 
neurons, it was found that there was a significant increase in the number of 
pERK+/TPH+ double labelled neurons (p = 0.0309) and an overall increase in 
total pERK+ labelled neurons (p = 0.0082) at 6h post CFA injection 
(independent samples t-tests). No significant increase in the number of 
pERK+/TPH- neurons was found. This indicates that the increase pERK 
expression occurs within the TPH+ population of the RVM (figure 3.4b). 
Table 3.2 gives the numbers of pERK+/TPH+, pERK+/TPH- and total pERK+ 
neurons at 6h post CFA.  
 CFA Sham p value 
pERK+/TPH+ 131 ± 15.3 83 ± 8.3 0.0309 
pERK+/TPH- 23 ± 7 22.8 ± 2 0.9703 
pERK+ total 154 ± 9.6 105.8 ± 6.7 0.0082 
% pERK+/TPH+ over 
total pERK+ 
84.6 ± 5 78 ± 2.8 0.2743 
Table 3.2  Numbers of pERK+/TPH+ neurons at 6h post CFA. 
 The number of pERK+/TPH+ double labelled neurons, pERK+/TPH- neurons and total pERK+ 
neurons are shown, along with the percentage of pERK+/TPH+ double labelled neurons over 
total pERK+ neurons. The p values for independent samples t-tests between CFA (n = 3) and 
sham (n = 4) groups are also shown. 
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Figure 3.4 Increase in pERK+/TPH+ double labelled neurons at 6h post CFA.  
A). Representative images of pERK+ (green) and TPH+ (red) cells within the NRM in the 6h 
CFA treated group. Scale bar indicates 100µm. B).  Numbers of double labelled neurons in 
the RVM at 6h following ankle injection of CFA (black) or sham treatment (white). The 
numbers of pERK+/TPH+, pERK+/TPH- and total number of pERK+ cells for the top 5 pERK+ 
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sections per animal are shown. n = 3 - 4, data is presented as mean ± SEM, * p < 0.05, 
independent samples t-test. 
3.3.4 Labelling of active GABAergic synapses within the RVM 
Pilot experiments were carried out to determine if injection of a VGAT-C 
specific antibody to the RVM in naive animals could be used as a measure of 
GABAergic activity within the region as described previously in the 
hippocampus (Martens et al., 2008). Animals were perfused 24h following a 
unilateral microinjection, and 40μm RVM sections were obtained. The VGAT-
C antibody is tagged with Oyster-550, however weak fluorescence was 
observed following sectioning, and immunohistochemistry was carried out 
to enhance the signal. It was found that a single, unilateral microinjection of 
the VGAT-C antibody produced extensive labelling of the RVM region both 
ipsilateral and contralateral to injection site (figure 3.5). Punctate VGAT-C 
labelling was observed throughout the RVM with the most intense labelling 
close to the site of microinjection. The rostral-caudal distribution ran from 
approximately -9.5mm to -12mm from Bregma, with most intense labelling 
at approximately -11mm from Bregma. 
 
Figure 3.5 Labelling of active GABAergic synapses in vivo. 
Schematic illustrating the approximate site of VGAT-C antibody microinjection. The red 
asterix indicates the site of microinjection, at approximately -11mm from Bregma, +0.6mm 
laterally from the midline and -9.5mm from the surface of the brain. Immunohistochemistry 
using tyramide signal amplification allowed the visualisation of the VGAT-C antibody in RVM 
sections. The top panel illustrates a sample immunofluorescence image of VGAT-C staining 
in a naive animal, at approximately -11mm from Bregma. The white asterix indicates the site 
of injection. Below, higher power images of the ipsilateral and contralateral sides are 
shown. As clear labelling was observed contralaterally, these images were used for 
quantitative analysis (the area used for analysis is outlined in by the white box in the top 
panel). Scale bars indicate 50µm. 
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Notably, VGAT-C labelling appeared most prominent in the more ventral and 
lateral portions of the RVM, with considerable labelling spreading into the 
pyramidal tracts. This suggests there is dense GABAergic innervation of the 
area in which pERK labelling is observed following ankle injection of CFA 
(figure 3.3a). To determine if these active GABAergic synapses are formed 
onto 5-HT containing RVM neurons, double labelling of VGAT-C and TPH was 
carried out. It was found that although some close contact could be 
identified between VGAT-C labelled punctae and TPH, not all VGAT-C 
punctae are associated with TPH suggesting that GABAergic neurons 
synapse onto a mixed population of RVM neurons (figure 3.6). 
 
Figure 3.6 VGAT-C and TPH fluorescence immunohistochemistry. 
Single plane confocal images illustrate that some VGAT-C punctae (red) appear to form 
close contact with TPH labelled neurons (green), with an example indicated by the solid 
white arrow. The dashed arrow indicates an example of VGAT-C labelling independent of 
TPH. Scale bar indicates 200µm. 
3.3.5 Decrease in the proportion of active GABAergic synapses in the 
RVM at 3d following ankle injection of CFA 
To determine if changes in GABAergic transmission occur within the RVM 
during persistent ankle inflammation, microinjection of the VGAT-C antibody 
was carried out in animals at 3d following injection of CFA or sham 
procedure (n = 3 per group). All quantitative analysis was carried out on the 
side contralateral to the injection site to minimise variation in labelling due 
to the minor damage caused by the microinjection needle tract (see figure 
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3.5). Animals were perfused at 24h following microinjection, and 
immunohistochemistry carried out to visualise the VGAT-C antibody. Double 
labelling for both isoforms of the glutamate decarboxylase enzyme 
(GAD65/67), a marker of GABAergic neurons, confirmed that the VGAT-C 
punctae corresponded to GABAergic synapses. A series of confocal images 
were taken for further analysis, with sample images from CFA treated and 
sham animals shown (figure 3.7a). Quantification of the total number of 
GAD65/67+ punctae and double labelled VGAT-C+ and GAD65/67+ punctae 
was carried out using the Fiji image analysis programme (see table 3.3). Two 
methods of statistical analysis were used. 
The first analysis used each of the 9 sections per treatment group as 
individual data points. No significant difference in the number of GAD65/67+ 
punctae was observed between the groups (p = 0.1563, independent 
samples t-test, n = 9). Similarly no significant difference was found in the raw 
number of GAD65/67+ and VGAT-C+ overlapping punctae (p = 0.957, 
independent samples t-test, n = 9). However, when the data was expressed 
as the percentage of overlapping punctae over total GAD65/67+ punctae, a 
significant decrease was found in CFA treated animals compared to the 
sham treated group (figure 3.7b, independent samples t-test, p = 0.0011, n = 
9). 
The second analysis used the average of the 3 sections per animal as data 
points (n = 3). This analysis generates the same values for the group means, 
but results in a more stringent statistical test, due to the smaller n number. 
In this case the decrease in the percentage of overlapping punctae over total 
GAD65/67+ punctae in the CFA treated group fell just short of statistical 
significance (figure 3.7c, independent samples t-test, p = 0.0559, n = 3). 
Although this method is the preferred test for this type of data, as this was a 
small pilot experiment it was deemed appropriate to conclude that a 
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decrease in the proportion of double labelled punctae occurred in the CFA 
group. 
 
 
 
CFA Sham p value 
Analysis 1: n = 9 
   GAD65/67 21103 ± 8380.2 7439.6 ± 3758.3 0.1563 
Double 3682.2 ± 1831.2 3849.9 ± 2336.5 0.9557 
% Double/GAD65/67 14.63 ± 3.91 44.93 ± 6.6 0.0011 
    
    Analysis 2: n = 3 
   GAD65/67 21103 ± 4841.46 7439.56 ± 2992.78 0.0743 
Double 3682.22 ± 980.38 3849.9 ± 2263.47 0.9491 
% Double/GAD65/67 14.63 ± 5.02 44.93 ±  10.18 0.0559 
Table 3.3 Numbers of GAD65/67+ and VGAT-C+ punctae at 3d post CFA. 
Values were determined by Fiji image analysis. The results of both statistical analyses are 
shown. Analysis 1 considered each section as a data point, with n = 9. Analysis 2 considered 
each animal as a data point, with n = 3 (based on the mean of 3 sections per animal). The p 
values for independent samples t-tests are shown for each comparison. 
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Figure 3.7 Decrease in the proportion of active GABAergic synapses at 3d post CFA. 
A). Single plane confocal images from CFA and sham treated animals illustrate that the 
majority of VGAT-C labelled punctae (red) colabel with GAD65/67 (green). These double 
labelled punctae correspond to active GABAergic synapses. Not all the GAD65/67+ punctae 
are colabelled with VGAT-C, suggesting the antibody is specific for active synapses only. 
Scale bars indicate 50μm.  B). Image analysis indicated that there is a decrease in the % of 
VGAT-C+ and GAD65/67+ double labelled punctae in the CFA treated group, over total 
GAD65/67 punctae. Data is expressed as the mean ± SEM of all 9 sections per group (n = 9, 
3 sections per animal, 3 animals per group), p = 0.0011, independent samples t-test. C). The 
same image analysis data is presented as the group mean (n = 3 animals) where the value 
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per animal is calculated as the average of the 3 sections per animal. p = 0.0559, 
independent samples t-test. 
3.4  Discussion 
The RVM is a key structure involved in the relay of descending information 
to the dorsal horn of the spinal cord and is known to be activated in a 
number of models of persistent pain. Despite considerable evidence for a 
role of the RVM in descending facilitation of neuropathic pain as well as 
cutaneous inflammation (Burgess et al., 2002; Géranton et al., 2008; Wei et 
al., 2010), little is known regarding the role of the RVM in joint pain. This 
chapter describes experiments designed to determine if neuronal activation 
in the RVM is altered following ankle joint inflammation. Two separate 
immunohistochemistry approaches were used, investigating levels of pERK 
expression and GABAergic inhibition. Consideration of both findings 
together provides insight into the different time dependent changes that 
occur within the RVM in this model, with ERK activation within 5-HT neurons 
in the acute phase, and decreased GABAergic inhibition in the maintenance 
phase.  
3.4.1 ERK activation in the RVM: a role in the induction of joint pain 
ERK activation is widely used as a marker of stimulus induced activity in the 
CNS. In studies of nociception, ERK phosphorylation has been shown to 
occur in neurons of the dorsal horn in a number of pain models.  RVM 
activation has also been demonstrated using pERK staining in the CFA model 
of cutaneous inflammation and spared nerve injury model of neuropathic 
pain (Géranton et al., 2010; Imbe et al., 2005). To investigate if similar RVM 
activation occurs in a model of joint pain, pERK immunohistochemistry was 
carried out at three time points following ankle injection of CFA.  
Interestingly it was found that in the sham treated animals there was a high 
level of ERK activation within the NRM and GiA regions of the RVM, 
suggesting that this region may be sensitive to the anaesthesia and 
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perfusion methods used. The RVM plays a role in acute nociception and 
phosphorylation of ERK is known to occur rapidly in stimulated neurons (Ji et 
al., 2002). This could explain the high level of ERK activation observed in the 
sham groups as the injection of pentobarbital and the perfusion process 
could cause rapid activation of ERK within the RVM. 
Despite the high basal level of pERK+ neurons in sham animals, comparison 
of the number of pERK+ neurons in CFA and sham treated groups indicated 
there was an increase in pERK+ cells at 6h post inflammation. No significant 
increase was found at the later time points suggesting that ERK activation 
may play a role in the induction but not the maintenance of the pain state. 
The data presented here supports findings by others in the CFA model of 
cutaneous inflammation, in which peak ERK activation occurs at 7h post 
inflammation and pERK levels remain elevated until 1d (Imbe et al., 2005). 
Our findings suggest that the time course of ERK phosphorylation in the 
RVM is similar in models of joint and cutaneous inflammation. 
Although the 6h time point correlates with peak mechanical hypersensitivity 
in our model, and can be considered representative of the acute phase of 
the pain state (Géranton et al., 2007), it is possible that ERK activation may 
occur at even earlier time points. For example in the Imbe et al. study an 
initial activation period was identified at 30min following plantar 
inflammation. This time point mirrors activation of ERK within spinal 
neurons following noxious stimulation (Ji et al., 1999). It is likely that a 
similar initial activation of ERK may occur in the RVM within minutes 
following ankle injection of CFA, and so an earlier time point may warrant 
investigation. If this proves to be the case, the two windows of ERK 
activation within the RVM may represent different aspects of nociceptive 
processing in the pain model. Activation of ERK within minutes may be arise 
due to the initial process of injection and inflammation, and could indicate 
activation of descending inhibitory neurons. Subsequent activation, within 
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hours, could represent recruitment of facilitatory pathways as mechanical 
hypersensitivity begins to stabilise and enters the maintenance phase. 
Attenuation of cutaneous thermal hypersensitivity by microinjection of a 
MEK inhibitor to the RVM has been demonstrated (Imbe et al., 2008). 
Although ERK phosphorylation was decreased within hours of drug 
administration the effects of ERK inhibition on pain sensitivity did not occur 
until 1d post CFA injection. This suggests that the effects of ERK activation 
on behavioural hypersensitivity may not be observed until several hours 
later which would correlate with a role for ERK in long term transcriptional 
changes in the activated neurons. In the present study behavioural testing 
was not carried out, to eliminate the possibility that nociceptive testing itself 
could contribute to ERK activation in the RVM. Nonetheless behavioural 
testing may be of interest in future experiments, in particular to investigate 
if activation of ERK within the RVM has a facilitatory effect on mechanical 
paw withdrawal thresholds in this model. A useful future experiment would 
be to administer a MEK inhibitor directly to the RVM to establish if inhibition 
of ERK phosphorylation attenuates joint pain behaviour. 
In the present study ERK activation is not observed at later time points, with 
no significant increase observed at either 3d or 7d post CFA injection. Again 
this correlates with previous findings in cutaneous inflammation (Imbe et al., 
2005) but contrasts with work using the spared nerve injury model of 
neuropathic pain (Géranton et al., 2010). In this neuropathic pain model 
biphasic activation of ERK occurs, with increases in pERK+ neurons observed 
both during the induction phase of the pain state at (3d post nerve injury) 
and in the maintenance phase  (8d post injury) (Géranton et al., 2010). This 
suggests that cutaneous and joint inflammation result in different patterns 
of ERK activation within the RVM when compared to neuropathic pain 
states. This may reflect differences in neuronal activity and descending 
modulation of pain in inflammatory and neuropathic models. It is possible 
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however that ERK activation could be maintained in the present model, at 
least up to 1d post inflammation as observed in cutaneous inflammation 
(Imbe et al., 2005). Further work is required to confirm that there is no 
further activation of ERK after the 6h time point, but at present the absence 
of activation at 3d and 7d suggests that in this model ERK activation does 
not occur in the later stages of inflammation. As mentioned above, 
pharmacological studies suggest there may be a delay between ERK 
activation and behavioural effects on descending modulation of pain, and it 
is possible that early ERK activation contributes to long term transcriptional 
changes and plasticity within the RVM. 
It was found that approximately 80% of pERK expressing neurons in the RVM 
were TPH positive at 6h post inflammation. This proportion is higher than 
that reported in the cutaneous inflammation (Imbe et al., 2004) and may 
suggest greater activation of 5-HT neurons in the ankle joint model. 5-HT 
containing neurons represent approximately 20% of the RVM cell population 
(Gu and Wessendorf, 2007; Potrebic et al., 1994; Zhang et al., 2006) and 
many of these 5-HT neurons project to the dorsal horn (Bowker et al., 1982; 
Skagerberg and Björklund, 1985). Descending 5-HT fibres can have both pro- 
and anti-nociceptive effects within the dorsal horn, depending on the 
receptor subtype activated (Bardin, 2011; Millan, 2002). Increased activation 
of 5-HT neurons in the RVM following joint inflammation may therefore lead 
to increased descending inhibition, facilitation or a combination of the two. 
The next chapter describes experiments which aimed to investigate the role 
of descending 5-HT fibres in mediating behavioural hypersensitivity 
associated with joint inflammation.  
Not all 5-HT neurons in the RVM project to the dorsal horn (Marinelli et al., 
2002) and it would be of interest to determine the proportion of 
pERK+/TPH+ neurons that are projection neurons. Retrograde tracing from 
the dorsal horn would be useful in conjunction with pERK and TPH labelling. 
Chapter 3 
90 
 
Of those pERK+/TPH+ neurons that terminate within the RVM, it would be of 
interest to determine if these are either excitatory or inhibitory 
interneurons, by triple labelling with either VGLUT1 (the vesicular glutamate 
transporter) or GAD65/67. 
Although these findings strongly suggest a role for 5-HT RVM neurons in the 
ankle joint model, the relatively low level of pERK expression in non-5-HT 
cell types is intriguing. The RVM is a heterogeneous population of cells, with 
physiologically defined ON, OFF and NEUTRAL cells being described 
throughout the region and these are not anatomically separated (Fields and 
Heinricher, 1985; Fields et al., 1983). It is interesting to note that little 
activation of ERK occurs in the more dorsal and lateral portions of the RVM, 
as at least some of these physiologically defined cells are present in the 
outer regions (Barbaro et al., 1986; Fields et al., 1983). This suggests that the 
signalling pathway contributing to ERK activation is not active in some of 
these electrophysiologically defined cells. Although ERK can be activated by 
Ca2+ influx via activated ionotropic receptors, another pathway which could 
contribute to ERK activation in TPH neurons is BDNF signalling (Pezet et al., 
2002). Release of BDNF within the RVM from neurons arising in the PAG 
contributes to hyperalgesia (Guo et al., 2006) and this hyperalgesia appears 
to require release of 5-HT in the dorsal horn (Wei et al., 2010). Therefore 
BDNF activation of the TrkB receptor on 5-HT neurons of the RVM could lead 
to preferential activation of ERK in those neurons.  
3.4.2 Decreased GABAergic transmission in the RVM following joint 
inflammation 
In a separate experiment it was investigated if activity at GABAergic 
synapses within the RVM is altered in response to joint inflammation. In the 
normal animal GABAergic signalling in the RVM is pro-nociceptive, as 
microinjection of GABAA agonists to the region facilitates the tail flick reflex 
(Gilbert and Franklin, 2001; Heinricher et al., 1994). The proposed 
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mechanism underlying this effect is that increased GABAergic inhibition of 
inhibitory RVM neurons that project to the spinal cord results in a reduction 
in descending inhibition. Recently however it has been proposed that in 
persistent pain states decreased GABAergic inhibition within the RVM could 
lead to enhanced excitation of pain facilitating neurons projecting to the 
spinal cord. In the CFA model of plantar inflammation a decrease in 
inhibitory post synaptic currents occurs in the RVM. This effect is seen at 3 
days but not at earlier time points following induction of the pain state 
(Zhang et al. 2011). In this study it was also shown that microinjection of a 
GABAA agonist to the RVM reduced thermal hypersensitivity. This strongly 
suggests that GABAergic transmission in altered in the maintenance phase of 
hypersensitivity (3d) following plantar inflammation. 
To investigate if changes in GABAergic activity in the RVM occur in the ankle 
joint model a novel method of labelling active GABAergic synapses in vivo 
was used. Microinjection of the VGAT-C antibody to the RVM of naïve rats 
and subsequent detection by immunohistochemistry suggested that as 
described previously by others in the hippocampus (Martens et al., 2008) 
this technique could be a useful measure of GABAergic activity in the RVM. 
GAD65/67 double labelling indicated that the majority of these VGAT-C 
positive punctae were at GABAergic synapses. Furthermore the GAD65/67 
labelling indicated that not all GAD65/67 positive punctae were positive for 
the VGAT-C terminus epitope, which is only exposed during synaptic release 
of neurotransmitter (figure 3.2). This suggests that as anticipated only a 
subset of active GABAergic synapses were labelled by VGAT-C 
(approximately 50% in the sham treated animals) and not all those 
containing GABA. 
Using this labelling technique we wished to investigate if active GABAergic 
synapses are decreased in the RVM following ankle injection of CFA. Animals 
received VGAT-C microinjection at 3 days following CFA injection or sham 
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procedure. Analysis of the number of VGAT-C and GAD65/67 positive 
punctae in a sample of RVM sections from each group found that at 3 days 
following ankle inflammation there was a significant decrease in GABAergic 
signalling compared to sham controls. This supports the previous data on 
plantar inflammation in which GABAergic signalling is decreased at 3 days 
post CFA but not at earlier time points (Zhang et al., 2011). Although we 
have not carried out VGAT-C labelling at earlier time points, the results 
presented here indicate that decreased GABAergic transmission can be 
identified in the maintenance phase of the pain state. The origin of the 
GABAergic synapses characterised in this study is not addressed. Other brain 
regions which project to the RVM including the PAG may also be sources of 
GABAergic input however retrograde labelling from the PAG suggests that 
this GABAergic input is minimal (Jones et al. 1991). Therefore it is likely that 
many of the synapses quantified here arise from local inhibitory 
interneurons. 
Further work is needed to characterise the functional role of GABAergic 
signalling within the RVM particularly in persistent pain states. Most 
previous studies have investigated GABAergic mechanisms in acute 
nociception using pharmacological manipulations (Drower and Hammond, 
1988; Gilbert and Franklin, 2001; Heinricher and Kaplan, 1991; Heinricher et 
al., 1994). The role of the endogenous GABAergic signalling system within 
the RVM in pathological pain states following peripheral injury or 
inflammation is not well established. Increased descending facilitation from 
the RVM has been shown to play a role in behavioural hypersensitivity in 
neuropathic pain (Burgess et al., 2002; Porreca et al., 2001) and cutaneous 
inflammation (Géranton et al., 2008; LaGraize et al., 2010; Wei et al., 2010). 
The decrease in GABAergic signalling observed in this study and by others 
(Zhang et al., 2011) may therefore reflect a decrease in inhibitory control 
over facilitatory output neurons. Previously it has been reported that 
approximately 45% of all identified synapses in the rat RVM region are 
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GABAergic (Cho and Basbaum, 1991). The diffuse VGAT-C labelling observed 
throughout the RVM observed in naive rats is consistent with this. The high 
proportion of GABAergic synapses within the region and the presence of 
GABAA receptors on approximately 30% of RVM projection neurons (Hama 
et al., 1997) suggests that GABAergic inhibition is an important mechanism 
in the regulation of RVM to dorsal horn signalling. 
It has been shown previously that at least some of the RVM 5-HT neurons 
have GABAergic input (Jones et al., 1991), and the finding that some TPH 
neurons have close labelling with VGAT-C supports this. Therefore the 
decreased GABAergic activity following ankle injection of CFA may result in a 
decrease in the inhibition of these neurons and increased 5-HT release in the 
spinal cord. However, only 20% of 5-HT neurons express the GABAA receptor 
(Hama et al., 1997) so it is likely that the decrease in GABAergic inhibition 
will also affect other cell types. Interestingly the Zhang et al. study (2011) 
suggested that decreased GABAergic inhibition may occur preferentially on 
cells expressing the mu opioid receptor (MOR), as MOR+ cell excitability is 
increased after inflammation. Further work is needed to determine if this is 
the case following ankle joint inflammation.  
3.4.3 VGAT-C labelling technique: technical considerations 
Labelling of active GABAergic synapses by application of a VGAT-C specific 
antibody is a relatively novel technique, and to date has been used in vivo 
only within the hippocampus in naïve animals, and not under experimental 
conditions (Martens et al., 2008). Although the results described in this 
chapter are promising, these should be considered pilot experiments and 
further work is needed to optimise the protocol. An important future 
experiment is to test a variety of VGAT-C concentrations in vivo to determine 
the optimal dose for TSA immunohistochemistry. As discussed above, the 
side contralateral to microinjection was used for analysis due to minor tissue 
damage caused at the injection site. A lower dose may reduce this effect and 
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allow for reliable analysis of the ipsilateral side. In addition, a single injection 
along the midline may be preferable as this would allow labelling and 
quantification of both sides of the RVM.  
Specificity of the VGAT-C antibody for actively recycling GABAergic vesicles 
has been established by others previously (Hughes et al., 2010; Martens et 
al., 2008), however nonetheless a number of controls should be included in 
our future studies. Firstly, to ensure that the VGAT-C antibody is specific for 
active GABAergic synapses, a third antigen could be stained in addition to 
GAD65/67, such as VGAT-N or gephyrin, and only those punctae positive for 
all three would be counted as active GABAergic synapses. Secondly, to 
ensure that the VGAT-C antibody is not non-selectively labelling active 
synapses in all types of neurons, confirmation of a lack of double labelling 
with VGLUT1 (vesicular glutamate transporter) or SERT (5-HT transporter) 
could be carried out.  
It has been reported that VGAT-C treatment of neurons in vitro does not 
impair vesicle filling, but may lead to a small reduction in vesicle release 
probability (Martens et al., 2008). The possibility that GABAergic 
transmission will be impaired following injection in vivo may warrant 
investigation, and suggests that combining behavioural studies with VGAT-C 
labelling may be problematic. Despite this limitation, and subject to 
confirmation of antibody specificity, the VGAT-C labelling technique may 
prove useful for quantifying GABAergic transmission within the RVM during 
ankle joint inflammation and other chronic pain states. 
3.4.4 Conclusions 
The aim of this chapter was to determine if changes in RVM activity occur 
following ankle joint inflammation, as described previously following 
induction of cutaneous inflammation or neuropathic injury. I have shown 
that following joint inflammation, ERK activation occurs mainly within 5-HT 
neurons. By labelling active GABAergic synapses in vivo, I have shown that 
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changes in inhibitory transmission also occur following joint inflammation. 
The following chapters describe experiments designed to determine the 
contribution of descending facilitation via the RVM to behavioural 
hypersensitivity in this model. 
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4. The role of descending 5-HT in inflammatory 
joint pain  
4.1  Introduction 
The majority of 5-HT fibres terminating in the dorsal horn originate in the 
RVM (Kwiat and Basbaum, 1992) and as demonstrated in chapter 3, 
activation of many of these neurons occurs in the hours following ankle joint 
inflammation. This chapter describes behavioural experiments carried out to 
investigate the role of spinal 5-HT in mediating behavioural hypersensitivity 
associated with this model. 
4.1.1 The role of spinal 5-HT in nociceptive processing 
5-hydroxytryptamine (5-HT) is a monoamine neurotransmitter found 
extensively in the periphery including the cardiovascular, gastrointestinal 
and pulmonary systems. Within the CNS 5-HT plays an important role in the 
modulation of many neurological processes including mood, sleep, 
autonomic function and sensory processing. Central 5-HT is produced largely 
in neurons of the midline raphe nuclei of the brainstem, which project to 
almost all brain areas and also the spinal cord (Berger et al., 2009). 
The RVM is an important site in the descending modulation of nociceptive 
processing, and the majority of 5-HT fibres within the dorsal horn originate 
here (Kwiat and Basbaum, 1992). 5-HT containing fibres have been shown to 
form synapses onto projection neurons and local inhibitory interneurons  
(Millan, 2002; Ruda, 1988; Ruda et al., 1986). Therefore spinal 5-HT fibres 
arising from the RVM are ideally placed to modulate nociceptive processing 
in the dorsal horn. 
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In normal animals spinal 5-HT has been shown to play an inhibitory role in 
nociception. Direct application of 5-HT to the spinal cord in naive animals 
has an anti-nociceptive effect on behavioural responses to acute thermal 
(Crisp et al., 1991; Xu et al., 1994a; Yaksh and Wilson, 1979) and mechanical 
(Bardin et al., 1997) stimuli. In addition, the full analgesic effects of systemic 
morphine (Deakin and Dostrovsky, 1978) and clonidine (Duan and Sawynok, 
1987) require an intact spinal 5-HT system suggesting 5-HT is a key 
component of endogenous inhibitory pathways.  
These early studies established an important role for spinal 5-HT in 
mediating descending inhibition in the naive animal. Later work found that 
that in addition to mediating descending inhibition, the RVM could also play 
a role in facilitating nociception as high and low frequency stimulation of the 
region produced inhibition and facilitation respectively (Zhuo and Gebhart, 
1990). It was found that the pro-nociceptive effect of low frequency 
stimulation in the RVM was blocked by 5-HT₁ receptor antagonism within 
the spinal cord (Zhuo and Gebhart, 1991) suggesting that spinal 5-HT may 
also facilitate spinal processing of pain.  
4.1.2 5-HT receptor subtypes in the dorsal horn 
At the spinal cord level the ability of 5-HT to enhance or inhibit nociceptive 
processing may be explained by activation of different receptor subtypes 
and multiple cellular locations within the dorsal horn (Millan, 2002). The 5-
HT receptors are divided into 7 families, containing a total of 15 distinct 
receptors (Hannon and Hoyer, 2008). All are G protein-coupled, except for 
the 5-HT₃ receptor, which is a ligand gated ion channel. All the known 5-HT 
receptor subtypes are expressed within the spinal cord. The 5-HT₁ and 5-HT₂ 
groups and the individual 5-HT₃ and 5-HT₇ receptors are the most widely 
studied in terms of nociception (Millan, 2002). The functional response to 5-
HT will depend on the physiological effect of receptor activation, i.e. if it has 
an inhibitory or excitatory role within the target neuron, and the cell type on 
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which it is located. The dorsal horn is a complex network of projection 
neurons, descending fibres, local inhibitory and excitatory interneurons, as 
well as containing the primary afferent terminals (Todd, 2010). 5-HT 
receptors are located on all of these cell types and therefore the net effect 
of 5-HT will depend on the balance between these components. 
The 5-HT₁ subtype accounts for the majority of 5-HT receptors within the 
spinal cord. 5-HT1A receptor activation has an inhibitory effect on neurons by 
negative coupling to adenylyl cyclase. 5-HT1A  activation has been shown to 
exert facilitatory effects on the nociceptive responses of spinal wide 
dynamic range neurons following carrageenan induced inflammation (Zhang 
et al., 2001) and are required for RVM stimulation induced facilitation of 
nociceptive reflexes (Ren, Randich, and Gebhart 1991; Zhuo and Gebhart 
1991). Upregulation of this receptor occurs following peripheral carrageenan 
inflammation (Zhang et al. 2002) and hyperalgesia induced by plantar 
injection of bee venom (Wang et al., 2003). The facilitatory effects of 5-HT1A  
receptor activation are thought to be mediated indirectly by inhibition of 
GABAergic interneurons (Wang et al., 2009). However inhibitory effects of 5-
HT1A  on nociception have also been described, for example in the formalin 
test, and this may be mediated by direct inhibitory effects on projection 
neurons (Bardin et al., 2001; Oyama et al., 1996). Therefore the 5-HT1A 
receptor subtype can have dual effects on nociception depending on the cell 
type activated.  
The 5-HT2A receptor has also been implicated in descending facilitation. It 
has an excitatory effect on neurons, by positive coupling to phospholipase C 
(Millan, 2002). The 5-HT2A receptor is expressed at relatively low levels 
within the dorsal horn but is highly expressed in the DRG. Therefore the 
effects of 5-HT2A activation in the spinal cord are likely to be mediated by the 
primary afferent terminals. Spinal administration of a 5-HT2A antagonist has 
anti-nociceptive effects in models of neuropathic pain (Obata et al., 2004, 
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2001) and the formalin test (Nitanda et al., 2005). This receptor is therefore 
also a likely candidate in mediating descending facilitation via 5-HT. 
The 5-HT₃ receptor has been the most widely studied in terms of mediating 
descending facilitation. This subtype is unique among the 5-HT receptors as 
it is a ligand gated ion channel. Activation of the 5-HT₃ receptor in neurons 
has an excitatory effect on target neurons, by positive coupling to 
phospholipase C. The 5-HT₃ receptor localises to primary afferent terminals 
(Maxwell et al., 2003) and one mechanism by which 5-HT₃ activation could 
enhance nociception is by increasing transmitter release from terminals. The 
5-HT₃ receptor is also found on spinal interneurons and projection neurons 
(Conte et al., 2005; Huang et al., 2004; Kawasaki et al., 2004; Maxwell et al., 
2003; Zeitz et al., 2002).  
5-HT₃ knockout animals display normal acute pain behaviour but show an 
attenuated response to the second phase of the formalin test (Zeitz et al., 
2002). This suggests that baseline pain responses are not modulated by 5-
HT₃ but that in persistent pain states increased 5-HT drive to the spinal cord 
may activate these receptors. This is also observed pharmacologically 
whereby intrathecal administration of ondansetron, a selective 5-HT₃ 
antagonist, attenuates the second phase of the formalin response (Okamoto 
et al., 2004). Intrathecal administration of 5-HT₃ receptor antagonists has 
also been shown to attenuate behavioural hypersensitivity in a number of 
persistent pain models including spinal cord injury (Oatway et al., 2004), 
cancer induced bone pain (Donovan-Rodriguez et al., 2006), neuropathic 
pain (Dogrul et al., 2009) and cutaneous inflammation by CFA (LaGraize et 
al., 2010). Facilitation of dorsal horn neuronal excitability has also been 
shown to be mediated by the 5-HT₃ receptor in the formalin test (Suzuki et 
al., 2002) and in the monosodium iodoacetate (MIA) model of osteoarthritis 
(Rahman et al., 2009). Importantly these findings have been validated to 
some extent in patients with neuropathic pain, where a single intrathecal 
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dose of ondansetron led to a small decrease in overall pain scores, 
suggesting that targeting the spinal facilitation of pain via the 5-HT₃ receptor 
may a useful target in the treatment of chronic pain states  (McCleane et al., 
2003). 
The 5-HT₇ receptor has only been studied in pain relatively recently, and 
most studies suggest it plays a role in the inhibitory effects of 5-HT. 
Activation of the 5-HT₇ receptor leads to excitatory effects within neurons 
and the receptor has been shown to localise both to primary afferent 
terminals and intrinsic dorsal horn neurons (Doly et al., 2005). In 
neuropathic pain, 5-HT₇ plays an inhibitory role (Dogrul et al., 2009) and this 
is thought to be mediated via activation of GABAergic interneurons in the 
dorsal horn (Yanarates et al., 2010). In addition, this receptor is required for 
morphine (Dogrul and Seyrek, 2006) and tramadol (Yanarates et al., 2010) 
mediated analgesia. These studies strongly support a role for the 5-HT₇ 
receptor in mediating descending inhibition by 5-HT. 
4.1.3 The role of descending 5-HT in persistent pain states: evidence from 
lesion studies 
The net effect of endogenous descending 5-HT in pain behaviour has been 
investigated using selective lesion of 5-HT containing fibres by the 
neurotoxin 5,7-dihydroxytryptamine. This technique has been used in a 
number of pain models, including the formalin model (Svensson et al., 
2006), neuropathic injury (Rahman et al., 2006) and plantar inflammation by 
CFA (Géranton et al., 2008). These studies have illustrated that depletion of 
spinal 5-HT has no effect on baseline pain responses but that in models of 
persistent pain, lack of 5-HT fibres leads to an attenuation of behavioural 
hypersensitivity. This suggests that endogenous 5-HT exerts a net facilitatory 
effect on nociceptive processing in these pain models. More recently 
molecular depletion of descending 5-HT by silencing of tryptophan 
hydroxylase (TPH), the enzyme that synthesises 5-HT, has also been used to 
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demonstrate that descending 5-HT has a pro-nociceptive role in cutaneous 
inflammation (Wei et al., 2010). Collectively these studies suggest a role for 
descending 5-HT in increasing pain sensitivity across a variety of pain 
models. 
4.1.4 Hypothesis 
In this chapter I have tested the hypothesis that descending 5-HT facilitates 
behavioural hypersensitivity following joint inflammation and that this is 
mediated by the spinal 5-HT₃ receptor. 
4.2  Methods 
4.2.1 Intrathecal injection 
Isoflurane anaesthesia (5% isoflurane for induction, 1.5 – 2% for 
maintenance, combined with 100% O2 (1l/min)) was used during surgery. 
Animals were secured in a stereotaxic frame and the head was shaved and 
sterilised. A skin incision was made from the base of the skull to the first 
vertebra, and the muscle separated in layers to reveal the atlanto-occipital 
membrane. A small incision was made and the membrane cleared to allow 
cannula access. Polyethene tubing (diameter 0.28mm), prefilled with 
solution and attached to a 50µl Hamilton syringe was then inserted carefully 
was into the subarachnoid space, terminating in L4-5 region. Care was taken 
to prevent damage to the spinal cord or roots. Toxin, drug or vehicle was 
injected in a volume of 10µl. The tubing was then withdrawn, and the 
muscle was sutured with 1 – 2 stiches of 3-0 Mersilk, and the skin sutured 
with 5-0 Mersilk. As with intra-RVM injections animals were monitored 
closely for weight loss, signs of neurological impairments or general distress. 
4.2.1.1  5,7-Dihydroxytryptamine lesion 
Animals were pre-treated with 25mg/kg i.p. desipramine hydrochloride 
(Sigma) dissolved in saline to protect against noradrenergic toxicity one hour 
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prior to surgery.  Animals received 10μl of 5,7-dihydroxytryptamine (5,7-
DHT) in saline (6μg/μl, Fluka) or saline only. The animals were allowed to 
recover over 6 days to allow for depletion of 5-HT fibres before CFA 
injection. 
4.2.1.2  5-HT₃ antagonist 
In a separate experiment animals were injected intrathecally with drug or 
vehicle at 1d following CFA injection to the ankle. Ondansetron 
hydrochloride (Tocris Bioscience), a selective 5-HT₃ antagonist was dissolved 
in saline and injected in a volume of 10µl at a dose of 1µg/1µl. This dose was 
chosen based on a previous study of thermal hyperalgesia following 
cutaneous inflammation (LaGraize et al., 2010). 
4.2.2 Inflammatory pain model and behavioural testing 
Animals received ankle injection of CFA or underwent a sham procedure. 
Paw withdrawal thresholds were measured and log2 transformation was 
carried out to normalise the data (see section 2.2). 
To measure relative weight bearing on the ipsilateral and contralateral 
hindpaws following induction of joint inflammation an incapcitance tester 
(Linton Instrumentation) was used. Animals were placed in a plexiglass box 
with front paws leaning on a slope and each hindpaw on a separate 
weighing scale. The force of each hindpaw on its scale was then measured 
and averaged over a 5 second period, and 5 measurements were taken for 
each animal. Data is presented as the mean ipsilateral weight bearing over 
total weight bearing: (Ipsilateral weight (g)/ (Ipsilateral weight (g) + 
contralateral weight (g))) x 100. 
Statistical analysis for both mechanical paw withdrawal thresholds and 
weight bearing data was carried out in SPSS. Analysis of variance (ANOVA) 
with repeated measures was carried out with time as the within subjects 
factor, and CFA and 5,7-DHT/ondansetron treatment as the between 
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subjects factors. A significant main effect of CFA was a prerequisite for 
subsequent ANOVAs or post hoc analysis. 
4.2.3 5-HT immunohistochemistry 
To determine the extent of 5,7-DHT lesion of spinal 5-HT fibres, direct 
fluorescence immunohistochemistry was carried out using a 5-HT specific 
antibody (rat host, concentration 1:75, Chemicon) in 40µm lumbar spinal 
cord sections from 5,7-DHT and saline injected animals. The 5-HT 
immunohistochemistry protocol used the avidin-biotin steps of the TSA 
protocol, but without the biotinylated tyramide step (section 2.4). 
4.3  Results 
4.3.1 Lesion of descending 5-HT fibres by 5,7-DHT attenuates mechanical 
hypersensitivity   
Following intrathecal injection animals were monitored closely for 
neurological damage. In a small number of animals, cannula insertion 
resulted in dorsal root injury which caused clear motor deficits apparent 
upon recovery from the anaesthesia. These were culled immediately and 
removed from further analysis. Following a 6d recovery period animals were 
subjected to either ankle injection of CFA or sham procedure and paw 
withdrawal thresholds were monitored up to 7d post inflammation.  
Three-way analysis of variance (ANOVA) with repeated measures was 
carried out on the ipsilateral paw withdrawal thresholds, with time as the 
within-subject factor and intrathecal injection (5,7-DHT or saline) and CFA 
injection (CFA or sham) as the between-subjects factors (n = 6 - 7). Main 
effects of time, CFA, and a time x CFA interaction were observed. The full 
results of this analysis are shown in table 4.1. 
Subsequently a two-way ANOVA with repeated measures was carried out to 
determine if there was an overall effect of 5,7-DHT from 2h to 7d following 
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CFA treatment. The results of this analysis indicated there was no overall 
effect of 5,7-DHT treatment (p = 0.271) and no 5,7-DHT x CFA interaction (p 
= 0.293) but there was a main effect of time (p < 0.001). One-way ANOVAs at 
each time point following CFA injection were then carried out to determine 
the source of this variation. These indicated that there was a significant 
effect of 5,7-DHT treatment at days 1 and 2 post CFA injection (p = 0.01 and 
0.037 respectively, LSD post hoc test, figure 4.1a).  
Factor df F Error P 
Time  13 20.8 286 < 0.001 
CFA  1 64 22 < 0.001 
5,7-DHT  1 0.36 22 0.555 
5,7-DHT x CFA 1 16.5 22 0.198 
Time x 5,7-DHT 13 0.771 286 0.691 
Time x CFA 13 23.7 286 < 0.001 
Time x CFA x 5,7-DHT 13 1.25 286 0.244 
Table 4.1 Results of three-way ANOVA with repeated measures on ipsilateral paw 
withdrawal thresholds following 5,7-DHT. 
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Figure 4.1 Attenuation of mechanical hypersensitivity by 5,7-DHT. 
A). Attenuation of mechanical hypersensitivity in 5,7-dihydroxytryptamine treated rats 
following ankle joint inflammation. Ipsilateral paw withdrawal thresholds were significantly 
higher in 5,7-DHT treated animals compared with saline controls, at 1d and 2d following 
CFA injection. Pre-IT indicates the baseline prior to intrathecal injection, post-IT indicates 
baseline after IT injection. B). Paw withdrawal thresholds of the contralateral hindpaw were 
not altered by CFA injection or by 5,7-DHT pre-treatment. Data is presented as log2 (paw 
withdrawal threshold in g) and mean ± SEM. * p < 0.05, two-way ANOVA with repeated 
measures, and LSD post hoc analysis. n = 6 - 7. 
 
A three-way ANOVA with repeated measures was also carried out on the 
paw withdrawal thresholds of the contralateral hindpaw (figure 4.1b). This 
analysis indicated that although there was a significant effect of time (p < 
0.001) there was no time x 5,7-DHT interaction (p = 0.59), time x CFA 
interaction (p = 0.651) or time x 5,7-DHT x CFA interaction (p = 0.604). The 
between subjects effects indicated no effect of 5,7-DHT (p = 0.922), CFA 
(0.129) or CFA x 5,7-DHT interaction (p = 0.393). As there were no significant 
main effects of CFA treatment on paw withdrawal thresholds post hoc 
analysis was not carried out.  
These findings indicate that 5,7-DHT treatment has no effect on baseline 
mechanical paw withdrawal thresholds, and attenuates mechanical 
hypersensitivity at 1d and 2d post inflammation only.  
4.3.2 No effect of 5,7-DHT on weight bearing 
Use of von Frey hairs allows the characterisation of cutaneous mechanical 
hypersensitivity of tissue adjacent to the inflamed joint, which may be 
considered a measure of secondary hyperalgesia. To study the sensitivity of 
the joint (primary hyperalgesia) weight bearing on the hindpaws was 
assessed. Readings were taken of weight placed on the ipsilateral and the 
contralateral hindpaws, and data is expressed as ipsilateral weight 
bearing/total hindpaw weight bearing (ipsilateral + contralateral). Three-way 
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ANOVA with repeated measures was carried out as for the paw withdrawal 
thresholds. The within-subjects tests indicated there was a main effect of 
time but no time x 5,7-DHT, time x CFA or time x 5,7-DHT x CFA interactions. 
The between-subjects tests indicated that there was no overall effect of 
drug or drug x treatment interaction but there was a main effect of 
treatment. The results of this analysis are shown in table 4.2. 
As there was a main effect of time and CFA treatment, post-hoc analysis was 
carried out using one-way ANOVAs at each time point following CFA 
injection. This indicated that at all time points there was a significant effect 
of CFA treatment (p < 0.03) but no effect 5,7-DHT. These findings indicate 
that while CFA treatment reduces weight bearing on the ipsilateral hindpaw, 
there was no attenuation of this shift in weight bearing by 5,7-DHT 
treatment (figure 4.2). 
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Figure 4.2 No effect on weight bearing following 5,7-DHT. 
CFA treatment led to a decrease in weight bearing on the ipsilateral hindpaw in both 5,7-
DHT and saline treated groups (** p = 0.001, three-way ANOVA with repeated measures) 
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however 5,7-DHT treatment had no effect on this decrease. Data is presented as mean ± 
SEM, n = 6 – 7. 
 
Factor df F Error P 
Time  5 4.72 110 0.001 
CFA  1 14.892 303.737 0.001 
5,7-DHT 1 0.06 303.737 0.809 
5,7-DHT x CFA 1 0.034 303.737 0.855 
Time x 5,7-DHT 5 1.225 110 0.302 
Time x CFA 5 1.05 110 0.392 
Time x CFA x 5,7-DHT 5 2.101 110 0.071 
Table 4.2 Results of three-way ANOVA with repeated measures on weight bearing 
following 5,7-DHT. 
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4.3.3 Confirmation of 5-HT depletion by immunohistochemistry 
Ablation of central 5-HT containing neurons by administration of 5,7-DHT is 
a widely used lesion technique in many areas of neuroscience and has been 
used by our research group previously to ablate descending 5-HT fibres 
within the dorsal horn of the spinal cord (Géranton et al., 2008). 5-HT 
immunohistochemistry was carried out in 40µm sections of the lumbar L4-L6 
region spinal cord in a total of 8 rats (2 from each treatment group, in each 
of the two experimental batches). In all 5,7-DHT treated animals it was 
found that as expected,  5-HT positive punctae were almost completely 
absent within the dorsal horn, compared with saline injected controls in 
which extensive 5-HT labelling was observed. Representative images of 5,7-
DHT treated and saline control animals are shown in figure 4.3. 
 
Figure 4.3 5-HT immunohistochemistry following at 13d following 5,7-DHT depletion (7d 
post CFA). 
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Representative images indicate that 5,7-DHT treatment leads to a complete loss of 5-HT 
punctate immunoreactivity within the dorsal horn. Top row x 5 magnification, scale bar 
indicates 400µm, bottom row x 10 magnification, scale bar indicates 200µm. 
4.3.4 Effect of an intrathecal 5-HT₃ antagonist on established 
hypersensitivity 
To determine the role of the 5-HT₃ receptor in mediating descending 
facilitation by 5-HT, the 5-HT₃ specific antagonist ondansetron was 
intrathecally administered to animals 24h following induction of 
inflammation. A two-way ANOVA with repeated measures was carried out 
with time as the within-subjects factor and drug treatment as the between-
subjects factor. The results of this analysis are shown in table 4.4. 
Factor df F Error P 
Time 5 49.118 20 < 0.001 
Drug 1 0.923 4 0.391 
Time x Drug 5 3.805 20 0.014 
Table 4.3 Results of two–way ANOVA with repeated measures on ipsilateral paw 
withdrawal thresholds following intrathecal ondansetron. 
As there was a time x drug interaction, further analysis was carried out on 
time points after intrathecal injection of ondansetron. Two-way ANOVA with 
repeated measures from 2h – 3h indicated that at these time points there 
was an overall effect of ondansetron treatment (p = 0.015). This indicates 
that intrathecal antagonism of the 5-HT₃ receptor in animals with 
established inflammation can transiently attenuate behavioural 
hypersensitivity (figure 4.4).  
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Figure 4.4 Attenuation of mechanical hypersensitivity by intrathecal ondansetron. 
All animals received ankle injection of CFA which caused a decrease in paw withdrawal 
thresholds from baseline at 24h. They were then divided into two groups, one receiving 
intrathecal injection of ondansetron (10µg/10µl) and the other saline (10µl). Ondansetron 
treatment increased paw withdrawal thresholds at 2h and 3h post injection compared to 
saline injected controls, * p < 0.05, two-way ANOVA with repeated measures. Data is 
presented as log2 (paw withdrawal threshold in g) and mean ± SEM, n = 3. At the 3h time 
point no error bars are shown as the three values in each group were the same. 
4.4  Discussion 
Joint inflammation results in hyperalgesia and allodynia and this is driven 
partly by peripheral sensitisation by inflammatory mediators, however 
central sensitisation of the spinal cord has also been shown to contribute 
(Neugebauer and Schaible, 1990) and (Naeini et al., 2005). Interestingly 
enhanced descending inhibition of spinal excitability has also been shown to 
occur at least in the acute phase of joint inflammation (Cervero et al., 1991; 
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Schaible et al., 1991), however the potential contribution of descending 
facilitation to pain associated with joint inflammation is relatively unknown. 
The role of 5-HT in models of pain is somewhat controversial, with some 
studies suggesting spinal 5-HT is anti-nociceptive and others describing a 
pronociceptive role. In this chapter the contribution of descending 5-HT 
fibres to behavioural hypersensitivity associated with CFA induced joint 
inflammation was investigated. It was found that 5-HT fibres play a small, 
time dependent role in the facilitation of joint pain behaviour. In a separate 
experiment it was shown that a single intrathecal injection of a 5-HT₃ 
receptor antagonist could transiently reverse mechanical hypersensitivity. 
4.4.1 Time dependent role of 5-HT fibres in secondary mechanical 
hyperalgesia following joint inflammation 
In studies of neuropathic pain it has been shown that descending 5-HT is 
required for the maintenance but not the induction of behavioural 
hypersensitivity (Rahman et al. 2006). In contrast our findings suggest that 
depletion of spinal 5-HT fibres attenuates mechanical hypersensitivity at 
days 1 and 2, but not days 3 – 7, after the induction of joint inflammation. 
One possible explanation is that the differences in the peripheral input 
generating hypersensitivity in these models leads to different patterns of 
activation of descending 5-HT neurons. In neuropathic pain, although 
mechanical hypersensitivity occurs within 24h, the peak behavioural 
response occurs days or weeks following the nerve injury (Decosterd and 
Woolf, 2000). In contrast following joint inflammation, peak mechanical 
hypersensitivity occurs within 6h, suggesting earlier activation of spinal and 
supraspinal neurons in this model. Therefore it seems likely that the 
different time course of 5-HT mediated facilitation observed in these models 
reflects the dynamics of peripheral input inducing the pain states. 
Interestingly the role of descending 5-HT fibres in the ankle joint model also 
differs from that described previously following plantar inflammation in 
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which it has been demonstrated that in animals with 5,7-DHT pre-treatment, 
mechanical hypersensitivity is attenuated almost immediately following 
plantar injection of CFA (Géranton et al., 2008). The slightly later onset of 5-
HT mediated facilitation in the present study may reflect subtle differences 
in the degree of peripheral inflammation and intensity of noxious input to 
the spinal cord. Peak mechanical hypersensitivity occurs at 6h following 
ankle injection of CFA, and the plantar model induces a more rapid decrease 
in paw withdrawal threshold. In addition the distribution of primary afferent 
terminals in the dorsal horn is different for cutaneous and joint nociceptors. 
Cutaneous fibres terminate in lamina I and II, while joint afferents terminate 
preferentially in lamina I (Doyle and Hunt, 1999; Neugebauer et al., 1994). 
These anatomical differences in the cutaneous and ankle models many 
explain the differences in behaviour observed following 5,7-DHT depletion. 
Selective chemical depletion of 5-HT neurons by administration of 5,7-DHT is 
a widely used technique in the investigation of 5-HT function within the CNS 
(Baumgarten and Lachenmayer, 2004). Previous studies have demonstrated 
that axonal degeneration following 5,7-DHT treatment begins as early as 3d 
post injection (Frankfurt and Azmitia, 1984; Wiklund and Björklund, 1980). 
This suggests that the absence of an effect of 5,7-DHT treatment on paw 
withdrawal thresholds at 6h and 24h post CFA was not due to inadequate 5-
HT depletion, as these time points correspond to 7d and 8d post 5,7-DHT 
treatment, at which time 5-HT axonal loss is optimal. In addition, although 
regeneration of 5-HT axons may occur after longer periods, this process does 
not begin until 14d post 5,7-DHT treatment and full restoration of 5-HT 
fibres takes many months (Wiklund and Björklund, 1980). Therefore the 
observation that paw withdrawal thresholds at 7d post CFA (corresponding 
to 13d post 5,7-DHT treatment) are unaffected by 5-HT fibre depletion is 
unlikely to be due to regeneration.  
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Immunohistochemistry using a 5-HT specific antibody allowed us to confirm 
this, indicating that 5-HT punctae are absent from the dorsal horn in rats at 
13d following 5,7-DHT treatment. One limitation to this is the high 
background staining observed using the 5-HT antibody. It has been 
demonstrated that immunohistochemistry for the 5-HT transporter (SERT), 
which localises to 5-HT containing axons, has an equivalent distribution to 
staining for 5-HT itself, and produces a stronger signal with less background 
labelling (Nielsen et al., 2006). SERT labelling may therefore be useful as an 
additional marker of 5-HT fibres in the dorsal horn for future studies, in 
particular for a quantitative analysis of the depletion. 
The time course of activation of the descending 5-HT system in ankle joint 
inflammation correlates with the pERK data presented in the previous 
chapter, in which activation of ERK in 5-HT producing RVM neurons was 
shown to occur at 6h but not at 3d or 7d following joint inflammation. 
Although the behavioural effect of 5,7-DHT lesion on paw withdrawal 
threshold is not significant at 6h following CFA treatment, activation of ERK 
at this time point may contribute to activation of the descending 5-HT 
pathway leading to subsequent behavioural facilitation at days 1 and 2. 
Indeed it has been demonstrated by others that injection of an ERK inhibitor 
to the RVM attenuates behavioural hypersensitivity at 24h post CFA. This 
attenuation does not occur at 7h, despite significant ERK activation at that 
time (Imbe et al., 2008). Our data supports this finding and suggests that 
although peripheral inflammation leads to molecular changes in the RVM 
within hours, the behavioural effects of those changes are not observed 
until later. 
The time-dependence of facilitation by spinal 5-HT fibres identified here 
does support the findings of a recent study which investigated the 
contribution of 5-HT to inflammatory pain by molecular silencing of the 
tryptophan hydroxylase enzyme (TPH), required for 5-HT synthesis, within 
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the RVM (Wei et al., 2010). This method results in inhibition of 5-HT 
synthesis within all 5-HT neurons within the RVM, and not only those 
projecting to the spinal cord. The similarities between their findings and the 
data presented in this chapter are striking. In the Wei et al. study the 
greatest attenuation of mechanical hypersensitivity was detected at day 1 
and day 3 following plantar inflammation, with only a small attenuation at 
earlier (6 hours) and later (5 days) time points. The magnitude of 
attenuation observed is larger than that identified here, but this may be due 
to the additional loss of 5-HT in locally terminating neurons of the RVM. 
Taken together these studies suggest a unique window of activation of the 
descending 5-HT system from 1 to 3 days after peripheral inflammation. 
4.4.2 No effect of 5,7-DHT depletion on primary hyperalgesia 
Paw withdrawal thresholds to mechanical stimuli using von Frey hairs reflect 
sensitivity to a punctate mechanical stimulus of the plantar surface adjacent 
to the inflamed ankle. As this measures pain hypersensitivity of a site 
removed from the initial inflammatory insult, this can generally be 
considered as a correlate of secondary hyperalgesia. Many studies of joint 
pain make use of additional outcome measures such as weight bearing 
asymmetry to reflect primary hyperalgesia of the joint itself (Sagar et al., 
2011; Thakur et al., 2012). In this study it was found that as expected, CFA 
injection produces a significant shift in weight bearing from the ipsilateral 
paw. Notably 5,7-DHT treatment had no effect on weight bearing at any 
time point. This suggests that although cutaneous mechanical 
hypersensitivity is reduced by 5,7-DHT lesion, there is no effect on the 
primary hyperalgesia of the joint itself. It has long been suggested that 
descending facilitation is required for secondary but not primary 
hyperalgesia (Urban et al., 1996). Our finding that weight bearing is 
unaffected by 5,7-DHT depletion adds to this evidence suggesting 
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differences in the descending modulation of primary and secondary 
hyperalgesia. 
4.4.3 The facilitatory effects of 5-HT are mediated via the 5-HT₃ receptor 
The 5-HT₃ receptor has been implicated in the facilitatory actions of 5-HT 
within the spinal cord in a variety of pain models (Bardin, 2011). It is a ligand 
gated ion channel, unlike the other members of the 5-HT receptor family 
which are all G-protein coupled. Its permeability to cations means that 
activation of this receptor on the intrinsic neurons of the spinal cord would 
have an excitatory effect (Millan, 2002). Expression of the 5-HT₃ receptor has 
also been reported on the primary afferent terminals of the dorsal horn 
(Maxwell et al., 2003) and so 5-HT₃ receptor activation may also lead to 
enhanced neurotransmitter release. The Maxwell et al. study investigated 
expression of the 5-HT₃ receptor within the L4 region of the spinal cord, 
which receives input from the ankle joint. Notably the majority of the 5-HT₃ 
receptor positive afferent terminals double labelled with CGRP, and 
relatively few expressed IB4. As the joints are innervated largely with 
peptidergic afferents and few IB4 positive afferents (Ivanavicius et al., 2004), 
it is likely that many of the CGRP+ joint afferent terminals in the dorsal horn 
will express 5-HT₃ receptor. At the peripheral terminal, it has been directly 
established that ankle joint afferents express the 5-HT₃ receptor and 
respond directly to 5-HT (Birrell et al., 1990). 
Intrathecal administration of 5-HT₃ specific antagonists has confirmed that 
this receptor plays a pro-nociceptive role in a number of pain models 
including the formalin test (Zeitz et al., 2002), spinal cord injury (Oatway et 
al., 2004), cancer induced bone pain (Donovan-Rodriguez et al., 2006), 
neuropathic pain (Dogrul et al., 2009) and plantar injection of CFA (LaGraize 
et al., 2010). The present finding that a single intrathecal injection of 
ondansetron transiently modifies secondary hyperalgesia following joint 
inflammation further supports the role of the 5-HT₃ receptor in descending 
Chapter 4 
117 
 
facilitation. Notably, the magnitude of attenuation was similar to that 
observed in the 5,7-DHT lesion experiment.  
 
Interestingly it has been demonstrated that cannabinoids are also capable of 
binding to the 5-HT₃ receptor, and have an inhibitory effect (Oz et al., 2002; 
Yang et al., 2010). Within the dorsal horn, endogenous cannabinoids have 
been shown to have an antinociceptive effect and so may act as a protective 
mechanism to counteract central sensitisation in chronic joint pain (Sagar et 
al., 2010). This protective mechanism may be mediated via inhibition of the 
5-HT₃ receptor. 
 
The facilitatory role of other 5-HT receptors cannot be ruled out however, 
and in particular the contribution of 5-HT1A and 5-HT2A may warrant further 
investigation as these have been implicated in facilitation of pain behaviour 
in neuropathic and inflammatory models (Aira et al., 2012; Zhang et al., 
2001). The 5-HT2A receptor may be of particular interest in the modulation 
of spinal cord excitability, as it has been shown to form heterodimers with 
the mGluR2 receptor, suggesting activation of this 5-HT receptor subtype 
may enhance glutamatergic signalling (González-Maeso et al., 2008). 
 
4.4.4 Modest effects of 5,7-DHT depletion: possible inhibitory effects of 
5-HT 
The modest and short lived magnitude of attenuation in hypersensitivity 
identified here may be due to the complexity of the role of 5-HT within the 
spinal cord. Considerable evidence exists to suggest that both inhibitory and 
facilitatory roles for 5-HT can occur within the spinal cord and that this is 
likely to be due to the activation of different receptor subtypes (Millan, 
2002; Wei et al., 2010). Electrophysiological studies of joint inflammatory 
pain models have suggested that in the acute phase of inflammation there is 
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an increase in descending inhibition from the RVM (Cervero et al., 1991; 
Schaible et al., 1991). Therefore in addition to an increased facilitatory drive 
mediated by the 5-HT₃ receptor, there may be a parallel increase in 
inhibition at other receptor subtypes. The 5-HT₇ receptor has been shown to 
contribute to descending inhibition in neuropathic pain (Brenchat et al., 
2010; Dogrul et al., 2009) and so may also be involved in the present model. 
Lesion of spinal 5-HT fibres would therefore include both of these aspects, 
and so these would ‘cancel out’ one another at the behavioural level in the 
animal. The window of attenuation observed at 1 and 2 days could reflect 
the period at which the pro-nociceptive influence of 5-HT predominates in 
this model. With this in mind it seems unlikely that loss of spinal 5-HT fibres 
would completely reverse behavioural hypersensitivity. The behavioural 
findings following 5,7-DHT depletion reflect the net effect of depletion of 5-
HT fibres within the spinal cord, which incorporates both inhibitory and 
facilitatory influences. 
The modest effects of 5,7-DHT depletion and 5-HT₃ receptor antagonism 
observed in this model may also be due to the reliance on paw withdrawal 
thresholds as our primary outcome measure. This method reflects evoked 
cutaneous hypersensitivity and does not reflect other features of joint pain 
such as spontaneous and movement-evoked pain (Mogil, 2009). Combining 
lesion of the descending 5-HT pathway with other measures to address 
these aspects may be of interest for future studies. For example measures 
such as burrowing behaviour (Andrews et al., 2011) and hind limb grip force 
(Chandran et al., 2009; Lee et al., 2011b) have been used effectively in 
models of neuropathic and osteoarthritic pain. These measures may also 
prove useful in understanding the contribution of descending facilitation to 
inflammatory joint pain. 
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4.4.5 Conclusion 
The aim of this chapter was to determine if the descending 5-HT system 
contributes to pain behaviour following joint inflammation. A time-
dependent role for descending 5-HT fibres in mechanical hypersensitivity in 
this pain model was identified, and this effect is mediated by the 5-HT₃ 
receptor. 
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5. The role of mu opioid receptor expressing RVM 
neurons in inflammatory joint pain 
5.1  Introduction 
The previous chapters have shown that the RVM is activated following joint 
inflammation, and that the descending 5-HT pathway arising in this region 
contributes in a time dependent manner to the associated mechanical 
hypersensitivity. However many of the electrophysiologically defined ON 
cells of the RVM do not contain 5-HT (Potrebic et al., 1994) suggesting that 
other facilitatory pathways are also in place. It has been shown previously 
that the mu opioid receptor (MOR+) expressing population plays a crucial 
role in the maintenance but not the initiation of neuropathic pain states 
(Bee and Dickenson, 2008; Burgess et al., 2002; Porreca et al., 2001). This 
chapter describes behavioural experiments carried out to investigate the 
role of MOR+ neurons in mediating behavioural hypersensitivity associated 
joint inflammation. 
5.1.1 Role of mu opioid receptor expressing neurons in nociception 
RVM neurons can be defined by their electrophysiological properties prior to 
a nociceptive reflex. OFF cells show a decrease in firing before the tail flick 
reflex, while ON cells show an increase in firing and NEUTRAL cells do not 
change their firing properties (Fields and Heinricher, 1985; Fields et al., 
1983). These cell types can only be characterised in the lightly anaesthetised 
animal, by application of an acute noxious stimulus, and are not 
anatomically separated within the RVM. Nonetheless this classification 
system provides a physiological correlate for the bidirectional modulation of 
pain states by the RVM. ON cells are the only population which respond 
directly to morphine, resulting in decreased excitability (Heinricher et al., 
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1994; Marinelli et al., 2002). This suggests that only ON cells express the mu 
opioid receptor (MOR).  
MOR expressing (MOR+) cells have a pro-nociceptive role, as inhibition by 
MOR activation leads to reduced nociceptive responses (Heinricher and 
Kaplan, 1991; Heinricher et al., 1994; Marinelli et al., 2002). In contrast OFF 
cells are indirectly activated by MOR agonists, and this is thought to occur 
via inhibition of  MOR+ GABAergic interneurons, which inhibit OFF cells 
(Heinricher et al., 1992). In addition to these MOR+ interneurons, some ON 
cells project directly to the spinal cord (Fields et al., 1995). This indicates 
that there are two ways by which MOR agonists may exert an 
antinociceptive role within the RVM. One proposed mechanism is that 
MOR+ neurons act indirectly by disinhibiting spinally projecting inhibitory 
neurons (Heinricher, Morgan, and Fields 1992; Heinricher et al. 1994; Fields 
and Heinricher 1985). The other is that some MOR+ neurons are excitatory 
and project directly to the spinal cord to enhance pain (Marinelli et al., 
2002). Anatomical studies have demonstrated that a proportion of 5-HT 
(Marinelli et al. 2002), and GABA (Kalyuzhny and Wessendorf 1998) 
expressing RVM neurons also express the MOR. Therefore it is clear that 
MOR+ RVM neurons are a mixed population, which contain a number of 
transmitters, and may be either spinally projecting or non-projecting 
(Marinelli et al. 2002). The net effect of MOR agonism within the RVM is to 
reduce nociception, directly by decreasing the excitability of pro-nociceptive 
projection neurons and indirectly by disinhibition of anti-nociceptive 
projection neurons (figure 5.1). 
Regardless of the precise nature of MOR mediated analgesia, it is likely that 
MOR+ cells are facilitatory in the context of persistent pain. A number of 
studies have demonstrated that in models of neuropathic (Carlson et al., 
2007; Gonçalves et al., 2007) and visceral pain (Sanoja et al., 2010) ON cells 
show an increase in spontaneous firing.  
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Figure 5.1 Cell types within the RVM. 
ON cells are directly inhibited by morphine microinjection to the RVM (Heinricher et al., 
1994) suggesting they express the mu opioid receptor (MOR+). OFF cells are not directly 
modulated by morphine as they do not express the MOR. 1). Some ON cells are locally 
projecting GABAergic interneurons, which inhibit OFF cell firing (Kaplan and Fields, 1991). 
2). Other MOR+ cells express 5-HT, and many of these project to the dorsal horn (Marinelli 
et al., 2002). Some spinally projecting MOR+ cells also express GABA (Kalyuzhyny and 
Wessendorf, 1998). The ‘?’ represents non-5-HT, non-GABAergic neurons. 3). OFF cells are 
MOR-, and these may project directly to the spinal cord and may also contain 5-HT and 
GABA. GABA and glycine are co-expressed in dorsal horn projection neurons (Hossaini et al., 
2012). These OFF cells may be inhibited by morphine indirectly via MOR expressing 
GABAergic interneurons. Non projecting 5-HT neurons, both MOR+ and MOR-, may also be 
found in the region, however for simplicity these are not illustrated here.  
5.1.2 Saporin-conjugates as selective neurotoxins 
The facilitatory role of MOR+ RVM neurons has been investigated previously 
using a selective targeted toxin delivered to the region. Saporin is a 
ribosomal inactivating protein which is derived from the plant Saponaria 
officinalis. Upon cell internalisation saporin inhibits protein synthesis and 
leads to cell death. Alone the saporin peptide cannot be endocytosed. 
However conjugation to a peptide which can be internalised, such as an 
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antibody or receptor agonist, allows for internalisation. By choosing peptides 
that can only be recognised by specific cell types this allows for selective 
internalisation (Wiley, 1992). Saporin conjugates have proved useful in a 
number of neurobiological studies by allowing the selective lesion of specific 
neuronal populations. This lesion technique was first described for NGF 
receptor expressing neurons of the cholinergic basal forebrain (Wiley et al., 
1991). Since then a number of different saporin conjugates have been used 
to lesion specific cell populations of the nervous system. For example NK1 
receptor expressing neurons can be targeted by use of substance P-saporin 
conjugate  (Nichols et al., 1999). This technique allowed for a better 
understanding of the role of the NK1 receptor positive neurons of the dorsal 
horn in various models of pain. 
5.1.3 Previous studies of pain using dermorphin-saporin 
More recently the conjugate dermorphin-saporin has been used to elucidate 
the role of MOR+ RVM neurons in persistent pain states. In contrast to 
traditional lesion techniques which are non-selective, dermorphin-saporin 
microinjection allows for the selective lesion of a subpopulation of pro-
nociceptive cells. Dermorphin-saporin has been used extensively to address 
the role of the RVM in neuropathic pain models, in which MOR+ neurons are 
required for the maintenance but not the induction of hypersensitivity 
(Burgess et al., 2002; Porreca et al., 2001). Similarly in a model of 
pancreatitis, a model of visceral pain, dermorphin-saporin lesion attenuates 
the maintenance phase of the pain state (Vera-Portocarrero et al., 2006).  
Furthermore studies using the conjugate CCK-saporin have shown that 
cholecystokinin receptor expressing RVM neurons are also required for 
maintenance of neuropathic pain (Zhang et al., 2009). Interestingly this 
population overlaps with the MOR+ population, adding further to the 
evidence that these neurons are facilitatory in nature and therefore may 
correspond to the electrophysiologically defined ON cell population. 
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Depletion of MOR+ RVM cells has also been used to demonstrate that these 
neurons contribute to increased neuronal excitability in the dorsal horn (Bee 
and Dickenson, 2008), as well as being required for  enhanced evoked 
neurotransmitter release from primary afferent fibres (Gardell et al., 2003). 
These studies demonstrate an important contribution of the MOR+ cell 
descending pathway in a number of pain models.   
5.1.4 Hypothesis 
In this chapter I have tested the hypothesis that descending facilitation via 
MOR+ neurons of the RVM contributes to mechanical hypersensitivity 
associated with joint inflammation. 
5.2  Methods 
5.2.1 Dermorphin-saporin and microinjection to RVM 
Bilateral microinjection to the RVM was carried out as described in section 
2.1.2. Dermorphin-saporin was obtained from Advanced Targeting Systems. 
This was prepared in sterile saline to generate final injection volumes of 
0.5μl for each side of the RVM. A dose of 3pmole dermorphin-saporin 
(1.5pmole per side) was used in our initial studies, based on previous work 
by others (Bee and Dickenson, 2008; Burgess et al., 2002; Porreca et al., 
2001; Zhang et al., 2009).  
The molecular weight of dermorphin-saporin is 32kDA and is purchased in 
solution, at a concentration of 1.4μg/μl. The number of moles per μl of 
purchased stock solution was calculated from the following: 
Weight (g) = no. moles x MW (kDa) x 10³ 
1.4μg = no. moles x 32kDA x 10³ 
no. moles = 43.73pmole per 1μl of stock solution 
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The total injection volume used was 1μl (0.5μl each side) and dermorphin-
saporin was made up to contain 3pmole (96ng) dermorphin-saporin in total. 
This corresponds to a final molarity of 3μM.  
As adverse effects were observed at this dose (see below, section 5.3.1), it 
was decided to use two lower doses, of 1.5μM (containing 1.5pmole/48ng) 
and 0.75μM (containing 0.75pmole/24ng). 
5.2.2 Inflammatory pain model and behavioural testing 
Animals received ankle injection of CFA or underwent a sham procedure at 
28-35 days post RVM injection. Paw withdrawal thresholds were measured 
and log2 transformation was carried out to normalise the data (see section 
2.2). Statistical analysis was carried out in SPSS. Analysis of variance 
(ANOVA) with repeated measures was carried out with time as the within 
subjects factor, and CFA and dermorphin-saporin treatment as the between 
subjects factors. A significant main effect of CFA was a prerequisite for 
subsequent ANOVAs or post-hoc analysis. 
5.2.3 MOR immunohistochemistry 
To determine the accuracy of injection sites and extent of MOR+ cell 
depletion within the RVM dermorphin-saporin treated and control animals 
were perfused and immunohistochemistry carried out as described in 
section 2.4. For each animal a set of 40µm sections representing the RVM 
region, with all sections at least 240µm apart were used for MOR 
immunohistochemistry. Staining was carried out using a MOR specific 
antibody (1:10,000, rabbit, Neuromics) and tyramide signal amplification 
(see section 2.4.3). Counterstaining with NeuN (1:1000, mouse, Cell 
Signalling) was used to detect all neurons. Imaging was carried out using a 
fluorescence microscope (see section 2.4.5). MOR+ cells were counted 
manually, while blind to the treatment group of the animal. The RVM was 
defined as the regions containing the NRM and GiA at approximately -10.3 
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to -11.3 mm from Bregma. The anatomical boundaries used to define the 
region were the presence of the facial nuclei and pyramidal tracts. Sections 
were deemed caudal of the RVM if the nucleus ambiguus was present. The 
number of MOR+ cell bodies per section was counted and recorded. The five 
highest scoring sections per animal were used as representative of the RVM 
region. The total number of MOR+ cells across the five sections was 
calculated and the data is presented as the mean ± SEM per group. 
Representative images were acquired using a Hamamatsu digital camera and 
Openlab 4.0.4 software from Improvision. In some cases, confocal imaging 
was carried out using a laser scanning Leica TCS NT SP microscope.  
5.2.4 Localisation of needle tracts 
At the end of the final experiment which involved injection of 1.5pmole 
dermorphin-saporin (experiment 3, see below section 5.3.3) animals were 
culled by CO₂ asphyxiation to allow fresh tissue dissection for RNA 
extraction, brains were removed fresh and post fixed for 2 days in 4% PFA. 
Sectioning was carried out as for immunohistochemistry and sections were 
incubated briefly with DAPI (4',6-diamidino-2-phenylindole, 1:10,000 in 
0.1M PB for 10mins). DAPI labelling was used to visualise the outline of the 
needle tracts for each animal. Using the rat brain atlas (George Paxinos, 
1998) the approximate anterior-posterior, dorsal-ventral and lateral 
coordinates were noted for each animal. 
5.3  Results 
5.3.1 Experiment 1: Dermorphin-saporin (3pmole) microinjection to the 
RVM attenuates inflammatory pain 
Animals underwent RVM microinjection of either dermorphin-saporin 
(1.5pmole each side) or saline and allowed to recover for 28-35 days. 
Baseline mechanical paw withdrawal thresholds were taken each day for 
three days prior to CFA injection. The saline injected animals were divided 
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into two groups, one receiving CFA injection to the ankle and the other a 
sham procedure (n = 8 in CFA groups, n = 4 in sham group). All dermorphin-
saporin treated animals received CFA injection. A three-way analysis of 
variance (ANOVA) with repeated measures was carried out to determine if 
CFA and dermorphin-saporin treatment had significant effects on paw 
withdrawal threshold. Time was the within-subject factor and dermorphin-
saporin treatment and CFA were the between-subjects factors. The tests of 
within-subjects effects indicated there was a significant effect of time (p < 
0.001), a time x dermorphin-saporin interaction (p < 0.001) and a time x CFA 
interaction (p < 0.001). The between-subjects analysis indicated there was 
an overall effect of dermorphin-saporin (p = 0.024) and CFA (p = 0.001). See 
table 5.1 for a summary of this analysis. 
Factor df F Error P 
Time 10 11.4 170 < 0.001 
CFA 1 17 14.8 0.001 
Dermorphin-saporin 1 17 6.2 0.024 
Time x CFA 10 6.9 170 <0.001 
Time x Dermorphin-saporin 10 4.3 170 <0.001 
Table 5.1 Results of three-way ANOVA with repeated measures on ipsilateral paw 
withdrawal thresholds following 3pmole dermorphin-saporin. 
As there were main effects of both dermorphin-saporin and CFA, a 
subsequent two-way ANOVA with repeated measures was carried out on the 
two CFA injected groups, to determine if there was an overall effect of 
dermorphin-saporin from 2h to 7d post CFA injection (table 5.2). It was 
found that there was an overall effect of dermorphin-saporin on paw 
withdrawal thresholds (p = 0.023) from 2h to 7d following CFA injection 
(figure 5.2a).  
Factor df F Error P 
Time 7 9.3 98 0.0001 
Dermorphin-saporin 1 6.479 14 0.023 
Time x Dermorphin-saporin 7 2.6 98 0.018 
Table 5.2 Results of two-way ANOVA with repeated measures on ipsilateral paw withdrawal 
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thresholds form 2h – 7d post CFA following 3pmole dermorphin-saporin. 
 
Figure 5.2 Attenuation of mechanical hypersensitivity by 3pmole dermorphin-saporin. 
A). Attenuation of mechanical hypersensitivity in dermorphin-saporin (DS, 3pmole in total, 
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1.5pmole each side) microinjected rats following ankle joint inflammation by CFA injection.  
Ipsilateral paw withdrawal thresholds were significantly higher in the dermorphin-saporin group 
compared with saline injected controls. * p = 0.023, overall effect of dermorphin-saporin pre-
treatment from 2h to 7d following ankle injection of CFA, two-way ANOVA with repeated 
measures. B). Paw withdrawal thresholds of the contralateral hindpaw were not altered by CFA 
injection or by dermorphin-saporin pre-treatment, p > 0.05, three-way ANOVA with repeated 
measures. Data is presented as log2 (paw withdrawal threshold in g) and mean ± SEM, n = 8 in CFA 
groups, n = 4 in saline + sham group. 
On the contralateral paw, the within-subjects effects indicated that there a 
main effect of time (p = 0.011), but not of CFA or dermorphin-saporin (p > 
0.05). As there was no main effects of CFA or dermorphin-saporin no further 
analysis was carried out. This indicates contralateral paw withdrawal 
thresholds were unaffected by either dermorphin-saporin pre-treatment or 
CFA injection (figure 5.2b).  
To confirm the efficacy of dermorphin-saporin in ablating MOR+ RVM 
neurons, MOR immunohistochemistry was carried out at the end of the 
experiment in a subset of animals (n = 4 – 5, CFA treated groups only). 
Sample immunohistochemistry from animals treated with this dose of 
dermorphin-saporin compared with saline controls is shown (figure 5.3c). 
Cell counts indicated there was a significant decrease in MOR+ neurons with 
197 ± 17.61 in saline compared with 131.4 ± 9.56 in the dermorphin-saporin 
treated group at this dose (3pmole in total, 1.5pmole each side)  
(independent samples t-test, p = 0.0145, figure 5.3d). The approximate area 
used for cell counts is outlined (figure 5.3a) and corresponds to 
approximately 1.56mm² per section. Notably the distribution of MOR+ cells 
identified by immunohistochemistry here is similar to that of a recent 
report, which studied MOR+ cell distribution in the RVM by microinjection of 
dermorphin conjugated to the fluorophore Alexa 594 (Phillips et al., 2012).  
 
Figure 5.3  Decrease in MOR+ cell numbers by 3pmole dermorphin-saporin. 
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A). The area used for cell counting is outlined by the red triangle, with each section 
corresponding to approximately 1.56mm². Image adapted from the rat brain atlas (George 
Paxinos, 1998) B). The image in B is from Phillips et al., 2012, and illustrates the distribution 
of MOR expressing neurons within the RVM, based on labelling by microinjection of 
dermorphin conjugated to Alexa 594.  C). Representative images illustrate MOR+ expression 
in a saline injected animal, illustrating that MOR immunohistochemistry identified a 
population of neurons similar to that in Phillips et al., 2012. Depletion of MOR+ cells can be 
observed in the bilaterally injected dermorphin-saporin (DS, 3pmole/96ng) animal. Scale bar 
indicates 200µm. D). Cell counts indicate a significant decrease in MOR+ cell number within 
the RVM of dermorphin-saporin animals. Cell counts were calculated as the sum of the top 
five sections per animal, and data is shown here as mean ± SEM per group.  n = 5 in 
dermorphin-saporin group, n = 4 saline, * p  =  0.0145 independent samples t-test. 
A decrease in MOR mRNA expressing neurons within the RVM and 
attenuation of neuropathic pain behaviour had been shown previously using 
this dose of dermorphin-saporin (Bee and Dickenson, 2008; Burgess et al., 
2002; Porreca et al., 2001). However in our study adverse effects were 
observed in a number of dermorphin-saporin treated animals. These effects 
included weight loss, motor impairment, and ataxia. These effects became 
noticeable at approximately 2 weeks following microinjection to the RVM. 
Of the 16 animals injected with dermorphin-saporin, 8 were culled due to 
these adverse effects. We attributed these effects to non-specific loss of 
neurons in the RVM and surrounding regions, as there was some evidence of 
necrosis at the sites of injection. For this reason we aimed to determine if 
lower doses of dermorphin-saporin could lead to attenuation of behavioural 
hypersensitivity without these adverse effects. 
5.3.2 Experiment 2: Dose dependent effects of dermorphin-saporin 
A pilot experiment was carried out to determine if lower doses of 
dermorphin-saporin would attenuate pain behaviour and decrease MOR+ 
neuron numbers in the RVM without adverse effects. Animals were injected 
with saline, 1.5pmole (0.75pmole each side) or 0.75pmole (0.375pmole each 
side) dermorphin-saporin and allowed to recover for 28 days. No adverse 
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effects were observed in either of the dermorphin-saporin groups (n = 3 – 
4). Baseline mechanical paw withdrawal thresholds were measured each day 
for three days prior to CFA injection, and up to 7 days later. A two-way 
ANOVA with repeated measures was carried out to compare the ipsilateral 
paw withdrawal thresholds across these doses compared to saline 
microinjected animals, with time as the within-subjects factor and dose 
(1.5pmole, 0.75pmole or saline) as the between-subjects factor. The within-
subjects effects indicated a significant effect of time (p < 0.001) and a 
significant time x dose interaction (p = 0.015). The between-subjects effects 
indicated an overall effect of dose (p = 0.007). The results of this analysis are 
shown in table 5.3. As there was a significant effect of dose and a dose x 
time interaction, one-way ANOVAs at each time point were subsequently 
carried out to identify the source of variation. LSD post hoc analysis 
indicated there was a significant difference in paw withdrawal thresholds at 
all time points post CFA between the 1.5pmole dose and saline groups (p = 
0.004) and between the 0.75pmole dose and saline groups (p = 0.005). 
There was no difference between 1.5pmole and 0.75pmole groups (p = 
0.649). This suggested that lower doses of dermorphin-saporin could be 
used to attenuate behavioural hypersensitivity (figure 5.4a). 
 df F Error p 
Time 12 80.5 84 0.000 
Dose 2 10.89 7 0.007 
Time x dose 24 80.5 1.9 0.015 
Table 5.3 Results of two-way ANOVA with repeated measures on ipsilateral paw 
withdrawal thresholds following 1.5pmole or 0.75pmole dermorphin-saporin. 
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Figure 5.4 Attenuation of mechanical hypersensitivity and depletion of MOR+ cells by 
1.5pmole and 0.75pmole dermorphin-saporin. 
A). Attenuation of mechanical hypersensitivity of the ipsilateral hindpaw in dermorphin-
saporin (1.5pmole in total, 0.75pmole each side) pre-treated rats following ankle joint 
inflammation. Both the 1.5pmole and 0.75pmole doses of dermorphin-saporin significantly 
attenuated paw withdrawal threshold from 2h – 7d post CFA injection. * indicates p = 0.004 
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for the 1.5pmole v saline comparison, and p = 0.005 for the 0.75pmole v saline comparison, 
two-way ANOVA with repeated measures and LSD post hoc test. Data is presented as log2 
(paw withdrawal threshold in g) and mean ± SEM, n = 3 – 4. B). Representative confocal 
images of MOR immunohistochemistry in the 1.5pmole dermorphin-saporin group and 
saline control. Double labelling with NeuN indicated that although many MOR+ neurons are 
depleted at this dose, some surviving MOR- neurons remain in the region. Scale bars 
indicate 25μm. 
Single plane confocal images taken from animals with and without 
dermorphin-saporin (1.5pmole dose) indicated that although this dose 
results in depletion of MOR+ neurons as expected, there are some NeuN 
positive cells remaining (figure 5.4b). This suggests that at this dose 
dermorphin-saporin is selectively toxic to MOR+ neurons. MOR+ cell counts 
were carried out at both doses as before. A decrease in MOR+ cell numbers 
in the 1.5pmole group (155 ± 4) was found when compared with saline 
control (208.7 ± 14.2) (one-way ANOVA with LSD post hoc test, p = 0.009, 
1.5pmole v saline, see figure 5.5a). The decrease in cell numbers in the 
0.75pmole treated group was not significant (188.75 ± 4.5, p = 0.124).  
Plotting the number of MOR+ cells against paw withdrawal thresholds per 
animal in each of the three groups (figure 5.5b, illustrated for the 6h, d1, d2 
and d7 time points) indicated that there was a significant correlation 
between cell number and paw withdrawal threshold at the 6h (R² = 0.4643 
and p = 0.003),  1d (R² = 0.7548 and p = 0.0011),  2d (R² = 0.7337 and p = 
0.016) and 7d (R² =0.416 and p=0.042) time points using the Pearson 
correlation. At other time points no significant correlation was found 
between MOR+ cell number and paw withdrawal threshold (table 5.4). 
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Time point p R² 
2H 0.151 0.2354 
6H 0.003 0.4643 
D1 0.0011 0.7548 
D2 0.0016 0.7337 
D3 0.2136 0.1786 
D4 0.3224 0.1221 
D5 0.4564 0.07110 
D6 0.02948 0.6353 
D7 0.0452 0.416 
Table 5.4 Results of Pearson correlation analysis of number of MOR+ cells and ipsilateral 
paw withdrawal thresholds for individual animals following dermorphin-saporin. 
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Figure 5.5 Dose dependent decrease in MOR+ cell number by dermorphin-saporin. 
A). Cell counts indicate a significant decrease in MOR+ cell number in animals treated with 
1.5pmole dermorphin-saporin (DS) but not 0.75pmole dermorphin-saporin. Cell counts 
were calculated as the sum of the top five sections per animal, and data shown here as 
mean ± SEM per group. n = 3 – 4, one-way ANOA with LSD post hoc test, * p  =  0.009. B). 
Plot of paw withdrawal thresholds presented as log2 (paw withdrawal threshold in g), and 
number of MOR+ cells per animal at 6h, 1d, 2d and 7d  following ankle injection of CFA. 
Green dots represent saline treated animals, blue dots represent 0.75pmole treated animals 
and red dots represent 1.5pmole treated animals. p < 0.05, Pearson correlation.  
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5.3.3 Experiment 3: Attenuation of behavioural hypersensitivity from 1 – 
7d post CFA injection by microinjection of 1.5pmole 
dermorphin-saporin 
In all further experiments the 1.5pmole dose (0.75pmole each size) was 
used. A complete, fully blind experiment was carried out with 4 groups of 
animals: dermorphin-saporin + CFA, saline + CFA, dermorphin-saporin + 
sham and saline + sham (figure 5.6). Three-way ANOVA with repeated 
measures was used to analyse the ipsilateral paw withdrawal thresholds. 
The within-subjects effects indicated a significant effect of time, time x CFA 
interaction and  time x dermorphin-saporin x CFA interaction, but no time x 
dermorphin-saporin interaction (p = 0.625). The between-subjects tests 
indicated a significant effect of CFA (p < 0.001) but not of dermorphin-
saporin (p = 0.15) or dermorphin-saporin x CFA interaction (p = 0.534). The 
tests of within-subjects effects indicated there was a significant effect of 
time (p < 0.001), a time x CFA interaction (p < 0.001) but no time x 
dermorphin-saporin interaction. The between-subjects analysis indicated 
there was no overall effect of dermorphin-saporin but there was an overall 
effect of CFA (p < 0.001). Table 5.5 is a summary of this analysis. 
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Factor df F Error P 
Time 15 46 375 0.001 
CFA 1 164 25 0.000 
Dermorphin-saporin 1 2.21 25 0.15 
CFA x  Dermorphin-saporin 1 0.397 25 0.534 
Time x CFA 15 44.2 375 0.001 
Time x Dermorphin-saporin 15 0.847 375 0.625 
Time x CFA x Dermorphin-
saporin 
15 2.416 375 0.002 
Table 5.5 Results of three-way ANOVA with repeated measures on ipsilateral paw 
withdrawal thresholds following 1.5pmole dermorphin-saporin. 
A subsequent two-way ANOVA with repeated measures was carried out on 
the two CFA treated groups, from 1d to 7d  post CFA,  and it was found that 
there was an overall main effect of dermorphin-saporin treatment on paw 
withdrawal thresholds from 1 to 7d post CFA injection (p = 0.018). Table 5.6 
lists the results of this analysis. This indicates that dermorphin-saporin pre-
treatment leads to attenuation of mechanical hypersensitivity from 1 to 7 
days post CFA injection (figure 5.6a). 
Factor df F Error p 
Time 1 3.7 14 0.075 
Dermorphin-saporin 1 7.161 14 0.018 
Time x dermorphin-saporin 1 7.326 14 0.017 
Table 5.6 Results of two-way ANOVA with repeated measures on ipsilateral paw 
withdrawal thresholds from 1 – 7 d post CFA following 1.5pmole dermorphin-saporin. 
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Figure 5.6 Attenuation of mechanical hypersensitivity by  1.5pmole dermorphin-saporin. 
A). Attenuation of mechanical hypersensitivity of the ipsilateral hindpaw in dermorphin-
saporin (DS, 1.5pmole in total, 0.75pmole each side) pretreated rats following ankle joint 
inflammation. Paw withdrawal thresholds were significantly higher in the dermorphin-
saporin group than in saline injected controls from 1 to 7d post CFA injection * p = 0.018, 
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dermorphin-saporin CFA v saline CFA, two-way ANOVA with repeated measures. There was 
no effect of pre-treatment on baseline paw withdrawal thresholds. B). Paw withdrawal 
thresholds of the contralateral hindpaw were not altered by CFA injection or by 
dermorphin-saporin pre-treatment, p > 0.05, three-way ANOVA with repeated measures. 
Data is presented as log2 (paw withdrawal threshold in g) and mean ± SEM, n = 8 in CFA 
groups, n = 6 /7 in sham groups. 
 
The contralateral paw withdrawal thresholds were analysed in the same way 
using a three-way ANOVA with repeated measures but no main effects of 
time, CFA or dermorphin-saporin were found. The results of this analysis are 
given in table 5.7. This indicates neither CFA nor dermorphin-saporin 
treatment affected contralateral paw withdrawal thresholds (figure 5.6b). 
Factor df F Error P 
Time 14 1.273 350 0.222 
Dermorphin-saporin 1 25 2677.524 0.897 
CFA 1 0.467 25 0.349 
Time x Dermorphin-saporin 14 0.647 350 0.825 
Time x CFA 14 1.063 350 0.391 
Time x Dermorphin-saporin x 
CFA 14 0.76 350 0.712 
Table 5.7  Results of three-way ANOVA with repeated measures on contralateral paw 
withdrawal thresholds following 1.5pmole dermorphin-saporin. 
 
At the end of the experiment, animals were culled by CO₂ asphyxiation and 
the dorsal quadrants of the lumbar spinal cord were dissected and frozen 
rapidly at -80ºC for later experiments (see chapter 6). The brains of these 
animals were also removed fresh and immersion fixed for 48h in 4% PFA. All 
brains were sectioned and stained using DAPI to identify the needle tracts. 
The approximate anterior-posterior, dorsal-ventral and lateral coordinates 
for the visible needle tracts were noted for all the animals from this 
experiment (table 5.8) and the approximate locations are illustrated for 
those in the CFA groups are shown (figure 5.7). The needle tracts of two 
animals from the saline-CFA group could not be identified, but for all other 
animals it was found that at least one of the bilateral injections was within 
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or close to the dorsal-ventral boundary of the RVM. Similarly the anterior-
posterior coordinates were satisfactory for all animals (within the region of -
10.5mm to -11.8mm from Bregma). Although those at -11.6mm and -
11.8mm could be deemed caudal, the spread of the toxin is likely to be 
sufficient to ensure considerable depletion in the target area. For example in 
experiment 1, depletion of neurons was noted as far rostral as -10mm and 
as far caudal as -12.3mm from Bregma. The lateral coordinates were 
somewhat variable but bilateral injection would be expected to produce a 
sufficient distribution throughout the RVM. 
 
Figure 5.7 Confirmation of bilateral microinjection sites of animals used in experiment 3.  
Only animals from the dermorpin-saporin + CFA group (dots labelled DS) and saline + CFA 
group (dots labelled saline) are shown. The numbers indicate the approximate anterior-
posterior distance from Bregma in mm. 
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Group Animal AP  Right  Left  DV 
Saline + CFA 1 11 0.8 0.8 9.2 
 15 10.52 1 0.8 8.5 
 19 11 0.4 0.4 8 
 29 x x X X 
 39 x x X X 
 47 10.52 0.6 0.4 10 
 49 10.52 0.3 0.9 10 
 59 10.52 0.8 0.4 8.5 
      
DS + CFA 3 11.8 0.6 0.8 9 
 13 11 0.9 0.8 8.2 
 21 10.8 0.6 0.5 8.8 
 31 10.8 1 0.5 9.5 
 35 10.8 0.5 0.6 9.5 
 37 10.52 0.5 0.5 10 
 45 11.6 1.2 0.4 9.5 
 53 10.8 0.5 0.5 9.5 
      
Saline + Sham 7 11 0.8 0.6 9 
 9 10.8 0.8 0.6 8.7 
 17 11.6 0.8 0.7 9.2 
 25 10.52 0.8 0.6 9 
 41 10.8 1 0 8 
 51 10.52 0.4 0.4 10 
      
DS + Sham 5 10.8 0.8 0.8 10 
 11 11 0.8 0.4 9.5 
 23 11.3 0.6 0.6 9.5 
 27 10.8 0.4 0.4 9.5 
 33 11 0.6 0.6 9.5 
 55 10.3 0.5 0.8 10 
 57 10.52 0.9 0.3 9 
 
 
Table 5.8 Bilateral microinjection sites for all animals in experiment 3. 
DS = dermorphin-saporin, AP = anterior-posterior (from Bregma), DV = dorsal-ventral (from top of brain 
surface), and right and left indicate lateral values are from the midline. Values are in mm. 
5.4  Discussion 
The selective neurotoxin dermorphin-saporin has been used in a number of 
studies to demonstrate a role for MOR+ neurons of the RVM in the 
maintenance phase of neuropathic pain behaviour (Bee and Dickenson, 
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2008; Burgess et al., 2002; Porreca et al., 2001; Zhang et al., 2009). As 
discussed in chapter 4, considerable evidence suggests a role for spinal 5-HT 
in the descending facilitation of cutaneous inflammatory pain (Géranton et 
al., 2008; LaGraize et al., 2010) and dorsal horn excitability in the MIA model 
of osteoarthritis (Rahman et al., 2009). Although it is known that some of 
the MOR+ neurons contain 5-HT (Marinelli et al., 2002; Wang and 
Wessendorf, 1999) to date the specific role of MOR+ neurons has not been 
studied in inflammatory joint pain. Using dermorphin-saporin lesion of the 
RVM we have demonstrated a role for these cells in the facilitation of 
inflammatory joint pain behaviour, suggesting that the 5-HT and MOR+ 
neurons of the RVM serve as partially overlapping but synergistic pathways 
in joint inflammation.  
5.4.1 Dermorphin-saporin treatment: investigation of doses and side 
effects 
The first experiment described in this chapter involved the use of 3pmole 
dermorphin-saporin injected into the RVM to ablate the MOR+ population of 
neurons within the region. This dose has been described previously in the 
literature, by a number of groups and in various pain models (Bee and 
Dickenson, 2008; Burgess et al., 2002; Vera-Portocarrero et al., 2006). These 
studies demonstrated that in neuropathic and pancreatitis-induced pain 
dermorphin-saporin pre-treatment attenuated the maintenance of 
behavioural hypersensitivity to mechanical stimuli but had no effect on the 
initial phase of the pain state. This chapter describes a similar experiment 
which found that this dose is also effective in attenuating inflammatory joint 
pain. Compared with behavioural studies of neuropathy and pancreatitis, 
the magnitude of the effect described here is smaller as we do not see a 
complete reversal of behavioural hypersensitivity (Bee and Dickenson, 2008; 
Burgess et al., 2002; Vera-Portocarrero et al., 2006). Also notable is that 
even at 6h post CFA injection attenuation of behavioural hypersensitivity is 
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observed. This suggests that this dose of dermorphin-saporin is effective in 
attenuating both the early (6h) and late (up to 7d) phases of inflammatory 
joint pain. 
Importantly however it was found in the initial pilot study that bilateral 
injections of this dose resulted in adverse effects in 50% of animals, 
requiring them to be culled. These effects included motor impairments such 
as loss of balance, catalepsy and lack of coordination of limbs. Considerable 
weight loss was also observed in some animals. No previous reports of 
unwanted effects with this dose have been described (Porreca et al. 2001; 
Burgess et al. 2002; Vera-Portocarrero et al. 2006; Bee and Dickenson 2008; 
Zhang et al. 2009). However three observations suggest that these effects 
were indeed related to the extent of cell loss within the medulla. Firstly, 
saline injected control animals never developed any complications 
suggesting that it is not due to the microinjection technique or surgery. 
Second, these side effects consistently emerged at 1 to 2 weeks following 
microinjection. This is the point at which saporin is likely to cause cell death 
(Mantyh et al., 1997). Finally these adverse effects appear to be directly 
proportional to the number of MOR+ cells lost by dermorphin-saporin 
treatment as at the lower doses described in the second experiment, where 
the decrease in MOR+ cell number is reduced, no adverse effects were 
observed. It is also possible that higher doses of dermorphin-saporin could 
lead to dissociation of the complex, and death of non-specific death of MOR- 
cells. 
The finding that a ‘high’ dose of dermorphin-saporin results in adverse 
effects highlights the difficulty in using lesion techniques in a small, complex 
brain region. The RVM is typically defined as consisting of the NRM and GiA 
regions. However within the anatomical boundary outlined by the GiA are a 
number of additional nuclei, including the nucleus raphe pallidus (RPa). The 
RPa is located along the midline, ventral to the NRM. Although the role of 
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the RPa in nociception has not been directly investigated it is known that 
MOR+ cells are located in this region (Phillips et al., 2012) and therefore 
likely to be affected by dermorphin-saporin treatment. The RPa as well as 
the more caudal raphe obscurus (ROb) are implicated in the modulation of 
feeding behaviour (Takase and Nogueira, 2008) therefore depletion of 
neurons in these regions may contribute to the weight loss observed in a 
number of animals. In addition these regions project to brainstem regions 
involved in motor control and directly to the ventral horn (Veasey et al., 
1995) which may explain the motor impairments observed. Interestingly 
high doses of muscimol, a GABAA receptor agonist, was found to cause 
similar neurological impairments when injected to the RVM at co-ordinates 
comparable with those used here (Gilbert and Franklin, 2001). These authors 
suggest that at higher doses, the drug may reach more caudal regions of the 
RVM which play a role in motor control. The same may be true in our work. 
Higher doses of dermorphin-saporin may lead to a broader distribution and 
result in lesion of cells required for other important functions. In general it 
should be noted that the medullary raphe nuclei play a crucial role in 
cardiovascular, gastrointestinal and respiratory controls (Lovick 1997). 
Manipulation of the region in the study of nociceptive responses may 
therefore lead to alterations in these crucial homeostatic functions. 
Monitoring motor behaviours and weight gain following microinjection of 
toxins to the RVM is therefore important in these types of studies. 
By carrying out a small dose-response experiment, it was found that 
injection of lower doses of dermorphin-saporin also leads to attenuation of 
hypersensitivity, however importantly these lower doses do not result in the 
unwanted toxicity of the higher dose. The attenuation of hypersensitivity is 
smaller than that observed for the 3pmole dose, resulting in only a 20% 
reduction in mechanical hypersensitivity. The dose-response effect suggests 
this is due to fewer MOR+ cells depleted by lower dermorphin-saporin 
doses. This was confirmed by MOR+ cell counts, which indicated that at the 
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two lower doses fewer MOR+ cells are lost. Interestingly there was no 
significant effect of the lowest dose (0.75pmole) on MOR+ cell numbers 
compared to saline controls, despite a significant effect on behaviour at this 
dose. One possible explanation for this discrepancy is that lower doses of 
dermorphin-saporin may take longer to cause death of MOR+ neurons. 
Despite the immunohistochemical detection of many MOR+ neurons in this 
treatment group, some of these neurons may be in the process of dying and 
not functioning optimally, leading to significant attenuation of 
hypersensitivity compared to the saline group. At the 6h, 1d, 2d and 7d time 
points post CFA injection there is a direct correlation between MOR+ cell 
number and mechanical paw withdrawal thresholds per individual animal. 
This suggests that the behavioural effects observed in our lesion studies are 
strongly dependent on the number of cells depleted. 
This study is therefore the first to suggest that depletion of even a small 
number of MOR+ neurons can lead to a reduction in behavioural 
hypersensitivity. Conversely the complete reversal in neuropathic pain 
sensitivity described in previous studies (Burgess et al., 2002; Porreca et al., 
2001; Zhang et al., 2009) would likely require a complete ablation of MOR+ 
neurons. As demonstrated in this chapter this is difficult to achieve without 
considerable adverse effects. Interestingly, adverse effects of dermorphin-
saporin microinjection to the RVM had not been described by others 
previously and the source of this discrepancy is not clear. In most cases the 
same dose of toxin was used, in the same size and strain of rat, and at 
similar microinjection sites (Bee and Dickenson, 2008; Burgess et al., 2002; 
Porreca et al., 2001; Zhang et al., 2009). One possible explanation is batch to 
batch variation in dermorphin-saporin. Notably, one  recent study has 
described the use of a dose of 1.8pmole dermorphin-saporin in the study of 
stress induced hyperalgesia (Reynolds et al., 2011). These authors mention 
that this dose is modified from the Porreca et al. study, however do not 
discuss if adverse effects were identified at higher does. Nonetheless along 
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with our findings, this highlights the importance of determining an optimal 
working concentration by individual laboratories. 
Regardless of the cause of this discrepancy, in our studies a compromise 
between the extent of the lesion and efficacy in attenuation of behavioural 
hypersensitivity was required. Notably, survival of MOR- neurons within the 
RVM has not been convincingly demonstrated in these previous studies. 
Here we have demonstrated that the effects of dermorphin-saporin on 
behaviour are dose-dependent, and also that the selectivity of the lesion for 
MOR+ expressing neurons can be confirmed, at least at the lower doses than 
described previously in the literature. 
5.4.2 Role of MOR+ cells in descending facilitation from 1d post CFA 
injection 
Carrying out a complete, fully blinded and controlled experiment with this 
lower dose of dermorphin-saporin, it was found that attenuation of 
mechanical hypersensitivity only occurs from 1d onwards and that in the 
early stages of inflammation, at 2h and 6h post CFA, MOR+ cells are not 
required for behavioural hypersensitivity. As explained above, this may be 
due to insufficient ablation of MOR+ neurons, with the surviving cells having 
a facilitatory effect in this initial window. More likely however is that this 
behavioural experiment indicates important differences in the timing of 
descending modulation in neuropathic and inflammatory pain. Lesion of the 
RVM with dermorphin-saporin has no effect in the first 5 days of 
neuropathic pain behaviour (Burgess et al., 2002; Porreca et al., 2001; Zhang 
et al., 2009), and from that point onwards, a gradual reversal of sensitivity 
occurs. In contrast we find that attenuation of inflammatory joint pain 
occurs earlier but that the magnitude of attenuation is consistent 
throughout the period studied. This indicates that during joint inflammation 
descending facilitation via the MOR+ pathway becomes active from 24h 
onwards but does not increase or decrease in magnitude from that time. 
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This supports previous electrophysiological findings indicating that following 
inflammation, increased descending inhibition occurs in the acute phase 
(Cervero et al., 1991; Ren and Dubner, 1996; Schaible et al., 1991) but that 
this is not present in the maintenance phase (Danziger et al., 2001). In our 
experiment, in which descending facilitatory cells are depleted, this would 
explain why no apparent change occurs in the initial 24 hours of 
inflammation as at this point descending inhibitory controls may 
predominate. The effects of dermorphin-saporin lesion on descending 
facilitation are only unmasked later when descending inhibition is 
decreased. 
Notably, dermorphin-saporin lesion has no effect on paw withdrawal 
thresholds before CFA treatment. This suggests that in the normal healthy 
animal, before induction of hypersensitivity by injection of CFA, there is no 
effect of dermorphin-saporin lesion on the response to mechanical 
stimulation. Although this may be due to a failure of our measure of paw 
withdrawal threshold to detect changes in nociceptive responses, it most 
likely indicates that in order for the descending facilitatory system to 
become active there must be an initial increase in nociceptive input. This 
supports previous findings regarding the electrophysiological responses of 
dorsal horn neurons to stimulation following dermorphin-saporin depletion 
of the MOR+ cell population, in which innocuous mechanical stimulation 
with von Frey hairs is not affected by the depletion (Bee and Dickenson, 
2008) 
5.4.3 Potential mechanisms underlying descending facilitation via MOR+ 
cells 
MOR+ cells represent approximately half of all dorsal horn projecting RVM 
neurons (Gutstein et al., 1998; Kalyuzhny and Wessendorf, 1998; Mansour 
et al., 1994; Wang and Wessendorf, 1999), and approximately half of 
spinally projecting 5-HT expressing neurons are MOR+ (Kalyuzhny and 
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Wessendorf, 1998). Chapter 4 has described the role of descending 5-HT in 
facilitating behavioural hypersensitivity at 1d and 2d post inflammation. In 
this chapter the role of descending facilitation via MOR+ RVM neurons is 
addressed in a separate lesion experiment, however the results should be 
interpreted with the understanding that part of the effect of dermorphin-
saporin lesion is via a reduction in 5-HT fibres projecting to the dorsal horn. 
However in contrast to the data from the 5,7-DHT experiment, an overall 
attenuation of hypersensitivity is observed following dermorphin-saporin 
treatment from 1 – 7 d post inflammation. This suggests that other 
mechanisms besides descending 5-HT are involved in MOR+ cell mediated 
descending facilitation.  
Another important transmitter within the RVM during pain states is 
cholecystokinin (CCK).  CCK is a peptide expressed within many of the same 
regions as endogenous opioids and has been shown to antagonise their 
analgesic effects (Faris et al., 1983). Within the RVM CCK administration has 
pro-nociceptive effects on visceral pain by colorectal distension (Friedrich 
and Gebhart, 2003) and contributes to morphine induced hyperalgesia (Xie 
et al., 2005). Administration of a CCK₂ antagonist to the RVM has been 
shown to reverse neuropathic hypersensitivity (Kovelowski et al., 2000) and 
CCK is known to increase ON cell firing (Heinricher and Neubert, 2004). 
Recently it has been shown that the MOR+ population overlaps considerably 
with the CCK₂ receptor (Zhang et al., 2009). Importantly it was shown that 
depletion of these neurons by administration of CCK₂-saporin leads to 
attenuation of neuropathic pain sensitivity (Zhang et al., 2009), comparable 
to that observed previously following dermorphin-saporin lesion (Burgess et 
al., 2002). This strongly suggests that the effects of dermorphin-saporin 
observed in the present study are also driven through the loss of these CCK₂ 
expressing cells. Recently it has been shown that CCK administration to the 
RVM results in an increase in PGE₂ release in the dorsal horn (Marshall et al., 
2012). PGE₂ within the dorsal horn can cause central sensitisation (Baba et 
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al., 2001) and has been shown to contribute to inflammatory pain (Hay et 
al., 1997). Although the source of PGE₂ in response to CCK activation of RVM 
neurons is not clear, release within the spinal cord may play an important 
role in mediating descending facilitation by part of the ON cell population. 
Another mechanism of action of descending facilitation by the MOR+ cell 
population which has been proposed is increased release of 
neurotransmitters from primary afferent terminals, and indeed it has been 
shown that following dermorphin-saporin lesion of the RVM, enhanced 
capsaicin evoked release of CGRP in neuropathic rats is attenuated (Gardell 
et al., 2003). This study suggests the interesting concept whereby pain 
facilitating neurons could influence primary afferent release. One possible 
mechanism that could explain this is the activation of 5-HT₃ receptors, some 
of which are expressed on peripheral nerve terminals in the dorsal horn 
(Maxwell et al., 2003). As explained in chapter 4, the 5-HT₃ receptor is a 
ligand gated ion channel, and so its activation could lead to an influx of 
calcium and increased transmitter release. Recently it has been 
demonstrated that LTP at primary afferent-dorsal horn synapses is driven in 
part by presynaptic mechanisms of neurotransmitter release (Luo et al., 
2012). The ability of descending pathways to interact with primary afferent 
terminals may therefore contribute to presynaptic mechanisms of LTP within 
the dorsal horn.  
It should also be noted that  some GABA expressing projection neurons 
within the RVM are MOR+ and so may be lost by dermorphin-saporin lesion 
(Kalyuzhny and Wessendorf, 1998). Although these neurons would 
intuitively be expected to exert an inhibitory effect within the dorsal horn, 
the net effects of this inhibitory input will depend on the cell target within 
the dorsal horn. A facilitatory effect of these neurons via inhibition of 
inhibitory dorsal horn interneurons is a possibility, and loss of these neurons 
may contribute to the attenuation of hypersensitivity observed here. Further 
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immunohistochemical studies to quantify the extent of MOR+ double 
labelling with GABA and 5-HT, and their depletion following dermorphin-
saporin treatment, could be used to clarify the relative contribution of these 
two neurotransmitters to MOR+ mediated descending facilitation. 
5.4.4 Conclusion 
This study is the first to investigate the role of RVM MOR+ neurons in 
inflammatory joint pain behaviour. In contrast to previous findings in 
neuropathic pain the effect of MOR+ cell depletion is small, but is involved 
earlier in the pain process. Relatively little is known about the underlying 
mechanism of MOR+ cell facilitation of spinal cord excitability. To address 
this question, we next carried out microarray analysis to investigate the 
contribution of this pathway to gene expression changes within the dorsal 
horn. 
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6. Descending regulation of dorsal horn gene 
expression 
6.1  Introduction 
Long term plasticity requires changes in gene expression and protein 
synthesis, for example during memory formation (Bailey et al., 1996; Costa-
Mattioli et al., 2009) and central sensitisation (Kim et al., 1998). As shown in 
this thesis and by others previously, descending facilitation contributes to 
the development of increased spinal excitability and behavioural sensitivity. 
Therefore descending controls are also likely to drive molecular changes in 
the dorsal horn which are required for plasticity. Some studies have 
demonstrated that the expression of proteins in the dorsal horn such as the 
immediate-early genes c-Fos (Géranton et al., 2008) and zif-268 (Rygh et al., 
2006) as well as the transcriptional regulator MeCP2 (Géranton et al., 2008) 
are subject to regulation by descending controls, but in general the 
underlying molecular mechanisms in the dorsal horn are not well 
understood.  
Microarray analysis is a powerful technique used to study the expression 
levels of many genes within a sample simultaneously. The method was 
originally described by Schena et al., 1995 and involves binding of 
fluorescence-labelled cDNA, derived from a biological sample of interest, 
and applying it to a chip containing many probes representing individual 
genes. Hybridisation between cDNA strands of the sample and the probes 
on the chips allows for the extent of fluorescence at each probe to give a 
readout of levels of expression for that gene within the sample (Schena et 
al., 1995). Since its initial conception microarray technology has become 
progressively more sophisticated (including more and more genes on the 
chip) and is now a widely used technique in biology, including neuroscience 
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research. There are two main advantages to the use of microarrays to study 
gene expression. One is the high throughput nature of the microarray, 
allowing the screening of many thousands of genes at once within a sample. 
The other advantage is that it allows an unbiased approach to studying gene 
expression. Rather than selecting a gene of interest based on existing 
knowledge of the biological process, whole genome studies can reveal novel 
and unexpected roles for ‘new’ genes in a particular process (Mogil and 
McCarson, 2000).  
Microarrays have been used in a number of studies to investigate changes in 
gene expression in the different components of the pain pathway, including 
the dorsal horn. This has been carried out following peripheral nerve injury 
(Griffin et al., 2007; Lacroix-Fralish et al., 2006; Yang et al., 2004), herpes 
zoster induced allodynia (Takasaki et al., 2012), and plantar inflammation 
(Rodriguez Parkitna et al., 2006). Recently, a number of innovative studies 
have used microarrays of distinct groups of animals with different 
behavioural responses to identify molecular mechanisms underlying these 
distinct pain phenotypes. For example, in young rats neuropathic injury does 
not lead to pain as it does in the adult (Howard et al., 2005). Microarray 
analysis has proved useful in identifying a role for the complement signalling 
cascade in microglia which is active in the adult, but not in the young animal.  
This has been proposed as an explanation for the difference in pain response 
to neuropathic injury in these age groups (Costigan et al., 2009a). 
Microarrays of the dorsal horn have also been used to identify changes in 
gene expression associated with re-injury  after an earlier inflammatory 
insult with carrageenan (Yukhananov and Kissin, 2008), which suggests the 
existence of a molecular memory or trace of the initial pain state. Another 
interesting example is a recent investigation into electroacupuncture 
induced analgesia. This procedure is more successful in some animals than 
others, and microarray analysis has identified genes related to immune cell 
function, such as the pro-inflammatory cytokines Il-6, Il-1β and TNF-α, that 
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are expressed at a higher level in the low responders. This is believed to 
contribute to their insensitivity to the procedure (Wang et al., 2012). These 
studies demonstrate that comparing gene expression in groups with subtle 
differences in pain behaviours can provide important information on the 
molecular mechanisms underlying those differences. 
Our group has previously used microarray analysis to characterise changes in 
dorsal horn gene expression associated with ankle joint inflammation 
(Géranton et al., 2007a). This study revealed waves of transcriptional 
regulation at different stages following inflammation, with the induction 
phase (2 – 24h post inflammation) broadly associated with an increase in 
gene expression and the maintenance phase (7d) associated predominantly 
with downregulation of genes. This study demonstrated that in a model of 
joint pain substantial changes in dorsal horn gene expression occur, which 
may correlate with the behavioural changes observed. In this thesis, chapter 
4 and chapter 5 describe experiments which have demonstrated that 
descending facilitation contributes to behavioural hypersensitivity in this 
model. While the contribution of descending facilitation to central 
sensitisation and pain behaviour has been studied frequently (Bee and 
Dickenson, 2008; Burgess et al., 2002; Géranton et al., 2008; Wei et al., 
2010) little is known about the molecular mechanisms underlying 
descending facilitation.  
6.1.1 Hypothesis 
In this chapter I have tested the hypothesis that gene expression changes in 
the dorsal horn following ankle joint inflammation are regulated by 
descending facilitation via MOR+ neurons.  
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6.2  Methods 
6.2.1 Animals 
The first part of this chapter describes work which used tissue from the 
behavioural experiment described in section 5.3.3. This cohort of animals 
received microinjection to the RVM of either 1.5pmole (48ng, 0.75pmole 
each side) dermorphin-saporin or saline. The animals were subsequently 
divided into two groups receiving either CFA injection to the ankle or 
undergoing a sham procedure. The ipsilateral dorsal horn of a subset of 
these animals (n = 5, dermorphin-saporin + CFA and saline + CFA) was used 
for microarray analysis and qPCR validation of target genes (experiment 1). 
The aim of the part of the study was to focus on the specific contribution of 
descending facilitation to the regulation of dorsal horn gene expression at 
the 7d time point. For this reason, microarray analysis was carried out on 
two groups of animals only. Both groups underwent CFA injection, and 
dermorphin-saporin or saline pre-treatment was the only variable. In this 
way our analysis revealed genes that are differentially regulated in the pain 
state by the MOR+ cell pathway.  
The second part of this chapter describes immunohistochemistry and 
western blot experiments carried out on two other groups of animals. 
Animals underwent dermorphin-saporin or saline microinjection to the RVM 
followed by ankle injection of CFA (as before for the microarray experiment) 
and the ipsilateral dorsal horn of these animals (n= 6) were used for western 
blot analysis (experiment 2). A final group of animals were used which did 
not undergo RVM injection, and received either CFA injection or sham 
procedure (experiment 3). These were either perfused, or protein extracted 
from the ipsilateral dorsal horn for western blot analysis (n = 6 per group). In 
all cases tissue was collected at 7d post CFA injection. An outline of the 
treatment and tissue obtained from different sets of animals is listed in table 
6.1. 
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 Experiment 1 Experiment 2 Experiment 3 
RVM injection DS or saline DS or saline None 
CFA CFA or sham CFA or sham CFA or sham 
Used for RNA: microarray and 
RT-qPCR 
Protein: western blot  Protein: western blot or 
immunohistochemistry 
Table 6.1 Outline of experimental groups used in chapter 6.  
All tissue was obtained at 7d post CFA injection. DS = dermorphin-saporin. 
6.2.2 Microarray analysis 
6.2.2.1  RNA Extraction 
Tissue was homogenised by hand in 700ul Qiazol (Qiagen) for 1 to 2min. The 
sample was removed and passed through a Qiashredder column and spun in 
the centrifuge at 14,000rpm for 2min. The sample was then left at room 
temperature for 5min before the RNA was extracted using the Qiagen 
RNeasy kit. 140µl chloroform was added to the sample and the tube was 
capped and shaken vigorously for 15s. The samples were then left at room 
temperature for 3min followed by centrifugation at 12,000 rpm at 4°C for 
15min.  
The upper aqueous phase was transferred to a new tube, with care taken to 
minimise cellular debris remaining in the sample.  53% EtOH was added to 
the removed aqueous phase. This was mixed well by pipetting up and down, 
and added to the RNeasy spin column, and centrifuged to remove the EtOH. 
A wash step using buffer RW1 (from the RNeasy kit) was carried out before 
adding DNAase I incubation mix (Qiagen) to the column for 15min. A series 
of further washes using buffer RW1 and RPE from the RNeasy kit were then 
performed, before a final drying step and elution of the RNA in 25ul of 
RNase free H₂O. 1µl of each RNA sample was applied to a Nanodrop 
spectrophotometer and the concentration of RNA per sample was 
determined in ng/µl. The contamination levels of organic solvents (indicated 
by a low 260/230 value) and protein contamination (indicated by a low 
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260/280 value) were also determined using the Nanodrop. RNA was then 
stored at -80°C until further use. 
6.2.2.2  Microarray analysis 
RNA derived from the ipsilateral dorsal horn from two groups of animals, 
one group with dermorphin-saporin lesion of the RVM and the other 
without, was used for microarray analysis of gene expression (experiment 1, 
see table 6.1). 5 replicates per group were used. RNA samples were 
normalised to a concentration of 50ng/µl in RNase free H₂O before 
submission to the UCL genomics service. Complementary DNA (cDNA) 
synthesis was carried out using the Ambion WT expression kit (see below 
section 6.2.5 for description of cDNA synthesis for RT-qPCR experiments). 
This was followed by labelling of the cDNA using the Affymetrix WT terminal 
labelling kit. Labelled cDNA was then hybridised to Affymetrix rat gene 1.0 
ST arrays and the intensity of fluorescence of the arrays was measured using 
an Affymetrix gene chip scanner.  
6.2.2.3  Data analysis 
The raw data was obtained in the form of .CEL files, which contain the 
results of the intensity calculations per chip. Analysis of the raw data was 
carried out in the R, a language and environment for statistical computing 
and graphics (www.r-project.org), and the Bioconductor plugin for 
microarray analysis was used (www.bioconductor.org). The Bioconductor 
package was used for three different aspects of analysing the raw data: 
normalising, measuring differential expression of probe sets, and providing 
functional annotations for each probe from the gene ontology (GO) 
database.  
The robust multi-array average (RMA) package was used to generate an 
expression matrix from the CEL files and to normalise the data. Limma 
testing was used to assess differential expression between the two 
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treatment groups. Limma testing produces a table of containing the probe 
ID, the log-fold difference between the two treatment groups, the average 
expression across samples, the t-statistic describing the differential 
expression, the p value and adjusted p value for the significance of any 
expression difference, and the log odds ratio. The adjusted p values were 
not significant for any of the probe sets, and for further analysis, the non-
adjusted p value was used. Previous published work by our group has also 
used the non-adjusted p value (Géranton et al., 2007a).  
6.2.2.4  Bioinformatics analysis 
In order to identify biologically meaningful genes from this list, the online 
bioinformatics tool DAVID was used (http://david.abcc.ncifcrf.gov/). The 
DAVID functional annotation tool examines functional annotations of the 
genes in a list. It incorporates annotations from the gene ontology (GO) 
database and performs statistical analysis to identify annotations 
overrepresented in a gene list compared to the background list, in our case 
the rat genome. The advantage of using the DAVID analysis system rather 
than carrying out traditional gene annotation analysis is that it groups 
similar or redundant annotations together, minimising repetition and 
redundancy (Huang, Sherman, and Lempicki 2009). This is referred to as 
functional annotation clustering. Genes are grouped on the basis of 
similarities in functional annotations allowing the user to quickly identify 
common functions between genes. 
Following the microarray experiment, the gene list was inserted into the 
DAVID analysis system using the official gene symbols as identifiers. The 
background list was designated as the Rattus norvegicus genome. The 
source of annotations chosen for analysis was the Gene Ontology (GO) 
database. This consists of annotations of gene function using defined GO 
terms in three areas: biological process (BP), cellular compartment (CC) and 
molecular function (MF) (Ashburner et al., 2000). The analysis produced two 
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sets of findings, a list of enriched annotations by traditional analysis, and 
functional annotation clustering which groups similar and redundant 
annotations together to simplify the identification of biologically interesting 
groups of genes. 
The DAVID analysis system has two methods of studying functional 
annotations within a list of genes. The first lists all significantly enriched 
annotations found within the gene list. This is calculated from an EASE score, 
which is generated from a Fisher’s exact test to determine if the 
overrepresentation of the annotation is random or not, with a p value of < 
0.05 deemed to be a significant enrichment. As multiple annotations are 
tested in this way, a correction by Benjamini test is also carried out, and 
ideally these values should also be significant. This produces a list of 
significantly enriched annotations within the gene list. 
The second analysis method sorts similar annotations into clusters. Within 
these groups, the individual EASE scores for the annotation are combined to 
produce an overall enrichment score. This is the geometric mean of the p-
values for the individual annotations, followed by minus log transformation. 
This means that the higher the enrichment score the more significant the 
cluster is, and a value of approximately 1.3 corresponds to the non-
transformed value of p = 0.05. However this does not rule out further 
investigation into clusters with an enrichment value < 1.3, as within the 
clusters there may be many significantly enriched annotations. Furthermore, 
the number of genes in a cluster may be of interest. If a large number of 
genes with similar functions are all differentially regulated in the 
experiment, it provides a strong clue towards an underlying mechanism and 
may warrant further investigation (Huang et al., 2009). 
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6.2.3 Quantitative real-time PCR  (RT-qPCR) 
6.2.3.1  cDNA synthesis for RT-qPCR 
Complementary DNA (cDNA) was synthesised from the RNA samples. The 
reaction was carried by adding 0.5μg RNA sample to a mix of 0.2µl Oligo 
dT20 (Invitrogen), 0.8µl random nonamers (Sigma), 1µl PCR nucleotide mix 
(Promega) and bringing the reaction volume to 13µl by adding RNase free 
H20. This was then incubated at 65°C for 5min. The samples were then 
quickly chilled on ice for 5min. The tubes were briefly centrifuged to collect 
the mixture, and 4µl first strand buffer (Invitrogen), 1µl DTT (Invitrogen), 1µl 
RNaseIN ribonuclease inhibitor (Invitrogen) and 1µl of the key reaction 
component, reverse transcriptase (Superscript III, Invitrogen) were added. 
This was gently mixed by pipetting up and down and the samples were then 
incubated at 25°C for 5min, 50°C for 50min and 70°C for 15min. The cDNA 
samples were then placed quickly on ice before storage at -20°C until use in 
RT-qPCR assays. 
6.2.3.2  Reverse transcriptase real time qPCR (RT-qPCR) assay 
Oligonucleotide primers were designed to target selected genes based on 
the Affymetrix probe sequences (Sigma). A list of primer sequences is given 
in table 6.2. RT-qPCR assays were carried out on 96 well plates, with cDNA 
samples run in triplicate and controls for master mix contamination (no 
cDNA added) and cDNA contamination (negative control from the cDNA 
synthesis, without transcriptase added) included in each plate.  A master mix 
solution was prepared for each plate so that each well contained 12.5µl 
SYBR green (Sigma), 9.5µl RNase free H₂O, and 1µl stock solution of the 
forward and reverse primers of the target gene. 1µl cDNA was added to the 
wells after they were filled with the master solution.  
The Sigma 3-step amplification protocol was used with a Bio-Rad CFX96 PCR 
C100 thermal cycler (see table 6.3). Data was analysed using Bio-Rad CFX96 
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software. Ct values (threshold cycle, which is the number of cycles taken for 
the fluorescence labelling to increase above background) were obtained for 
each target gene. This value is inversely proportional to the log of the copy 
number of the cDNA in the sample.  Actin was used as a housekeeping gene. 
Relative gene expression was calculated using the 2ΔCt method, where the 
data for each gene is expressed in the form 2 to the power of (Ct Actin – Ct 
target). 
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Gene name Primer Sequence 
Cyclin B2 Ccnb2F CTAAGAGCCATGTGACTGTC 
 Ccnb2R CAGAACTGTAGGTTTCGG 
   
Chemokine (C-X-C motif) ligand 10 Cxcl10F ATACTCACAGGAACCTAGACAT 
 Cxcl10R CCATCCAACACATCTTGTAATATG 
   
Ribosomal protein L32 Rpl32F GTTCATCAGGCACCAGTC 
 Rpl32R TGACATCGTGGACCAGAA 
   
Chemokine (C-X-C motif) ligand 9 Cxcl9F GATGAAGCCCTTTCATACTGC 
 Cxcl9R GTGGTTGTGAGTTTTGCTCCAATC 
   
Chemokine (C-X-C motif) receptor 3 Cxcr3F AGCCCTCACCTGCATAGTTG 
 Cxcr3R GCCACTAGCTGCAGTACACG 
   
Nitric oxide synthase 2 Nos2F GATATCTTCGGTGCGGTCTT 
 Nos2R GGCCAGATGCTGTAACTCTT 
Table 6.2 Forward and reverse primer sequences used for RT-qPCR validation of selected 
genes. 
Step Temperature °C Time 
1. Denaturation 94 2min 
2. Denaturation 94 15s 
3. Annealing 60 30s 
4. Extension 72 30s 
5. Read Plate 
6. Return to step2, repeat x39 
  
Table 6.3 Sigma three step amplification protocol. 
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6.2.4 Western blot 
Full details of all solutions used for western blot analysis are listed in 
appendix A2. As the primary aim was to determine if some of the genes 
validated by RT-qPCR were also regulated at the protein level, we limited 
western blot analysis to two groups of animals only for the dermorphin-
saporin component of the experiment. As with the microarray analysis, both 
groups received CFA injection, and dermorphin-saporin or saline pre-
treatment was the only variable (tissue from experiment 2). However, 
separate experiments were carried out on ‘normal’ CFA and sham tissue, to 
determine if protein levels are modulated by CFA treatment alone (tissue 
from experiment 3). 
6.2.4.1  Protein extraction 
Tissue was homogenised in 1ml RIPA buffer, 10µl protease inhibitor (Sigma) 
10µl phosphatase inhibitor cocktail 1 (Sigma) and 10µl phosphatase inhibitor 
cocktail 2 (Sigma). 150µl of this mixture was used per dorsal horn quadrant. 
Tissue was placed in centrifuge tubes with ceramic beads and then placed in 
a FastPrep biopulverizer machine (MP Biomedicals Europe) for 20s at setting 
5. Tubes were spun twice and left on ice for 1h, followed by 2 more spins 
and a final 1h on ice. Finally tubes were centrifuged at 12,000rpm for 15min 
at 4°C. The supernatant was removed, leaving the pellet left behind. 
Samples were stored at -20°C until use.  
Protein quantity per sample was determined using a bicinchoninic acid (BCA) 
assay (Thermo Scientific). Bicinchoninic acid and 4 % copper sulphate 
solution were mixed in a 50:1 ratio, and 200μl of the mixture was added to 
protein standards, and unknown samples, on a 96-well plate. This was 
incubated at 37°C for 30min and a spectrophotometer was used to measure 
the colour emitted by the samples, allowing a standard curve to be 
generated and the unknown protein concentrations calculated.  
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6.2.4.2  Electrophoresis and protein transfer 
Samples for western blot were prepared by adding sufficient protein sample 
to obtain a standard protein concentration of 35µg. The appropriate amount 
of loading buffer (Invitrogen) was added to obtain a final volume of 19.5µl 
per sample. Samples were boiled for 5min to denature the proteins, and 
cooled on ice prior to loading of the gel. Samples were loaded alongside a 
protein standard ladder (Bio-Rad) to pre-cast 12% agarose gels (Bio-Rad 
Criterion) in a tank with MOPS running buffer. Proteins were separated using 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE), at 180V for 1hr using a 
power pack (Bio-Rad). 
Meanwhile transfer buffer was prepared (see appendix A.2) and 2 sponges 
and 4 filter papers per gel were soaked for 15min. PVDF membrane (Bio-
Rad) was activated in MeOH for 5min then soaked in transfer buffer prior to 
preparation of the sandwich within a plastic cassette. Sponges and filter 
paper (Bio-Rad) were also soaked in transfer buffer prior to use. This gel 
sandwich was prepared in the following order: sponge, 2 x filter paper, gel, 
PVDF membrane, 2x filter paper and sponge. The cassette was placed in a 
tank with transfer buffer and ran at 100V for 1h to complete the transfer, 
and the buffer was kept cool by addition of an ice pack. 
6.2.4.3  Blocking, primary antibody and detection 
Following completion of protein transfer, the membrane was blocked in 
blocking solution (4% skimmed milk solution in PBS-tween) for 1h. The 
primary antibody was diluted as required in blocking solution and the 
membrane incubated in a rolling tube overnight at 4°C. The primary 
antibodies and concentrations used are given in table 6.4.  
After the overnight incubation, the membrane was then washed 3 times for 
10min in PBS-tween on a rocker. The membrane was then incubated with a 
rabbit horseradish peroxidase-conjugated secondary antibody (Santa Cruz, 
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1:1000), diluted in blocking solution, for 1h at room temperature. This was 
followed by 3 more washes. The membrane was developed using the Bio-
Rad Chemi-doc system, with a horseradish peroxidase (HRP) substrate 
developing kit (Thermo-Scientific). The HRP developing substrate was 
applied to the membrane for as long as required to see bands at the target 
molecular weight. Images of the developed blots were saved for later 
analysis. 
All proteins of interest were normalised to the expression of calnexin, a 
housekeeping protein expressed in the endoplasmic reticulum membrane. 
Following the exposure of the first antibody, the membrane was incubated 
with the calnexin antibody (1:1000, rabbit, Biovision) overnight at 4°C. The 
next day the secondary HRP-conjugated antibody was applied, and 
developing of the blot was carried out as for the first primary antibody. 
Antigen Host Company Concentration Molecular Weight 
CXCL10 Rabbit Peprotech 1:500 10kDA 
CXCR3 Rabbit Santa Cruz 1:50 38kDA 
Calnexin Rabbit Biovision 1:1000 67kDA 
 
Table 6.4 Primary antibodies used for western blot analysis. 
6.2.4.4  Analysis 
Western blots were analysed using Bio-rad Quantity One software. The 
volume analysis tool was used to quantify the intensity of band staining. 
Volume analysis involves creating a rectangle of equal size around each of 
the bands, and measures the volume within that rectangle. The volume is 
defined as the sum of pixel intensities x the area within the defined 
boundary. The global background volume is subtracted from these values, 
and is obtained by combining intensity data from three separate objects as 
representative of the background. For each band the background-adjusted 
intensity of the band at the appropriate molecular weight was normalised to 
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the background-adjusted intensity of calnexin, imaged on the same blot. The 
normalised data is then expressed as a proportion of the mean of the 
control group (either saline + CFA or sham, depending on the experiment). 
6.2.5 Immunohistochemistry 
Fluorescence immunohistochemistry with tyramide signal amplification was 
carried out as described in section 2.4. 40µm sections of the lumbar spinal 
cord (L4-L6) were taken across 6 wells, so that within each well all sections 
were at least 240µm apart. 
Antibodies used were for CXCR3 and CXCL10, and double labelling was 
carried out with a number of cellular markers. These were NeuN (marker of 
neuronal nuclei), IBA1 (ionized calcium binding adaptor molecule 1, found in 
microglia), GFAP (glial fibrillary acidic protein, found in astrocytes) and CGRP 
(calcitonin gene related peptide, expressed in peptidergic primary afferents 
terminating in the dorsal horn), as appropriate. Primary antibodies and 
concentrations used for immunohistochemistry are given below in table 6.5.   
Confocal microscopy (see section 2.4.6) was carried out to determine the 
extent of colabelling of CXCR3 and CXCL10 with these markers in the dorsal 
horn of animals with ankle injection of CFA. Controls were carried out to 
ensure that the secondary antibodies were specific to their primary antibody 
targets. This was carried out by removing either the first primary antibody or 
the second primary antibody from the procedure, to ensure no non-specific 
labelling by the secondary antibodies.  
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Antigen Host Company Concentration Method Fluorophore 
CXCL10  Rabbit Peprotech 1:1000 TSA FITC 
CXCR3 Rabbit Santa Cruz 1:200 TSA FITC 
NeuN Mouse Chemicon 1:1000 Direct  Alexa 594 
CGRP Rabbit Sigma 1:4000 Direct  Alexa 594 
IBA1 Rabbit Wako 1:1000 Direct Alexa 594 
GFAP Rabbit Dako 1:4000 Direct Alexa 594 
Table 6.5 Primary antibodies, concentrations and detection methods for 
immunohistochemistry. 
6.2.6 Statistical analysis of RT-qPCR and western blot experiments 
For RT-qPCR and western blot experiments, data is presented as mean ± 
SEM per group. Independent samples t-tests were used to compare means 
between two groups and a p-value of < 0.05 was deemed significant. 
6.3  Results 
6.3.1 Microarray analysis 
Following analysis of the microarray data in Bioconductor a list of all genes 
with corresponding fold changes and significance values was generated. 
Only those genes with a non-adjusted p value of < 0.05 were included as 
differentially regulated (2616 transcripts in total). Genes without an official 
gene symbol were also removed (leaving 1668 transcripts in total). The 
remaining transcripts were then ranked by fold change. A fold change cut-off 
was set at 1.2 and this resulted in a final list of 129 genes which was used for 
further analysis. Table 6.6 lists these genes, along with their ranking on the 
list based on fold change, gene name, official gene symbol, direction of 
change in dermorphin-saporin group (+ = upregulated in dermorphin-
saporin, - = downregulated in dermorphin-saporin), fold change value, and 
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non-adjusted p value. The majority of the genes (76%) were downregulated 
in the dermorphin-saporin group. Within this list, two genes appear 
repeatedly (Rpl21 and Rpl7a). This repetition can arise as each gene is 
represented on the array with multiple probes targeting different regions on 
the same gene. For ease of reference, genes are listed in alphabetical order 
(based on gene symbol). 
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List of genes differentially regulated in dermorphin-saporin group 
Rank Gene Name Symbol  Fold  
p 
value 
27 ankyrin repeat, family A (RFXANK-like), 2 Ankra2  + 1.35 0.016 
39 brain expressed gene 4 Bex4  + 1.30 0.021 
26 biphenyl hydrolase-like (serine hydrolase) Bphl  -  1.35 0.001 
113 coiled-coil domain containing 79 Ccdc79  + 1.20 0.007 
4 cyclin B2 Ccnb2  + 1.85 0.015 
94 chemokine (C-C motif) receptor 1-like 1 Ccr1l1  -  1.21 0.000 
115 cholinergic receptor, nicotinic, beta 3 Chrnb3  -  1.20 0.014 
28 claudin 1 Cldn1  -  1.34 0.024 
99 clarin 2 Clrn2  -  1.21 0.002 
84 cytochrome c oxidase, subunit VIa, polypeptide 2 Cox6a2  -  1.22 0.005 
34 chemokine (C-X-C motif) ligand 10 Cxcl10  -  1.32 0.000 
42 chemokine (C-X-C motif) ligand 9 Cxcl9  -  1.30 0.042 
127 chemokine (C-X-C motif) receptor 3 Cxcr3  -  1.20 0.005 
109 cytochrome P450, family 2, subfamily b, polypeptide 12 Cyp2b12  -  1.20 0.010 
81 defensin, alpha 5, Paneth cell-specific Defa  -  1.22 0.001 
75 defensin beta 40 Defb40  -  1.22 0.031 
85 elongation factor RNA polymerase II-like 3 Ell3  -  1.22 0.003 
47 ferritin, light polypeptide Ftl  -  1.28 0.034 
119 glyceraldehyde-3-phosphate dehydrogenase Gapdh   -  1.20 0.013 
82 glycoprotein (transmembrane) nmb Gpnmb  -  1.22 0.021 
67 GTP binding protein 4 Gtpbp4  + 1.23 0.027 
51 histone cluster 1, H2bc Hist1h2bc  -  1.26 0.004 
54 histone cluster 1, H2bc Hist1h2bc  -  1.26 0.006 
102 histone cluster 3, H2a Hist3h2a  + 1.21 0.008 
40 high mobility group box 1  Hmgb1  -  1.30 0.006 
123 heterogeneous nuclear ribonucleoprotein A3 ABREVIATED Hnrnpa3  + 1.20 0.012 
122 5-hydroxytryptamine (serotonin) receptor 1D Htr1d  -  1.20 0.002 
3 isopentenyl-diphosphate delta isomerase 2-like Idi2l   -  1.98 0.043 
59 indolethylamine N-methyltransferase Inmt  -  1.25 0.005 
106 intelectin 1 (galactofuranose binding)  Itln1  -  1.21 0.007 
114 keratin 31 Krt31  -  1.20 0.037 
104 keratin associated protein 4-7 Krtap4-7   -  1.21 0.045 
19 NADH dehydrogenase (ubiquinone) 1 beta subcomplex 4 LOC100361934  -  1.38 0.006 
117 epithelial cell transforming sequence 2 oncogene-like LOC100361997  -  1.20 0.049 
45 rCG59045-like LOC100364529  -  1.29 0.002 
78 hypothetical LOC290577 LOC290577  -  1.22 0.004 
43 similar to hypothetical protein LOC292449  -  1.29 0.006 
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9 similar to hypothetical protein 4930509O22 LOC300308  -  1.67 0.001 
93 Ac2-224 LOC362921  -  1.21 0.000 
24 hypothetical protein LOC499339 LOC499339  + 1.36 0.002 
97 LRRGT00154 LOC499544  -  1.21 0.010 
68 similar to hypothetical protein FLJ25692 LOC500392  + 1.23 0.004 
52 hypothetical LOC502825 LOC502825  -  1.26 0.003 
2 similar to Discs large homolog 5  LOC681283   -  2.06 0.005 
76 hypothetical protein LOC683753 LOC683753  -  1.22 0.025 
15 similar to Heterogeneous nuclear ribonucleoprotein A1  LOC689196  -  1.44 0.010 
125 rCG20053-like /// mCG1042722-like LOC691054   -  1.20 0.009 
112 mast cell protease 8 Mcpt8  -  1.20 0.027 
36 mannosyl (alpha-1,3-) ABREVIATED Mgat4a  -  1.31 0.036 
66 similar to melanoma antigen family A, 5 MGC114492  -  1.23 0.015 
126 microRNA mir-152 Mir152  -  1.20 0.003 
17 microRNA mir-344-1 Mir344-1  + 1.41 0.013 
38 microRNA mir-374 Mir374  + 1.30 0.013 
69 microRNA mir-377 Mir377  + 1.23 0.009 
83 microRNA mir-384 Mir384  + 1.22 0.033 
25 microRNA mir-421 Mir421  + 1.36 0.011 
64 microRNA mir-544 Mir544  + 1.24 0.041 
111 M-phase phosphoprotein 8 Mphosph8  -  1.20 0.001 
58 mitochondrial ribosomal protein L18 Mrpl18  + 1.25 0.003 
91 melanoma associated antigen (mutated) 1-like 1 Mum1l1  + 1.21 0.005 
10 NADH dehydrogenase subunit 6 ND6  + 1.65 0.003 
62 neurogenin 1 Neurog1  -  1.24 0.010 
71 nuclear transcription factor, X-box binding-like 1 Nfxl1  + 1.23 0.015 
72 nuclear transcription factor, X-box binding-like 1 Nfxl1  + 1.22 0.004 
79 natural killer cell group 7 sequence Nkg7  -  1.22 0.011 
118 nitric oxide synthase 2, inducible Nos2  -  1.20 0.000 
31 NAD(P)H dehydrogenase, quinone 2 Nqo2  + 1.33 0.022 
49 olfactory receptor 1598 Olr1598  -  1.27 0.030 
95 olfactory receptor 1695 Olr1695  -  1.21 0.004 
128 olfactory receptor 1733 Olr1733  + 1.20 0.028 
63 olfactory receptor 1743 Olr1743  -  1.24 0.002 
80 olfactory receptor 326 Olr326  -  1.22 0.009 
65 olfactory receptor 446 Olr446  -  1.24 0.022 
90 olfactory receptor 514 Olr514  -  1.21 0.008 
13 olfactory receptor 707 Olr707  -  1.50 0.018 
44 olfactory receptor 733 Olr733  -  1.29 0.044 
5 olfactory receptor 780 /// olfactory receptor 779 Olr780   -  1.83 0.001 
60 olfactory receptor 94 Olr94  -  1.25 0.010 
124 polyadenylate-binding protein-interacting protein 2-like 1 Paip2l1  + 1.20 0.002 
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108 Prolactin family 3, subfamily d, member 1 ABREVIATED Prl3d1   -  1.21 0.035 
74 proline-rich protein 15 /// RGD1559532 Prp15  -  1.22 0.000 
120 parathyroid hormone Pth  -  1.20 0.000 
88 RNA binding motif 31, Y-linked Rbm31y  -  1.21 0.000 
23 REST corepressor 2 Rcor2  + 1.36 0.042 
107 renin Ren  -  1.21 0.002 
101 similar to Neuronal pentraxin II precursor (NP-II) (NP2)  RGD1311190  -  1.21 0.007 
20 similar to NADH:ubiquinone oxidoreductase B15 subunit RGD1560088  + 1.36 0.010 
11 similar to RIKEN cDNA 1700001F22 RGD1561558   + 1.56 0.014 
21 similar to putative protein kinase  RGD1561706  -  1.36 0.002 
35 similar to putative protein kinase  RGD1561706   -  1.32 0.040 
129 similar to Na+ dependent glucose transporter 1 RGD1561777  -  1.19 0.011 
18 similar to TDPOZ3 RGD1563667  + 1.40 0.020 
116 similar to chromosome 10 open reading frame 71 RGD1564899  -  1.20 0.004 
53 similar to ATP synthase, ABREVIATED RGD1565438  -  1.26 0.002 
70 similar to Spindlin-like protein 2 (SPIN-2) RGD1565862  -  1.23 0.007 
6 
similar to 60S ribosomal protein L12 /// ribosomal protein 
L12 Rpl12  + 1.81 0.016 
37 ribosomal protein L19 Rpl19  + 1.30 0.023 
12 ribosomal protein L21  Rpl21  -  1.51 0.050 
22 ribosomal protein L21  Rpl21  + 1.36 0.022 
32 ribosomal protein L21  Rpl21   + 1.33 0.025 
46 ribosomal protein L21  Rpl21   + 1.28 0.039 
8 ribosomal protein L32 Rpl32  -  1.68 0.015 
55 ribosomal protein L35a Rpl35a  + 1.26 0.025 
14 ribosomal protein L7a Rpl7a  -  1.45 0.011 
33 ribosomal protein L7a Rpl7a  -  1.32 0.014 
77 ribosomal protein L7a Rpl7a  -  1.22 0.020 
121 ribosomal protein L7a  Rpl7a   -  1.20 0.016 
29 ribosomal protein L9 Rpl9  -  1.34 0.018 
30 ribosomal protein S2 /// ribosomal protein S2-like Rps2  + 1.33 0.007 
96 ribosomal protein S23 /// similar to ribosomal protein S23 Rps23   + 1.21 0.016 
16 RT1 class Ib RT1-N1   -  1.42 0.041 
87 RT1 class Ib, locus O1 RT1-O1  + 1.22 0.040 
110 Sin3-associated polypeptide 18 Sap18  + 1.20 0.013 
86 SEC16 homolog B (S. cerevisiae) Sec16b  -  1.22 0.002 
73 sema domain Sema4c  -  1.22 0.003 
61 
serine (or cysteine) proteinase inhibitor, clade B, member 
1a Serpinb1a  -  1.24 0.001 
1 
serine (or cysteine) peptidase inhibitor, clade B, member 
1b Serpinb1b  -  4.08 0.002 
89 solute carrier family 7 ABREVIATED Slc7a7  -  1.21 0.003 
92 serine peptidase inhibitor, Kazal type 3 Spink3  -  1.21 0.045 
56 storkhead box 1 Stox1  -  1.26 0.014 
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50 taste receptor, type 2, member 38 Tas2r38  -  1.27 0.004 
105 tektin 5 Tekt5  -  1.21 0.001 
98 transmembrane protein 27 Tmem27  -  1.21 0.016 
57 transmembrane protease, serine 4 Tmprss4  -  1.25 0.002 
48 tripartite motif-containing 42 Trim42  -  1.27 0.000 
7 vomeronasal 1 receptor, D15 V1rd15   + 1.70 0.006 
103 vestigial like 2 (Drosophila) Vgll2  -  1.21 0.005 
100 vomeronasal 2 receptor, 51 Vom2r51  -  1.21 0.010 
41 xin actin-binding repeat containing 1 Xirp1  -  1.30 0.000 
 
 
Table 6.6 Genes identified by microarray analysis. 
129 genes with a p-value of < 0.05 and a fold change of  > 1.2 were identified. The + or – 
symbols indicate upregulation or downregulation in the dermorphin-saporin group. Genes 
are listed alphabetically, based on gene symbol. 
6.3.2 Bioinformatics analysis 
To identify biological functions of genes in this list which may be of interest, 
DAVID bioinformatics software was used. This is a freely available online tool 
(http://david.abcc.ncifcrf.gov), and it was used to perform functional 
annotation of the genes in the list based on the gene ontology (GO) 
database. This analysis indicated there are 35 GO terms enriched within the 
list, however many of these annotations are similar. Functional annotation 
clustering was then carried out, to identify groups of annotations with 
similar functions and the genes they contain. This resulted in the 
identification of 20 clusters. These clusters are illustrated in figure 6.1, and 
the genes contained in each cluster are shown in table 6.7.   
The enrichment score for each cluster was calculated as the log 
transformation of the geometric mean of the EASE scores for individual 
annotations within the cluster. Higher enrichment scores therefore 
correspond to greater significance. The enrichment scores for each cluster 
are also given in table 6.7 (values in bold). Interestingly, the most 
significantly enriched cluster corresponded to genes with ribosomal 
function. The annotations of this category refer to ribosomal structural 
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proteins, as well as genes involved in translation and those with a cytosolic 
location. This included several large ribosomal subunit components (e.g. 
Rpl32 and Rpl21). Also within this group was Ccnb2, which encodes the cell-
cycle mediator cyclin B2. This was one of the highest ranking fold changes 
identified with a 1.85 increase in the dermorphin-saporin group.  
The next most significant cluster contains genes with annotations for 
defence response, which includes a number of genes involved in immune 
system function. Among these was Nos2, which encodes the enzyme nitric 
oxide synthase 2 (inducible nitric oxide synthase), which is implicated in 
inflammatory responses (MacMicking et al., 1997). The next cluster contains 
genes associated with chemotaxis, which are also involved in immune 
system function and inflammatory responses. This cluster included the 
chemokines Cxcl9 and Cxcl10. All of these immune system and chemotaxis 
related genes were downregulated in the dermorphin-saporin group, 
suggesting that immune cell activation in the dorsal horn may be reduced in 
the dermorphin-saporin group. 
Surprisingly, no clusters directly related to neuronal activity were identified. 
However within the GPCR signalling cluster the 5-HT receptor 5-HT1D 
(Htr1d) and the nicotinic receptor β subunit (Chrnb3) were identified. Both 
were downregulated 1.2 fold in the dermorphin-saporin group. This cluster 
also contained a large number of olfactory receptors, as well as the 
chemokine receptor Cxcr3, which binds the chemotaxis ligands Cxcl9 and 
Cxcl10. 
These functional annotation clusters helped identify interesting biological 
roles for some of the genes identified in the array, with a particular role for 
ribosomal function and immune cell activity. 
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Figure 6.1 Functional annotation clustering analysis. 
20 functional annotation clusters were identified using the DAVID online bioinformatics 
tool. The horizontal bars indicate the number of genes that are upregulated (to the right) or 
downregulated (to the left) in each cluster. Joined bars indicate the up- and downregulated 
genes for each cluster. For clarity, alternate black and white bars are used between clusters. 
For details of the genes contained in each cluster see table 6.7. 
Chapter 6 
174 
 
Functional annotation clusters generated by DAVID analysis  
 Down Up 
1. Ribosome Cldn1 Ankra2 
2.88 Ftl Ccnb2 
 Gapdh Gtpbp4 
 Hist1h2bc Hist3h2a 
 Hmgb1 Rcor2 
 Hnrnpa3 Rpl12 
 Krt31 Rpl19 
 LOC499339 Rpl35a 
 Mphosph8 Rps2 
 Mrpl18 Rps23 
 Nos2 Tekt5 
 Rpl21  
 Rpl32  
 Rpl7a  
 Rpl9  
   
2. Defence response Cxcl10  
1.16 Defa  
 Defb40  
 Hist1h2bc  
 Mphosph8  
 Nos2  
   
3. Chemotaxis Cxcl10 Gtpbp4 
1.16 Cxcl9  
 Defa  
 Defb40  
 Hmgb1  
 Mcpt8  
 Mgat4a  
 Prl3d1  
 Pth  
 Ren  
 Spink3  
   
4. GPCR Chrnb3 ND6 
0.76 Cldn1 Nqo2 
 Cxcl10 Olr1733 
 Cxcl9 V1rd15 
 Cxcr3  
 Gpnmb  
 Htr1d  
 Mgat4a  
 Nkg7  
 Nos2  
 Olr1598  
 Olr1695  
 Olr1743  
 Olr326  
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 Olr446  
 Olr514  
 Olr707  
 Olr733  
 Olr780  
 Olr94  
 Pth  
 RT1-N1  
 Slc7a7  
 Tas2r38  
 Tmem27  
 Vom2r51  
   
5. Chromatin Hist1h2bc Hist3h2a 
0.64 Hmgb1 Rcor2 
 Mphosph8  
   
6. Cell migration Cxcl10 Gtpbp4 
0.62 Cxcl9 Hmgb1 
 Nos2 Xirp1 
   
   
7. Cell ion homeostasis Cldn1 Ccnb2 
0.55 Cxcr3  
 Ftl  
 Pth  
 Xirp1  
   
 Down Up 
8. RNA binding Ell3 Gtpbp4 
0.5  Hmgb1 
  Hnrnpa3 
  LOC499339 
  Rpl12 
  Rpl35a 
  Rpl9 
  Rps2 
   
9. Oxidation-reduction Cyp2b12 ND6 
0.43 Ftl Nqo2 
 Gapdh  
 Nos2  
   
10 Peptidase activity Mcpt8  
0.37 Ren  
 RGD1561777  
 Tmem27  
 Tmprss4  
   
   
11. Macromolecular biosythnthesis Chrnb3 Hist1h2bc 
0.29  Hist3h2a 
  Rps2 
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12. Regulation of protein 
modification 
Hmgb1 Gtpbp4 
0.24 Itln1  
 Spink3  
   
   
13.  Membrane fraction Chrnb3 Ankra2 
0.17 Cyp2b12 Ccnb2 
 Gapdh  
 Hmgb1  
 Rpl9  
   
   
   
   
   
   
   
14. Transcription Ell3  
0.17 Hmgb1  
 Itln1  
 Neurog1  
 Pth  
 Vgll2  
   
   
15. Cation binding Cyp2b12 ND6 
0.16 Ftl Nqo2 
 Gapdh  
 Mgat4a  
 Nos2  
 Rpl9  
 Spink3  
 Trim42  
   
   
16. Mitochondrial inner membrane Bphl Mrpl18 
0.13 Cox6a2 ND6 
 RGD1565438 RGD1560088 
 Rpl35a  
   
   
17. Negative regulation  Hmgb1 Gtpbp4 
of biosynthetic process Rcor2 
0.12  Spink3 
   
18. Response to hormone 
stimulation 
Cxcl10  
0.07 Cyp2b12  
 Hmgb1  
 Ren  
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19. Adenyl nucleotide binding Gapdh Hnrnpa3 
0.07 Gtpbp4 RGD1561706 
 LOC292449  
 LOC300308  
 LOC500392  
 Nos2  
 RGD1564899  
 Rpl9  
   
20. Phosphorylation LOC300308  
0.02 RGD1561706  
 RGD1565438  
 
 
 
Table 6.7  Functional annotation clustering using the DAVID bioinformatics tool. 
This analysis identified 20 clusters of genes with related annotations from the gene 
ontology (GO) database. Each cluster is listed with a sample annotation from that 
cluster (underlined). The genes in each cluster are divided into lists of upregulated 
(up) and downregulated (down) columns, and listed alphabetically by gene symbol. 
The full names of each gene can be found in table 6.6. The value highlighted in bold 
for each cluster is the enrichment score for that cluster. This is a measure of how 
significantly enriched the gene list is for that cluster of annotations, and is calculated 
as the geometric mean of the individual p value for each annotation in that cluster, 
and expressed on a log scale. Therefore the higher the enrichment value the greater 
the significance for that cluster. 
  
6.3.3 Validation of selected genes by RT-qPCR 
Following microarray analysis, it is necessary to validate gene expression 
changes by RT-qPCR. In choosing which genes to validate, a number of 
criteria are taken into account. A first consideration was the magnitude of 
fold changes observed for each gene, as genes with high fold changes may 
be of particular biological relevance. Another consideration is to identify 
genes on the list with known roles in nociceptive signalling within the dorsal 
horn, and those involved in other aspects of neuronal plasticity such as LTP. 
Genes related to molecular mechanisms such as the regulation of 
transcription and translation are also of interest, as these mechanisms are 
known to contribute to central sensitisation and behavioural hypersensitivity 
within the dorsal horn. Finally genes related to immune cell function may be 
of interest in pain studies, as immune cell related genes have been 
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previously identified in the dorsal horn in a number of pain models (Costigan 
et al., 2009a; Yukhananov and Kissin, 2008), and immune cells are known to 
contribute to central sensitisation and behavioural hypersensitivity in a 
number of different pain states (Calvo et al., 2012; Clark et al., 2012; Sagar 
et al., 2011). Based on these criteria a number of genes were selected for 
validation by RT-qPCR. 
Ccnb2, encoding the protein Cyclin B2, was one of the highest fold gene 
changes on the list with a 1.85 fold increase in the dermorphin-saporin 
treated animals and ranking number 4 on the list. It was also among the 
minority of genes that were upregulated in the dermorphin-saporin group. 
This increase was confirmed by RT-qPCR, with a significant increase in 
expression found in the dermorphin-saporin + CFA treated group compared 
with saline + CFA controls (p = 0.0041, figure 6.2). 
The next consideration was to investigate genes that were already known to 
contribute to central sensitisation within the dorsal horn. Relatively few 
genes fell into this category, however Nos2, encoding the enzyme nitric 
oxide synthase 2 (inducible nitric oxide synthase), is one example. Nos2 has 
been shown to play a role in central sensitisation in both inflammatory and 
neuropathic pain states (Gühring et al., 2000; Infante et al., 2007; Kuboyama 
et al., 2011; Tang et al., 2007). Nos2 was identified within the ‘response to 
infection’ cluster, which was the second most enriched cluster of genes and 
was found to be downregulated in the dermorphin-saporin group. RT-qPCR 
confirmed a significant decrease in Nos2 expression in the dermorphin-
saporin group (p = 0.022, figure 6.2). 
The most statistically significant cluster (with the highest enrichment score) 
contained genes with ribosomal functions. Ribosomal proteins are of 
interest because translation is important in many forms of neuronal 
plasticity, including pain states (Costa-Mattioli et al., 2009; Géranton et al., 
2009; Jiménez-Díaz et al., 2008). The ribosomal protein Rpl32 had a fold 
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decrease of 1.68 on the microarray. The decrease in Rpl32 was confirmed as 
significant by RT-qPCR (p = 0.0399, figure 6.2). 
Another consideration was to investigate genes with roles in mediating 
immune system processes, as immune cells play an important role in central 
sensitisation in the dorsal horn (Clark et al., 2012; Costigan et al., 2009a; 
Raghavendra et al., 2004; Sagar et al., 2011). Interestingly, immune cell 
responses did feature prominently within the list of genes identified, as 
‘response to infection’ and ‘chemotaxis’ were two of the most enriched 
clusters within the gene list. Cxcl9 and Cxcl10 were among the genes in the 
chemotaxis cluster. These are structurally similar chemokines from the same 
family, and are ligands for the G-protein coupled chemokine receptor Cxcr3 
(Müller et al., 2010) which was also identified on the microarray. Cxcl9, 
Cxcl10 and Cxcr3 were all downregulated in the dermorphin-saporin group 
in the microarray analysis, and RT-qPCR confirmed a significant decrease in 
all three genes (Cxcl10 p = 0.0132, Cxcl9 p = 0.0329, Cxcr3 p = 0.0379, figure 
6.2). This strongly suggested that this chemokine-receptor family is involved 
in mediating descending facilitation via the MOR+ cell pathway. As this 
chemokine family has not previously been described in the dorsal horn in 
pain states, it was decided to characterise the expression of CXCL10 and 
CXCR3 protein in the dorsal horn following CFA treatment, and dermorphin-
saporin treatment. 
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Figure 6.2  RT-qPCR validation of selected genes. 
 A number of genes were selected for validation by RT-qPCR. 2ΔCt values were obtained for 
each group, using actin as the housekeeping gene. Data is presented as % expression of the 
dermorphin-saporin (DS) + CFA group over the saline + CFA control group, mean ± SEM. n = 
4 – 6 per group, * p < 0.05 independent samples t-test. 
6.3.4 Characterising CXCL10 protein expression in the dorsal horn  
Western blot analysis of CXCL10 was carried out on tissue from dermorphin-
saporin + CFA and saline injected + CFA groups (experiment 2) and in 
‘normal’ CFA and sham animals (without RVM injection, experiment 3). 
Bands were detected at the correct molecular weight (at approximately 
10kDA), however comparison between groups indicated no significant 
differences when band intensity was normalised to the housekeeping 
protein calnexin, in either experiment 2 (dermorphin-saporin v saline, p = 
0.5753, independent samples t-test), or experiment 3 (CFA v sham, p = 0.96) 
(figure 6.3). Nonetheless the ability of western blot analysis to detect 
considerable levels of CXCL10 protein in all samples, including sham 
controls, suggests that this protein may be expressed constitutively in the 
dorsal horn. 
Chapter 6 
181 
 
 
Figure 6.3 No effect of CFA or dermorphin-saporin on CXCL10 protein levels. 
Two sets of tissue were used for western blot analysis. ‘Normal’ CFA corresponds to 
experiment 3, and dermorphin-saporin + CFA corresponds to experiment 2 (see table 6.1). 
Lanes are loaded alternately with CFA followed by Sham for the ‘normal CFA’ experiment 
and dermorphin-saporin (DS) followed by saline (sal) for the dermorphin-saporin + CFA 
experiment. No differences in CXCL10 expression were identified in either experiment. p > 
0.05, independent samples t-test, n = 6 all groups, data is presented as mean ± SEM. 
 
To identify the cellular localisation of CXCL10 protein within the dorsal horn, 
immunohistochemistry was carried out in animals at 7d following CFA 
injection or sham procedure. As with the western blot analysis, there did not 
appear to be any difference in CXCL10 expression between CFA and sham 
animals, with relatively high levels of staining in both groups. For this reason 
images from the sham treated group are not shown here. Confocal imaging 
was carried out with various cellular markers to identify the cellular 
localisation of CXCL10.  Analysis of single plane images indicated there was 
no colabelling of CXCL10 in IBA1 positive cells (microglia) or GFAP positive 
cells (astrocytes). Strikingly, most CXCXL10 labelling appeared to be within a 
subset of neurons (NeuN), both in the dorsal and ventral horns. This 
suggested that within the dorsal horn CXCL10 is predominantly neuronal 
(figure 6.4). 
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Figure 6.4 Neuronal localisation of CXCL10. 
Images shown are single plane confocal images, from 7d CFA treated animals. Green 
indicates CXCL10 and red indicates the double labelled antigen, as indicated. The top panel 
is a low power image of CXCL10 and NeuN in the dorsal horn, and the panel below is a high 
power image from the same region. The full arrows indicate examples of double labelled 
CXCL10 and NeuN cells, while the dashed arrow is an example of a NeuN positive, CXCL10 
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negative cell. No double labelling was observed with IBA1 (a marker of microglia) or GFAP (a 
maker of astrocytes). Scale bars indicate 100µm for top panel and 25µm in all other images.  
6.3.5 Characterising CXCR3 protein expression in the dorsal horn  
Western blot analysis of CXCR3 was also carried out on tissue from 
dermorphin-saporin + CFA and saline injected + CFA groups (experiment 2) 
and in ‘normal’ CFA and sham animals (without RVM injection, experiment 
3). Bands were detected at the correct molecular weight (at approximately 
38kDA), however comparison between groups indicated no differences 
when band intensity was normalised to the housekeeping protein calnexin, 
either in experiment 2 (dermorphin-saporin v saline, p = 0.98) or experiment 
3 (CFA v sham, p = 0.7188) (figure 6.5). 
 
Figure 6.5 No effect of CFA or dermorphin-saporin on CXCR3 protein levels. 
Two sets of tissue were used for western blot analysis. ‘Normal’ CFA corresponds to 
experiment 3, and dermorphin-saporin + CFA corresponds to experiment 2 (see table 6.1). 
Lanes are loaded alternately with CFA followed by Sham for the ‘normal CFA’ experiment 
and dermorphin-saporin (DS) followed by saline (sal) for the dermorphin-saporin + CFA 
experiment. No differences in CXCR3 expression were identified in either experiment. p > 
0.05, independent samples t-test, n = 6 all groups, data is presented as mean ± SEM. 
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To characterise the cellular localisation of CXCR3 protein within the dorsal 
horn, immunohistochemistry was carried out in animals at 7d following CFA 
injection or sham procedure. As with the western blot analysis, there did not 
appear to be any difference in CXCR3 expression between CFA and sham 
groups. For this reason images from the sham treated group are not shown 
here. In contrast to CXCL10 labelling, CXCR3 had a discrete, punctate pattern 
of staining within the superficial laminae of the dorsal horn. The punctate 
pattern of staining suggested that CXCR3 could be expressed on afferent 
terminals. Double labelling with CGRP, a marker of peptidergic primary 
afferents, indicated that CXCR3 is expressed in CGRP+ terminals in some 
cases (figure 6.6). Analysis of single plane images indicated there was no 
colabelling of CXCR3 in IBA1 positive cells (microglia) or GFAP positive cells 
(astrocytes) (figure 6.6).  
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Figure 6.6 Double labelling of CXCR3 and CGRP terminals.   
Images shown are single plane confocal images, from 7d CFA treated animals. Green 
indicates CXCR3 staining and red indicates the double labelled antigen. The top panel 
indicates a low power image of CXCR3 and CGRP labelling in the superficial dorsal horn, and 
directly below is a higher power image from the same area. Arrows indicate examples of 
CXCR3 double labelling with CGRP. No double labelling was observed with IBA1 (a marker of 
microglia) or GFAP (a maker of astrocytes). Scale bars indicate 100µm for top panel and 
25µm in all other images. 
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6.4  Discussion 
Previous work by others (Bee and Dickenson, 2008; Burgess et al., 2002; 
Porreca et al., 2001) has demonstrated that the MOR+ cells of the RVM 
contribute to behavioural sensitivity in neuropathic pain models. The 
previous chapter in this thesis has demonstrated that these cells also play a 
role in behavioural hypersensitivity following joint inflammation. Despite a 
number of studies on the role of these cells in facilitation of pain behaviour, 
relatively little is known regarding the spinal mechanisms underlying this 
facilitation. To investigate molecular mechanisms involved in descending 
facilitation by this pathway, we carried out microarray analysis of the dorsal 
horn following MOR+ cell depletion and CFA injection, compared with non-
lesioned controls.  
A number of cellular mechanisms could potentially contribute to descending 
facilitation of dorsal horn excitability. Changes in receptor availability, 
presynaptic release of neurotransmitters, post-synaptic changes in 
intracellular signalling pathways, transcriptional regulation and immune cell 
activation are all key features of central sensitisation (Latremoliere and 
Woolf, 2009) and could be subject to descending facilitation. However, 
surprisingly few genes with neuronal annotations were identified in our 
analysis, while many genes associated with immune cell function were 
identified. This fits with the prominent role of immune cells in the dorsal 
horn in mediating central sensitisation and behavioural hypersensitivity, and 
immune related genes are a feature of many other microarray studies of the 
dorsal horn (Costigan et al., 2009a; Griffin et al., 2007; Yukhananov and 
Kissin, 2008).  
Of particular interest was the identification of a number of genes from the 
CXC chemokine-receptor family, which were found to be downregulated in 
the dermorphin-saporin group. Chemokines have emerged as important 
mediators of immune cell activation and central sensitisation in the dorsal 
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horn (Old and Malcangio, 2012). The identification here of the CXC 
chemokine family, previously uncharacterised in the dorsal horn, is a 
promising subject for future work on the descending facilitation of pain. 
6.4.1 Dorsal horn genes regulated by descending facilitation 
6.4.1.1  Microarray analysis 
Microarray technology is widely used in many areas of biology as a high 
throughput method for identifying many differentially regulated genes in 
parallel. However one of the main limitations of this type of study is the 
generation of false positives and false negatives from the data set due to the 
high number of individual genes studied. To minimise the problem of false 
positives, fold change thresholds are often set at a high value, for example 
fold changes > 2. Used in conjunction with a p value of < 0.05, such strict 
criteria will reduce the likelihood of false positives. However the problem of 
false negatives remains, as many genes that are significantly regulated will 
not be identified as they fail to meet the conservative fold change 
requirement. In studies of the dorsal horn quadrant this can be a particular 
problem. Lamina I, II, and V are the key areas involved in receiving 
nociceptive input and projecting to the brain (Todd, 2002) and therefore 
inclusion of lamina III and IV as well as the surrounding white matter is likely 
to dilute the magnitude of gene expression changes within these laminae of 
interest. For this reason the use of lower fold changes as a cut-off may be 
more appropriate. 
 A recent study of the spinal cord in inflammatory pain has used a p value of 
< 0.01 as the sole criterion for identifying differentially regulated genes with 
no reference to fold changes (Yukhananov and Kissin, 2008). These authors 
were able to validate a number of targets by RT-qPCR suggesting that a fold 
change cut-off is not absolutely required in such studies. Our own group has 
also published data using a combination of statistical significance and fold 
change > 1.3 to identify gene changes in the dorsal horn associated with 
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ankle joint inflammation (Géranton et al., 2007a). In the Géranton et al. 
study comparison was made between naive and CFA treated animals, with 
an obvious difference in behaviour between these groups. Such a profound 
difference in the pain behaviour would suggest that a number of large 
increases in gene expression could occur within the dorsal horn. In the 
present study, microarray analysis was carried out on groups with and 
without RVM lesion by dermorphin-saporin, and both with CFA injection. As 
the lesioned group demonstrate a subtle attenuation of behavioural 
sensitivity it would be expected that the fold differences in gene expression 
changes would also be relatively low. For this reason it was decided that the 
fold change should be reduced to 1.2. This provided a balance between 
reducing false positives, by including a fold change in the interpretation of 
the results, while reducing the likelihood of false negatives by setting the 
fold change criterion at a relatively low level.  
Using these criteria, 129 Affymetrix gene IDs were identified as differentially 
regulated in the dermorphin-saporin treated group. This suggests that 
descending facilitation by RVM MOR+ cells contributes to changes in gene 
expression within the dorsal horn following ankle joint inflammation. The 
majority of these were downregulated in the dermorphin-saporin group 
suggesting that in the normal pain state, these genes are positively 
regulated by descending facilitation. Functional annotation analysis was 
carried out on these genes which revealed that two of the major categories 
of genes regulated by the MOR+ cell descending pathway were those 
associated with ribosomal function and immune cell processes. 
6.4.1.2  Ribosomal proteins regulated by descending facilitation 
Differences in the expression of ribosomal related genes in this study 
suggests that descending facilitation from the RVM has a profound effect on 
the transcription of ribosomal RNA (rRNA) within the dorsal horn. Decreased 
ribosome biogenesis is a feature of some neurodegenerative responses 
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(Rieker et al., 2011) however it has also been found that rRNA transcription 
is subject to regulation by the mammalian target of rapamycin (mTOR) 
signalling pathway (Iadevaia et al., 2012). It is known that translational 
regulation is a key component of neuronal plasticity (Costa-Mattioli et al., 
2009) and in particular the mTOR pathway is activated in the dorsal horn 
during persistent inflammation and contributes to behavioural 
hypersensitivity (Géranton et al., 2009; Norsted Gregory et al., 2010; Obara 
et al., 2011). It is possible that descending facilitation contributes to this 
activation which is reflected in changes in rRNA levels. Downregulation of 
the gene Rpl32 was confirmed by RT-qPCR and other genes in this category 
may warrant further investigation.  
Although RT-qPCR is widely used in the study of gene expression, and is an 
important step following microarray analysis for the validation of selected 
genes, there are some intrinsic limitations associated with this technique. 
One such limitation arises in the choice of a reference or housekeeping 
gene, required for the normalisation of expression data (Coulson et al., 
2008). The ideal reference gene is one that is expressed at a stable level in 
the tissue of interest under all experimental conditions. However it has been 
reported that many common reference genes, such as glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) are themselves differentially regulated 
under certain experimental conditions (Winer et al., 1999). Indeed the 
microarray data obtained in the present experiment indicated that Gapdh is 
downregulated in the dorsal horn group. Actin was used as the sole 
reference gene in the RT-qPCR validation experiments described in this 
chapter. Actin has been used widely as the single reference gene for many 
published studies of the dorsal horn of the rat (Fu et al., 2007; Géranton et 
al., 2007; Ren et al., 2005; Tochiki et al., 2012). However it has been 
proposed that use of more than one reference gene within an experiment 
can produce more reliable data (Huggett et al., 2005). Therefore in further 
studies it may beneficial to include additional appropriate housekeeping 
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genes, such as hypoxanthine guanine phosphoribosyl transferase (HGPRT) in 
the analysis of the RT-qPCR data (Tochiki et al., 2012). This would reduce the 
possibility of generating misleading data due to fluctuations in expression 
levels of actin within the dorsal horn. 
6.4.1.3  Immune system related genes regulated by descending 
facilitation 
It is now widely accepted that immune cells such as microglia, astrocytes 
and infiltrating T cells play a crucial role in a number of chronic pain states 
following nerve injury (Costigan et al., 2009a), cutaneous inflammation 
(Raghavendra et al., 2004), and  joint pain (Clark et al., 2012; Sagar et al., 
2011). Activation of dorsal horn immune cells is generally thought to be 
driven by nociceptive input from the periphery, particularly during 
neuropathic injury (Calvo et al., 2012; Meller et al., 1994). Recently however 
it has been suggested that descending facilitation could contribute to 
immune cell activation within the dorsal horn. It has been shown that 
activation of the spinal 5-HT₃ receptor leads to the release of the chemokine 
CX3CL1 (fractalkine) from primary afferent terminals and subsequent 
microglial and astrocytic activation leading to enhanced pain responses (Gu 
et al., 2011). This suggests that descending 5-HT is involved in the activation 
of spinal immune cells in pain states, and may be one way in which 
descending controls result in increased pain responses.  
In line with this hypothesis our study identified of a number of genes with 
functions within the immune system. Indeed the gene with the highest fold 
change was the serine peptidase inhibitor Serpinb1b, which was found to be 
downregulated 4-fold in the dermorphin-saporin treated group. A closely 
related gene Serpinb1a was also found to be significantly downregulated on 
the array. Serpin proteins are expressed in neutrophils and are required for 
the modulation of neutrophil serine protease activity and neutrophil survival 
(Benarafa et al., 2007). Neutrophil infiltration of the spinal cord (Mitchell et 
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al., 2008) and prefrontal cortex (Poh et al., 2012) has been shown to occur 
during peripheral inflammation and may contribute to increased pain 
processing in these regions. Downregulation of Serpinb1a and Serpinb1b in 
our study may therefore reflect a decrease in neutrophil activity within the 
spinal cord. This raises the interesting possibility that descending facilitation 
could contribute to immune cell infiltration and activation within the dorsal 
horn.  
The gene Nos2, which encodes the enzyme inducible nitric oxide synthase 
(iNOS), was also found to be downregulated in the dermorphin-saporin 
treated group, and this decrease was confirmed by RT-qPCR. Nos2 
expression is induced in peripheral immune cells during inflammation, and 
has also been shown to be upregulated in microglia and astrocytes (Amitai, 
2010). Nitric oxide (NO) itself has been implicated in central sensitisation in 
various pain states (Coderre and Yashpal, 1994; Gühring et al., 2000; 
Malmberg and Yaksh, 1993; Meller et al., 1994a; Moore et al., 1991; Wu et 
al., 2001). Although the focus has largely been on neuronal NOS as the 
enzyme responsible for spinal production of NO, a number of reports have 
implicated Nos2 gene (and iNOS protein) in inflammatory and neuropathic 
pain (Gühring et al., 2000; Infante et al., 2007; Kuboyama et al., 2011; Tang 
et al., 2007). Bilateral induction of Nos2 gene expression in the dorsal horn 
has been shown to occur following ankle injection of CFA (Infante et al., 
2007), and our present data suggests that Nos2 gene expression may be 
modulated, at least in part, by descending pathways. Interestingly 
upregulation of Nos2 occurs in the spinal cord in a model of stress induced 
hyperalgesia, and CCK signalling within the RVM is required for this process 
(Rivat et al., 2010). Our finding supports this work and suggests that Nos2 
may be an important mediator of descending facilitation within the spinal 
cord. 
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6.4.2 Regulation of CXC chemokines by descending facilitation 
Chemokines are small molecular weight proteins which traditionally have 
been shown to regulate leukocyte migration and activation and therefore 
act as a key component of the immune response (Fernandez and Lolis, 
2002).  There are four families of chemokine, based on the structural 
arrangements of cysteine residues in the N-terminus (see figure 6.7). 
Chemokines are involved in the migration of peripheral immune cells to the 
CNS during neuro-inflammatory disorders such as multiple sclerosis or viral 
infection (Ransohoff et al., 2007). In addition, chemokines and receptors 
have been found to be expressed on both neurons and glial cells within the 
normal, healthy CNS and may therefore play an intrinsic role in CNS function 
(Adler et al., 2005). Chemokines within the dorsal horn have been shown to 
play a role in a number of pain models. One well studied example is the 
chemokine CX3CL1 (fractalkine) which is released by neurons within the 
dorsal horn, and activates its receptor CX3CR1 on microglia, leading to 
enhanced release of pronociceptive mediators such as the cytokines IL-1β 
and IL-6, and nitric oxide (NO) (Old and Malcangio, 2012). CX3CL1 in the 
dorsal horn has been implicated in both neuropathic and inflammatory pain 
states (Clark et al., 2012). CCL2, a member of the CC family of chemokines, 
has also been implicated in neuropathic pain states (Zhang et al., 2007). In 
both cases, it appears that the chemokine is released by primary afferents 
and activates microglia or other cell types expressing the target receptor 
within the dorsal horn. 
 
Figure 6.7 Classification of chemokine families. 
Classification of chemokines into four families is based on the structural organisation of the 
N-terminus cysteine residues. To date, CCL2 and fractalkine are the most widely studied in 
the dorsal horn in pain states. Adapted from Old and Malcangio, 2011. 
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Given the established role of chemokines in a number of models of pain, one 
of the interesting findings of the functional annotation analysis was the 
enrichment of terms associated with chemotaxis. Within this cluster two 
members of the same family of chemokines were identified, Cxcl9 and 
Cxcl10. These are members of the interferon gamma (IFN-γ) inducible subset 
of CXC chemokines (figure 6.7). A number of previous studies have 
suggested a role for the cytokine IFN-y within the dorsal horn in chronic pain 
states. IFN-y receptor knockout mice show reduced mechanical 
hypersensitivity in a neuropathic pain model (Robertson et al., 1997).  
Application of IFN-y to the spinal cord increases nociceptive reflexes (Xu et 
al., 1994b) and the IFN-y receptor has been shown to be expressed at 
synapses in the dorsal horn (Vikman et al., 1998). Recently it has been 
shown that IFN-y  application to the spinal cord leads to reduced GABAergic 
inhibition which may contribute to increased nociception (Vikman et al., 
2007). As targets of IFN-y signalling, Cxcl9 and Cxcl10 may therefore be 
involved in nociception in the dorsal horn. Notably the shared receptor for 
these chemokines, Cxcr3, was also identified in the microarray analysis. RT-
qPCR analysis confirmed that Cxcl9, Cxcl10 and Cxcr3 are all downregulated 
in the dermorphin-saporin treated group, suggesting that this chemokine-
receptor signalling pathway may contribute to descending facilitation of the 
pain state.  
As mentioned above, a recent study has identified a role for descending 5-
HT in the release of CX3CL1 (fractalkine) from primary afferents, leading to 
the activation of microglia and astrocytes within the dorsal horn, which 
leads to behavioural hypersensitivity (Gu et al., 2011) . This work indicated 
that descending facilitation by 5-HT is mediated, at least in part, by primary 
afferent release of pro-inflammatory chemokines.  The findings presented in 
this chapter suggest that MOR+ cell mediated descending facilitation may 
act via a different subset of chemokines within the dorsal horn (figure 6.8). It 
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should be noted however that some of the data in the publication by Gu et 
al., 2011 has since been retracted, and therefore needs to be repeated. 
Western blot analysis indicated that both CXCL10 and CXCR3 are expressed 
in the dorsal horn, however no significant increase was found in protein 
levels of either the receptor or the ligand at 7d following ankle injection of 
CFA. In addition, no change in protein levels was identified in the 
dermorphin-saporin and saline treated animals. This suggests that although 
gene expression is decreased in the dorsal horn in the dermorphin-saporin 
group, this is not reflected in overall protein levels. This may be due to a 
difference in time course of the changes in mRNA levels and changes in 
expression of the protein itself. Both CXCL10 and CXCR3 were expressed 
within the dorsal horn in the sham treated animals, suggesting that this 
chemokine-receptor pathway may play a role in normal transmission within 
the spinal cord. For this reason it was of interest to determine the cellular 
localisation of both the receptor and ligand within the cord using 
immunohistochemistry. 
Surprisingly, no evidence was found for microglial or astrocytic expression of 
either CXCR3 or CXCL10. CXCL10 was found to be localised to a subset of 
neurons throughout the spinal cord, as identified by NeuN double labelling. 
Further work to determine the proportion of NeuN cells expressing CXCL10 
will be carried out, as well as double labelling studies to identify specific 
neuronal subpopulations that express CXCL10. Studies have reported 
upregulation of Cxcl10 within the DRG during inflammation and herpes 
zoster infection (Steain et al., 2011; Strong et al., 2012) and it is possible that 
Cxcl10 is also upregulated in the DRG following ankle injection of CFA. 
However we found no evidence for CXCL10 expression on afferent terminals 
within the dorsal horn, suggesting that if Cxcl10 is upregulated within DRG 
neurons in our model, the protein product is not transported to the primary 
afferent terminals. The immunohistochemistry data presented here suggests 
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that CXCL10 protein expression is restricted to a subpopulation of intrinsic 
dorsal horn neurons. 
As with western blot analysis, there was no apparent upregulation of CXCL10 
in the CFA treated animals, suggesting that the CXCL10 is constitutively 
expressed in these neurons. Although most studies of CXCL10 in the CNS 
have focused on its expression in immune cells and role in 
neuroinflammation (Müller et al., 2010), one study has demonstrated that 
CXCL10 is expressed constitutively in neurons in culture, and may be 
released tonically at low levels (Vinet et al., 2010). Furthermore exposure of 
hippocampal neurons in vitro to exogenous CXCL10 causes increased 
excitability (Cho et al., 2009). The identification of CXCL10 protein within 
dorsal horn neurons suggests that this ligand may be released by neurons 
within the dorsal horn and could contribute to synaptic activity in other 
neighbouring neurons. Although to date, chemokines within the CNS have 
been investigated predominantly as modulators of immune cells, in future it 
may be of interest to investigate their roles in neuronal transmission. Indeed 
chemokine-receptor interactions have previously been proposed as an 
additional neurotransmission system in the CNS, as a variety of chemokines 
and their corresponding G-protein coupled receptors have been identified in 
the CNS of healthy animals (Adler et al., 2005). 
In support of a direct role for CXCL10 in neuronal modulation, no evidence 
of expression of the receptor CXCR3 was found in microglia and astrocytes 
of the dorsal horn using immunohistochemistry. In contrast to the CXCL10 
ligand, the distribution of the receptor was restricted to the superficial 
laminae, and had a more punctate appearance. This suggested that CXCR3 
could be located either presynaptically or postsynaptically. As explained, 
activation of the CXCR3 receptor by CXCL10 in vitro causes increased 
neuronal excitability, suggesting that CXCR3 activation within the dorsal 
horn may similarly contribute to neuronal excitability.  Some double 
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labelling with CGRP was observed suggesting that CXCR3 expression occurs 
on a subset of peptidergic terminals in the dorsal horn. This suggests that 
CXCL10 (and other CXC ligands) could act directly on these terminals.  
Not all CGRP+ terminals express the CXCR3 receptor, and work is currently 
underway within the group to quantify the proportion of double labelled 
CXCR3+ CGRP terminals, and within the cell bodies of the DRG. As many joint 
nociceptors express CGRP (Ivanavicius et al., 2004; Jimenez-Andrade et al., 
2010; Nakajima et al., 2008) it would be expected that at least some of these 
double labelled afferent terminals originate in the joint. Future studies using 
anterograde tracing from the joint and skin could be used to determine the 
proportion of CGRP+/CXCR3+ terminals arising from the joint. 
Interestingly descending facilitation via the MOR+ cell pathway has been 
implicated in the release of CGRP from primary afferent terminals (Gardell et 
al., 2003). Therefore one mechanism by which dermorphin-saporin exerts its 
effects on pain behaviour may be via regulation of the CXCR3 receptor 
within peptidergic primary afferent terminals (figure 6.8). Recently it has 
been demonstrated that LTP at primary afferent-dorsal horn synapses is 
driven in part by presynaptic mechanisms of neurotransmitter release (Luo 
et al., 2012). The ability of descending pathways to interact with primary 
afferent terminals may therefore contribute to presynaptic mechanisms of 
LTP within the dorsal horn.  
 
Figure 6.8 Contribution of descending facilitation to immune cell and chemokine 
activation in the dorsal horn.  
Activation of 5-HT₃ receptors on primary afferent terminals in the dorsal horn has been 
shown to cause release of the chemokine fractalkine (CX3CL1) from primary afferent 
terminals. This leads to activation of microglia, release of Il-18, activation of astrocytes, and 
release of IL-1β, which contributes to central sensitisation in cutaneous inflammation (Gu et 
al., 2011). The data provided in this thesis suggests that the MOR+ cell pathway may also 
result in the activation of a chemokine-receptor signalling mechanism. The CXCR3-receptor 
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localises to primary afferent terminals expressing CGRP, and CXCL10 ligand localises to 
neuronal cell bodies in the dorsal horn. These may be regulated by descending facilitation 
via the MOR+ cell pathway, and contribute to behavioural hypersensitivity. (NB. Some of 
the data in the publication by Gu et al., 2011 has since been retracted, and therefore needs 
to be repeated). 
Chemokine receptors are G-protein coupled, signalling to Gi proteins and 
leading to activation of a variety of intracellular signalling pathways (Sallusto 
and Baggiolini, 2008). Therefore the expression of CXCR3 on primary 
afferent terminals suggests that activation could modulate the excitability of 
these fibres. In vitro studies have demonstrated that activation of the CXCR3 
receptor by CXCL10 results in ERK phosphorylation and increased neuronal 
excitability in hippocampal cultures (Bajova et al., 2008; Xia et al., 2000). 
Notably, exposure of DRG neurons in culture to CXCL10 can induce calcium 
transients suggesting that DRGs express the CXCR3 receptor and respond to 
CXCL10 binding (Oh et al., 2001). Neuronal expression of the CXCR3 receptor 
and excitation of neurons by CXCL10 has not been demonstrated previously 
in vivo, however it is an interesting possibility that CXCL10 - CXCR3 signalling 
could contribute to neuronal excitability in the nociceptive system. 
The expression of CXCR3 on primary afferent terminals is somewhat 
puzzling, given that our interest in this receptor arose from transcriptional 
changes in the dorsal horn, and these would largely reflects changes in 
transcription at the cell body. However it is known that local translation 
occurs in primary afferent terminals, presumably of mRNA transcripts that 
are present at those terminals (Géranton et al., 2009; Jiménez-Díaz et al., 
2008). Therefore it is possible that mRNA transcripts localised to primary 
afferent terminals contribute to the changes identified by microarray and 
RT-qPCR analysis of the dorsal horn.  
Upregulation of Cxcl0 has been shown previously within the dorsal horn in a 
model of post-herpetic allodynia (Takasaki et al., 2012), and upregulation of 
Cxcl10 has also been shown occur within the DRG during inflammation 
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(Strong et al., 2012) and following herpes zoster infection (Steain et al., 
2011). Our work is the first to identify changes in both Cxcl10 and Cxcr3 
genes simultaneously, and to attempt to characterise the cellular 
localisation of their protein products. Importantly changes in gene 
expression of Cxcr3 and Cxcl10 were only unmasked following depletion of 
the descending facilitatory system, suggesting an important role for the 
MOR+ pathway in the regulation of these molecules. Further work is needed 
to fully characterise this chemokine-receptor system in the dorsal horn but it 
is a promising target for further work on descending facilitation in pain. 
6.4.3 Conclusion 
Microarray analysis of the dorsal horn in animals with CFA injection and 
prior RVM injection of either dermorphin-saporin or saline led to the 
identification of genes regulated by descending facilitation. Many of these 
are immune related, and downregulated in the lesioned group. This fits with 
existing knowledge of the importance of immune cells to chronic pain states 
and the potential role of descending pathways in the activation of these 
processes.  
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7. General Discussion 
Joint pain is a significant clinical problem, and to date most research has 
focused on the peripheral causes of joint injury as the source of pain, rather 
than addressing plasticity in the nociceptive system. Treatment approaches 
are also based largely on modification of peripheral pathology, such as joint 
replacement in osteoarthritis, or the use of immunosuppressant drugs in 
rheumatoid arthritis.   
Clinically it has been demonstrated that patients with OA and RA have 
increased pain sensitivity at sites beyond the affected joints (Graven-Nielsen 
et al., 2012; Morris et al., 1997). This suggests that joint pain is caused in 
part by changes within the nociceptive system, in addition to the peripheral 
joint pathology. In some cases, pain may persist even after interventions to 
treat the peripheral cause of pain, such as joint replacement surgery (Wylde 
et al., 2011). Understanding the changes that occur in the nociceptive 
system during joint pain is important for the development of better 
pharmacological treatments (Kidd et al., 2007). 
Studies have begun to address the role of  dorsal horn sensitisation in animal 
models of joint pain (Schaible et al., 2009), and descending facilitation via 
the RVM is known to contribute to spinal excitability in other models, 
including neuropathic pain and cutaneous inflammation (Ossipov et al., 
2010). To date however relatively few studies have addressed the role of the 
descending system in joint pain, and those that have investigated the role of 
descending inhibition, and only in the acute phase of injury (Cervero et al., 
1991; Danziger et al., 1999; Schaible et al., 1991). The aim of this thesis was 
to investigate the role of descending facilitation in a model of joint 
inflammation. Using lesion techniques combined with behavioural studies 
and molecular analysis of the dorsal horn, I have demonstrated that 
descending facilitation contributes to mechanical hypersensitivity of the 
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hindpaw and transcriptional changes within the dorsal horn following joint 
inflammation. 
7.1  Summary of findings 
7.1.1 Changes in the RVM following joint inflammation 
Ankle injection of CFA in the rat is a widely used model of inflammatory joint 
pain (Butler et al., 1992). Recent studies have demonstrated that the dorsal 
horn of the spinal cord is involved in the development of behavioural 
hypersensitivity in this model (Géranton et al., 2007a; Shan et al., 2007; 
Vikman et al., 2003; Yao et al., 2011). To date however the role of the RVM 
has not been investigated. Chapter 3 of this thesis investigated if activation 
of the RVM occurs following ankle joint inflammation, which would suggest 
recruitment of descending controls. Activation of ERK by phosphorylation is 
considered a hallmark of neuronal activity, and pERK immunohistochemistry 
has been used previously to demonstrate activation of the RVM following 
cutaneous inflammation (Imbe et al., 2005) and in a model of neuropathic 
pain (Géranton et al., 2010). As in these other pain models, ankle joint 
inflammation led to an increase in pERK positive neurons within the RVM. 
This effect was transient, as pERK was only significantly increased at 6h post 
CFA injection and not at later time points. Furthermore it was shown that 
this increase in pERK occurs largely within the 5-HT expressing population of 
RVM neurons, supporting a role these neurons in the modulation of pain in 
this model. Importantly, mechanical hypersensitivity of the hindpaw remains 
elevated for many days after this time point, suggesting that the activation 
of the ERK signalling pathway in the RVM contributes to the induction, but 
not the maintenance, of the pain state. ERK activation at this early time 
point may indicate the onset of descending modulation via the RVM.   
Another approach used was to investigate if GABAergic signalling in the RVM 
is altered following joint inflammation. Many of the synapses formed onto 
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RVM neurons are GABAergic (Cho and Basbaum, 1991) suggesting an 
important role for GABA in modulating the output of the RVM. Recently it 
has been suggested that decreased GABAergic inhibition in the region 
contributes to increased excitability of the RVM-dorsal horn projection 
neurons in a model of cutaneous inflammation (Zhang et al., 2011). To 
investigate if this occurs in the ankle joint model, an antibody specific to C-
terminus of VGAT, which is only accessible within actively recycling 
synapses, was injected into the RVM at 3d post CFA injection. This method 
labels active GABAergic synapses in vivo and quantification of this labelling 
indicated a decrease in GABAergic transmission occurs at 3d post CFA 
injection. This provides evidence supporting the view that decreased 
inhibition of RVM neurons occurs during the maintenance of inflammatory 
joint pain. 
Taken together, these anatomical experiments have confirmed that the RVM 
is activated during joint inflammation, suggesting descending modulation 
from this region may contribute to behavioural hypersensitivity.  
7.1.2 Descending facilitation plays a time dependent role in mechanical 
hypersensitivity of the hindpaw following joint inflammation 
Behavioural hypersensitivity was measured following ankle injection of CFA 
using von Frey hairs applied to ipsilateral hindpaw. Increased mechanical 
hypersensitivity of the hindpaw is predominantly a reflection of secondary 
hyperalgesia and allodynia (see below section 7.2.1), which requires central 
sensitisation. To investigate the role of descending facilitation in this process 
two lesion experiments were carried out. Firstly lesion of the descending 5-
HT input to the dorsal horn was performed by intrathecal administration of 
the toxin 5,7-dihydroxytryptamine (5,7-DHT). This selectively ablates all 
fibres containing 5-HT. This lesion was found to attenuate mechanical 
hypersensitivity, but only at 1d and 2d post CFA injection. This suggested 
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that descending 5-HT containing neurons play a time dependent role in the 
development of mechanical hypersensitivity.  
As many previous studies had implicated the 5-HT₃ receptor in the 
facilitatory effects of 5-HT within the spinal cord (Dogrul et al., 2009; 
Donovan-Rodriguez et al., 2006; LaGraize et al., 2010; Suzuki et al., 2002), a 
further experiment investigated the role of this receptor. Intrathecal 
injection of ondansetron, a 5-HT₃ specific antagonist, was carried out at 1d 
following CFA injection. This led to a brief attenuation of established 
mechanical hypersensitivity. As the magnitude of attenuation was 
comparable to that observed following 5,7-DHT lesion, this suggested that 5-
HT acting at the 5-HT₃ receptor is an important facilitatory pathway in joint 
pain.  
Only a small proportion of electrophysiologically defined ON cells, believed 
to be facilitatory, contain 5-HT (Marinelli et al., 2002). This suggests other 
non-5-HT neurons are also likely to contribute to descending facilitation. 
Although ON cells do not have a single neurochemical identity, they can be 
identified by their direct responsiveness to morphine suggesting they 
express the mu opioid receptor (MOR) (Heinricher et al., 1994; Marinelli et 
al., 2002). This characteristic has been exploited previously to selectively 
ablate the MOR expressing (MOR+) neurons of the RVM using the selective 
neurotoxin dermorphin-saporin (Bee and Dickenson, 2008; Burgess et al., 
2002; Porreca et al., 2001; Zhang et al., 2009). To investigate the role of 
these neurons in the inflammatory joint pain model, microinjection of 
dermorphin-saporin to the RVM was carried out prior to CFA injection. 
Unlike previous studies of neuropathic pain (Burgess et al., 2002; Zhang et 
al., 2009), MOR+ cell depletion did not lead to a full reversal of mechanical 
hypersensitivity. Instead a significant attenuation of hypersensitivity, of a 
similar magnitude to that observed in the 5,7-DHT experiment, was found.  
However in contrast to the 5,7-DHT depletion experiment, MOR+ cell 
Chapter 7 
203 
 
depletion had a more prolonged effect on behavioural hypersensitivity, with 
significant attenuation observed from 1-7d post CFA injection.  
These behavioural experiments have demonstrated that both 5-HT and non-
5-HT mechanisms of descending facilitation contribute to secondary 
hyperalgesia following joint inflammation. The time course of attenuation by 
these two pathways overlaps but is not identical, suggesting that these two 
pathways have different roles in inflammatory joint pain.  
7.1.3 Changes in gene expression associated with descending facilitation 
In comparison to our understanding of descending facilitation via the 5-HT 
pathway, relatively little is known about the dorsal horn mechanisms 
underlying ON/MOR+ cell mediated facilitation. Chronic pain states are 
associated with transcriptional changes within the dorsal horn (Géranton et 
al., 2007; Kim et al., 1998), and indeed a number of molecular changes have 
been shown to occur directly in response to the 5-HT pathway (Géranton et 
al., 2008; Rygh et al., 2006). To identify possible mechanisms by which 
MOR+ cells contribute to pain facilitation in the spinal cord, microarray 
analysis was carried out to identify changes in dorsal horn gene expression 
associated with this descending pathway. 
This analysis led to the identification of a number of immune system related 
genes which may be of interest for further studies. This is in line with a 
number of other microarray studies which have found upregulation of 
immune related genes within the dorsal horn in persistent pain states 
(Costigan et al., 2009a; Yukhananov and Kissin, 2008). Of particular interest 
were the genes for the chemokine Cxcl10 and its receptor Cxcr3, both of 
which were downregulated in the dermorphin-saporin group. A number of 
other chemokines have been implicated in pain signalling within the dorsal 
horn (Old and Malcangio, 2012). However neither CXCL10 nor the CXCR3 
receptor proteins have been identified previously within the dorsal horn, 
although Cxcl10 expression has been identified in the DRG in a number of 
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experimental conditions such as inflammation and herpes zoster infection 
(Steain et al., 2011; Strong et al., 2012; Takasaki et al., 2012). The 
downregulation of both genes in the dermorphin-saporin group suggest they 
may be targets of MOR+ mediated descending facilitation at the dorsal horn 
level.  
Unexpectedly immunohistochemistry within the dorsal horn indicated that 
the protein products of these genes were not localised to microglia or 
astrocytes. The apparent neuronal localisation of CXCL10 and CXCR3 
suggests that these may play a role in attracting immune cells to the dorsal 
horn during inflammatory pain, or as a novel neuronal signalling pathway 
contributing to central sensitisation.  
7.2  Descending facilitation in joint inflammation 
7.2.1 Measuring mechanical hypersensitivity of the hindpaw: a note on 
terminology 
In humans, allodynia refers to an increased pain response to normally 
innocuous stimuli, and hyperalgesia refers to an increased response to 
painful stimuli. My behavioural experiments have investigated increased 
mechanical sensitivity of the hindpaw following joint inflammation in the 
rat. To avoid making assumptions as to whether this hypersensitivity is a 
reflection of allodynia or hyperalgesia, which is difficult to address in an 
animal model, I have used the term mechanical hypersensitivity to describe 
this data. However in this study it is important to distinguish between 
primary and secondary hyperalgesia. In models of cutaneous inflammation 
in humans, primary hyperalgesia refers to increased pain sensitivity that 
occurs at the site of injury while secondary hyperalgesia occurs at sites 
adjacent to but not at the site of injury (Hardy et al., 1950; Treede et al., 
1992). A comparable distinction can also be made in conditions of joint pain, 
where pain in the affected joint is primary, and pain arising distal to the 
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injured joint is secondary, and presumably driven by central mechanisms 
(Graven-Nielsen et al., 2012). In the experiments described in this thesis, 
mechanical hypersensitivity of the hindpaw predominantly reflects 
secondary mechanisms, as increased paw sensitivity is secondary to the site 
of injury within the ankle joint.  
To summarise, although I use the term mechanical hypersensitivity to 
describe the behavioural results in this thesis, this hypersensitivity is 
predominantly a reflection of secondary hyperalgesia (and/or allodynia), 
which is driven by central sensitisation (Treede et al., 1992). 
7.2.2 Descending facilitation of mechanical hypersensitivity of the 
hindpaw 
This study has provided new information regarding descending facilitation in 
chronic pain states. Although it seems that both descending 5-HT and the 
MOR+ cell pathway play a role in secondary hyperalgesia associated with 
joint inflammation, the magnitude of attenuation in both lesion studies is 
considerably smaller than that observed in neuropathic pain states. 
Depletion of MOR+ cells in the RVM results in a complete reversal of 
mechanical pain hypersensitivity at the later stages of neuropathic pain 
(Burgess et al., 2002; Zhang et al., 2009). Similarly 5-HT plays a small role in 
the behavioural experiments described in this thesis. This contrasts with 
previous findings in neuropathic pain, in which depletion of endogenous 5-
HT completely reverses hypersensitivity (Rahman et al., 2006). This suggests 
there are important differences in neuropathic and joint pain processing at 
the supraspinal level, with neuropathic pain models more heavily dependent 
upon facilitation from the RVM. 
The time of onset of descending facilitation is also different in the present 
study than that shown previously for neuropathic pain. The previous 
dermorphin-saporin studies of neuropathic pain indicated that descending 
facilitation is required for the maintenance but not the induction of 
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behavioural hypersensitivity (Bee and Dickenson, 2008; Burgess et al., 2002; 
Zhang et al., 2009). In contrast, descending facilitation of joint pain is 
evident from one day onwards. This suggests that in neuropathic pain, 
descending facilitation is required for the maintenance of pain, whereas in 
joint pain, descending facilitation contributes to both the induction and 
maintenance phases. Neuropathic and inflammatory pain models have 
different peripheral causes and onset of hypersensitivity. While peak 
behavioural hypersensitivity in the joint model is observed within hours, 
neuropathic pain may take longer to develop resulting in later activation of 
the descending facilitatory system. The differences in descending facilitation 
of joint pain and neuropathic pain may also indicate that central 
sensitisation, and subsequent secondary hyperalgesia, is more prominent in 
neuropathic than in joint pain. 
Not only do the present findings differ from those in neuropathic models, 
they also highlight some differences between 5-HT modulation of joint and 
cutaneous inflammation. The contribution of descending 5-HT to cutaneous 
inflammatory pain has been investigated in a number of studies. For 
example our group previously found that 5,7-DHT depletion attenuates 
mechanical hypersensitivity following plantar inflammation from 1h to 1d 
post CFA injection (Géranton et al., 2008). This contrasts with the present 
findings in which 5-HT does not play a significant role until 1d post CFA 
injection to the ankle. 
Interestingly a more recent study, which used siRNA within the RVM to 
silence the tryptophan hydroxylase (TPH) enzyme and so reduce 5-HT 
synthesis, showed slightly different results in the same cutaneous model 
(Wei et al., 2010). They found that there was no effect on mechanical 
hypersensitivity until 1d – 3d following plantar injection of CFA. The timing 
of the involvement of 5-HT in this study supports the present findings, 
suggesting that 5-HT plays a time dependent role in the facilitation of 
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inflammatory pain. Nonetheless the magnitude of changes observed in the 
Wei et al. study were larger than those identified here, again suggesting a 
greater contribution of descending facilitation to pain of cutaneous origin 
than that from arising the joint.  
One of the major anatomical differences between joint and cutaneous 
nociceptors is the termination of joint afferents in lamina I, and absence of 
direct joint terminations in lamina II (Doyle and Hunt, 1999; Mense and 
Prabhakar, 1986; Neugebauer et al., 1994). Lamina II interneurons are 
believed to play an important role in the development of mechanical 
hypersensitivity in neuropathic pain and cutaneous inflammation (Malmberg 
et al., 1997; Martin et al., 2001). More recently genetic ablation of the IB4+, 
non-peptidergic C-fibre population, which terminate in lamina II has been 
shown to reduce mechanical hypersensitivity in cutaneous inflammation and 
neuropathic pain (Cavanaugh et al., 2009). This population of fibres do not 
innervate the joint (Ivanavicius et al., 2004; Jimenez-Andrade et al., 2010; 
Nakajima et al., 2008). Therefore pain arising from the joint may not result in 
direct activation of lamina II neurons in the dorsal horn. As descending 
projections from the RVM terminate in both lamina I and lamina II, direct 
actions on the peripheral nociceptive terminals may be more prominent in 
cutaneous inflammation than in joint inflammation (Millan, 2002). 
These differences may also reflect a more prominent role of descending 
inhibition in joint pain than in cutaneous pain. The earliest investigations of 
descending controls in joint pain indicated that at least in the acute stage, 
inhibition of spinal nociception occurs (Cervero et al., 1991; Schaible et al., 
1991). Although this inhibition may not persist beyond the acute phase of 
inflammation it raises the possibility that both facilitation and inhibition 
occur simultaneously, and which system predominates may depend on the 
nature of the nociceptive input (cutaneous or joint). 
Chapter 7 
208 
 
The findings presented in this thesis indicate that during inflammation of the 
joint, descending facilitation from the RVM contributes in a time dependent 
manner to mechanical hypersensitivity of the hindpaw, a reflection of 
secondary hyperalgesia. Previous work on descending controls in joint pain 
has largely focused on descending inhibition of spinal excitability during joint 
inflammation (Cervero et al., 1991; Schaible et al., 1991), although one study 
has demonstrated a role for descending 5-HT in the facilitation of spinal 
excitability in osteoarthritic pain (Rahman et al., 2009). No behavioural 
studies have been carried out to date in a joint model. The lesion 
experiments described here demonstrate that in addition to these inhibitory 
influences descending facilitation is important, in particular in mediating 
secondary mechanical hyperalgesia. This supports previous findings 
suggesting that descending modulation differentially affects primary and 
secondary hyperalgesia during cutaneous inflammation (Pertovaara, 2000; 
Vanegas, 2004; Zhuo and Gebhart, 1990).  
Notably, no effect of descending 5-HT on weight bearing was observed in 
the present study suggesting that following ankle injection of CFA the same 
principles may apply. Primary hyperalgesia of the inflamed joint may be 
inhibited by descending controls, while descending facilitation could 
contribute to secondary mechanical hyperalgesia of the adjacent cutaneous 
tissue. Recent studies have addressed the role of descending 5-HT in pain 
behaviour following plantar inflammation, in which the primary and 
secondary components of hyperalgesia are difficult to distinguish (Géranton 
et al., 2008; LaGraize et al., 2010; Wei et al., 2010). The behavioural data 
presented in this thesis provides direct evidence that following peripheral 
inflammation, secondary hyperalgesia of adjacent non-inflamed tissue is 
facilitated by descending pathways from the RVM. Secondary hyperalgesia 
at sites distant from the inflamed joint has been reported in patients with RA 
(Edwards et al., 2009) and OA (Gwilym et al., 2009). Therefore cutaneous 
secondary mechanical hyperalgesia appears to be a clinically relevant 
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outcome measure in studies of joint pain. Secondary hyperalgesia requires 
central sensitisation (Treede et al., 1992), therefore studying secondary 
hyperalgesia in animal models is also useful as a measure of central 
sensitisation in the spinal cord.  
The size of the weight bearing chamber available during these experiments 
was a limiting factor, and we were unable to carry out weight bearing 
analysis on the larger animals (400 – 500g) of the dermorphin-saporin 
experiments. Future work with a modified weight bearing chamber could 
provide useful information on the relative contribution of the descending 5-
HT and MOR+ pathways to weight bearing on the inflamed joint. The 
question of primary hyperalgesia of the joint itself has not been explicitly 
addressed in this thesis, and it is possible that descending inhibition 
predominates over facilitation at the primary injury site. In future it would 
be of interest to fully characterise the role of descending facilitation in 
primary hyperalgesia of the inflamed joint using weight bearing apparatus, 
and indeed other measures such as hindlimb grip force (Chandran et al., 
2009; Lee et al., 2011b). 
7.2.2.1  Limitations of the lesion approach 
Traditional electrolytic lesion techniques have been used in the RVM to 
investigate the net contribution of the neurons of this region in pain 
processing in a number of models (Terayama et al., 2002; Urban and 
Gebhart, 1999). However interpretation of results from such studies is 
complicated as the RVM is a heterogeneous population of cells, and non-
selective ablation of the region will therefore include both the inhibitory and 
facilitatory circuitry. Selective lesion of components of the descending 
pathway such as those used in this thesis are an improvement on this 
technique, as it is possible to attribute the behavioural effects of the lesion 
to the loss of the cell type targeted. Nonetheless as with any experimental 
technique these methods are not without limitations.  
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Intrathecal administration of 5,7-DHT results in an almost complete loss of 
5-HT containing neurons that project to the dorsal horn. The results of the 
ondansetron experiment in chapter 4 strongly suggest that the behavioural 
effects observed by 5,7-DHT depletion are driven largely by a loss of 5-HT 
itself. However it is important to bear in mind that by using lesion of whole 
fibres, other transmitters contained within those descending 5-HT fibres will 
also be lost. The loss of other transmitters may contribute to the 
behavioural effects observed. This is also true of the dermorphin-saporin 
experiment described in chapter 5. As shown in this chapter, loss of neurons 
in the RVM region can have unintended adverse effects on the animal which 
must be avoided.  
7.2.3 Neurochemistry of descending facilitation 
In this thesis the roles of two distinct but overlapping descending pathways 
via 5-HT cells and MOR expressing (MOR+) neurons were investigated in 
parallel experiments. This allows conclusions to be drawn about how these 
pathways interact in the intact animal. It is known that some MOR+ neurons 
contain 5-HT (Marinelli et al., 2002; Sikandar et al., 2012), but there are also 
many MOR negative (MOR-) 5-HT neurons, and 5-HT negative MOR+ cells.  
These three different categories of RVM neurons may have different 
contributions to the facilitation of joint pain behaviour.  
Activation of ERK at 6h post CFA injection occurs largely within the 5-HT 
expressing population. This supports the behavioural findings in chapter 4 
which indicate that depletion of the 5-HT population attenuates behavioural 
hypersensitivity at 1 and 2d post CFA injection, but not at later time points. 
These effects of 5-HT will incorporate those neurons that also express the 
MOR, therefore the effects of dermorphin-saporin lesion at 1d and 2d 
following CFA injection may be mediated partly by a 5-HT mechanism. 
Notably, little pERK labelling is observed in the more dorsal regions of the 
RVM, which is rich in MOR+ neurons. Therefore it is likely that many of the 
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MOR+, 5-HT negative neurons do not express pERK following ankle injection 
of CFA. As peak ERK activation occurs at the 6h time point, this suggests that 
these pERK negative neurons may play a role in the later phase of 
facilitation, from 3 to 7d post CFA injection.   
By quantifying the number of active GABAergic synapses in the RVM it was 
found that inflammation induces a decrease in GABAergic inhibition in the 
RVM at 3d post CFA injection. This suggests that the effects of descending 
facilitation on pain maintenance are due in part to decreased inhibition in 
the RVM. Others have demonstrated previously that at 3d following 
cutaneous inflammation, GABAergic inhibition is decreased while MOR+ cell 
excitability increased, suggesting that MOR expressing cells are 
preferentially affected by this loss of inhibition (Zhang et al., 2011). Although 
here I have not addressed this directly it seems likely that decreased 
GABAergic inhibition of MOR+ cells at this later time point may contribute to 
facilitation by these neurons in the later phases of inflammation. 
One hypothesis based on the anatomical data presented in chapter 3 and 
the behavioural experiments in chapter 4 and 5 is that in the acute phase of 
inflammatory joint pain, descending facilitation does not contribute to 
behavioural hypersensitivity, as no effects are observed by either 5,7-DHT or 
dermorphin-saporin lesion. 5-HT contributes to behavioural hypersensitivity 
at 1 and 2 d following inflammation, but not at later time points. Activation 
of ERK within the TPH population at 6h following CFA may contribute to 
setting up this behavioural effect. MOR+ cell depletion results in a more 
prolonged attenuation. At the 1d and 2d time points, at least some of this 
effect may be mediated by 5-HT mechanisms. At the later time points, from 
3d to 7d, non 5-HT mechanisms must be involved. This would support a 
mechanism by which decreased GABAergic inhibition, as identified here at 
3d following CFA injection, could result in increased excitability of MOR+ 
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(non-5-HT) neurons, which contributes to the maintenance phase of 
behavioural hypersensitivity.  
The main limitation of the findings presented here is our lack of knowledge 
of the transmitter content of these MOR+, non-5-HT neurons. At least some 
of these are GABAergic (Kalyuzhny and Wessendorf, 1998). Crucially the 
effect of the MOR+ projection neurons will depend on the cell type they 
synapse onto within the cord. In the case of the MOR+ 5-HT population we 
could assume that at least part of the effect is mediated via the 5-HT₃ 
receptor. For GABAergic MOR+ neurons, the facilitatory effects would be 
expected to be mediated via a disinhibitory mechanism, by synapsing onto 
inhibitory interneurons of the cord. A further complication is that not all 
MOR+ cells project to the cord. Some GABAergic MOR+ expressing neurons 
act locally within the RVM, presumably inhibiting OFF cells or other 
inhibitory projection neurons (Kaplan and Fields, 1991).  
7.2.4 Immune related genes as targets of descending facilitation 
While the contribution of descending facilitation to central sensitisation and 
pain behaviour has been studied frequently (Bee and Dickenson, 2008; 
Burgess et al., 2002; Géranton et al., 2008; Wei et al., 2010) little is known 
about the molecular mechanisms underlying descending facilitation. Our 
group has previously used microarray analysis to characterise changes in 
dorsal horn gene expression at various time points following ankle injection 
of CFA (Géranton et al., 2007). The aim of the present study was to focus on 
the specific contribution of descending facilitation in the regulation of gene 
expression at the 7d time point. For this reason, microarray analysis was 
carried out on two groups of animals only, both groups with CFA 
inflammation and dermorphin-saporin or saline pretreatment as the only 
variable. In this way our analysis revealed genes that are differentially 
regulated in the pain state in the presence or absence of the MOR+ cell 
pathway. One limitation of this approach is that we are unable to compare 
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gene expression between CFA and sham animals in the present work, 
however dorsal horn gene expression changes at various times post 
inflammation have been investigated by our group previously (Géranton et 
al., 2007). 
Immune cells play an important role in mediating central sensitisation both 
in neuropathic (Beggs et al., 2012) and inflammatory (Clark et al., 2012; 
Sagar et al., 2011; Sun et al., 2012) pain states. Many molecular studies have 
identified immune related genes in the dorsal horn in various models of 
chronic pain (Costigan et al., 2009a; Yukhananov and Kissin, 2008). 
Therefore it was not surprising that in the microarray analysis carried out in 
this study many of the identified genes had immune system related 
annotations. Importantly this demonstrates that part of the mechanism by 
which descending controls mediate their effects in the spinal cord is via 
immune cell responses. This has been proposed by others for the 
descending 5-HT pathway (Gu et al., 2011). These authors suggest that 5-HT 
exerts its facilitatory effects via activation of the 5-HT₃ receptor on primary 
afferent terminals, which leads to the release of fractalkine (CX3CL1) from 
those terminals. CX3CL1 then signals to microglia and astrocytes, which 
contribute to behavioural hypersensitivity. This recent development 
provides an important framework in which our present molecular data can 
be interpreted. For example, descending signalling via the MOR+ pathway 
may contribute to the transcription of immune related genes such as Nos2, 
Serpinb1a and Serpinb1b. Exactly how this occurs is not yet established, as 
the neurochemical basis of descending facilitation by the MOR+ cell pathway 
within the dorsal horn is not clear. However the present data suggests that 
one mechanism by which descending facilitation has excitatory effects in the 
dorsal horn is via modulation of immune cells such as microglia and 
astrocytes. 
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The role of CXC chemokines is of particular interest as two chemokines of 
this family and their common receptor were simultaneously identified on 
the array. This strongly suggests that the downregulation of these genes is 
related to the decreased pain sensitivity observed in the dermorphin-saporin 
CFA group. CXCL10 and the receptor CXCR3 have previously been implicated 
in inflammatory disorders within the CNS, such as viral infection, multiple 
sclerosis and Alzheimer’s disease (Müller et al., 2010). Although this would 
suggest a prominent role for this ligand-receptor pathway in neuronal-
immune cell signalling in the dorsal horn, the immunohistochemistry data 
presented in chapter 6 suggests this is not in fact the case. Both the ligand 
and the receptor appear to be neuronally expressed, with no indication of 
being present within microglia or astrocytes. This poses an intriguing 
possibility in which chemokine-receptor signalling could be involved in the 
normal intrinsic function of the dorsal horn, as well as increased excitability 
in pain states. Some limited in vitro evidence is in place to suggest that 
CXCXL10-CXCR3 signalling is indeed involved in neuronal excitability. Firstly 
both the receptor and ligand have been localised to neurons (Vinet et al., 
2010), at least in culture. Secondly CXCL10 application to neurons leads to 
alterations in calcium transients and cell excitability (Cho et al., 2009). In 
addition CXCL10 treatment causes increases in levels of phosphorylated 
cAMP response element binding protein (CREB) and phosphorylated ERK in 
cells, which are both hallmarks of neuronal activation (Bajova et al., 2008). It 
will be of interest to determine if this occurs in vivo within the dorsal horn, 
as it could represent a novel interneuronal signalling mechanism. 
7.2.5 Clinical implications 
Rheumatoid arthritis (RA) affects 1% of the population (Lee and Weinblatt, 
2001) and is associated with resting pain in the joints, joint stiffness and 
inflammation. Although joint stiffness and functional disability are major 
symptoms which impair quality of life for patients, treatments which 
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suppress the peripheral inflammatory mechanisms are not always effective 
(Kidd et al., 2007). Therefore understanding changes in the nociceptive 
system and improving pain management remains an important goal.  
Rodent models of inflammatory polyarthritis can result in complications 
which may impair nociceptive testing, such as skin lesions and weight loss 
(Neugebauer et al., 2007). To address this problem, models of inflammatory 
monoarthritis have also been developed, including injection of CFA to the 
ankle joint (Butler et al., 1992). Although not a model of human RA per se, 
this method produces a reliable, localised inflammation of the ankle joint 
and results in stable behavioural hypersensitivity lasting up to 2 weeks post 
inflammation. RA patients have increased pain sensitivity at sites away from 
the inflamed joints (Edwards et al., 2009) and this may reflect increased 
central sensitisation within the dorsal horn of these patients (Kidd et al., 
2007; Morris et al., 1997, Lee et al., 2011). Ankle injection of CFA has been 
used to demonstrate that central sensitisation occurs within the dorsal horn 
following joint inflammation (Neugebauer and Schaible, 1990). Increased 
descending inhibition has been demonstrated in this model in the acute 
phase (Cervero et al., 1991; Schaible et al., 1991) suggesting that tonic 
inhibition from supraspinal regions is increased in the early stages of this 
model.  
To date, little is known regarding the role of descending facilitation via the 
RVM in inflammatory joint pain. The findings presented in this thesis 
demonstrate for the first time that behavioural hypersensitivity in 
inflammatory joint pain is dependent in part on descending facilitation via 
the RVM. In addition to peripheral pathology and spinal cord sensitisation, 
brainstem contributions should also be taken into account in the treatment 
of joint inflammatory conditions such as RA. Our findings may also be of 
relevance to other joint pain conditions such as osteoarthritis. In summary, 
the contribution of descending facilitation to behavioural hypersensitivity, 
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which has been established in models of neuropathic pain (Bee and 
Dickenson, 2008; Burgess et al., 2002; Rahman et al., 2009), should also be 
taken into account in the study and treatment of joint pain.  
7.3  Future directions 
The behavioural studies described in this thesis add to the existing body of 
evidence indicating that descending facilitation contributes to central 
sensitisation and hyperalgesia in a number of persistent pain states. 
However a number of questions remain regarding the role of the RVM in 
nociceptive processing, in this and other pain models. The identification of 
immune related genes in the dorsal horn also raises a number of interesting 
questions and possibilities for further study. 
One of the fundamental questions remaining regarding descending 
facilitation is the neurochemistry of the MOR+ neurons. It is thought that 
the ON cell, MOR+ population of neurons is a heterogeneous group of cells. 
Some of these contain 5-HT, which in part explains the facilitatory role of 
these cells, presumably acting via pro-nociceptive 5-HT₃ receptors in the 
dorsal horn (Bardin, 2011). Other MOR+ cells are known to be GABAergic 
(Kalyuzhny and Wessendorf, 1998), however if these are projection neurons 
it is not known which component of the dorsal horn circuitry they synapse 
onto.  Future work could include further characterisation of this cell 
population. Anatomical studies to quantify the numbers of MOR+ projection 
and non-projection neurons as well as double labelling studies to determine 
the proportion of 5-HT and GABA containing neurons within the RVM would 
be useful in this regard. Another transmitter which may be involved in 
descending facilitation is cholecystokinin (CCK). This peptidergic 
neurotransmitter has pronociceptive effects within the spinal cord, and has 
been shown to contribute to the descending facilitation of secondary 
hyperalgesia in a model of cutaneous mustard oil application (Urban et al., 
1996). CCK containing neurons are found in the RVM and many of these 
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project to the dorsal horn (Mantyh and Hunt, 1984). It is not known if these 
CCK expressing neurons are MOR+, and this would be an interesting 
possibility for investigation. Although this descending pathway has received 
little attention in comparison to the extensive investigation of 5-HT 
pathways it may be an important avenue for future research.  
The role of GABAergic signalling within the RVM has not been well studied to 
date. The method of labelling active GABAergic synapses in vivo described in 
chapter 3 would be a useful method of studying GABAergc signalling in 
further experiments. A starting point would be to study further time points 
after CFA injection. The time point of 3d was chosen based on previous 
findings that GABAergic signalling in the region is decreased at 3d following 
plantar inflammation (Zhang et al., 2011), however this does not rule out 
changes at earlier or later time points. Injection of a GABAergic agonist to 
the RVM would also be a useful functional experiment to determine if the 
decrease observed here is required for increased descending facilitation.  
My behavioural studies investigated the role of both the 5-HT and MOR+ 
mediated descending facilitatory pathways in mechanical hypersensitivity of 
the ipsilateral hindpaw in joint inflammation. This measure is a correlate of 
secondary hyperalgesia in the animal as it reflects hypersensitivity at a site 
adjacent to but removed from the inflamed region. It is known that 
secondary hyperalgesia is driven by central mechanisms and our work has 
demonstrated a role for descending facilitation in this process in the joint 
inflammation model. An investigation of weight bearing in the 5,7-DHT 
experiment, described in chapter 4, suggests that primary hyperalgesia of 
the inflamed joint itself is not attenuated by the depletion. This adds further 
evidence to the hypothesis that descending inhibition prevails in primary 
hyperalgesia, while descending facilitation contributes to secondary 
hyperalgesia (Urban et al., 1999; Vanegas and Schaible, 2004). An 
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investigation to determine how primary hyperalgesia is affected by the 
MOR+ cell or 5-HT descending pathways may be of interest in the future. 
The role of 5-HT in descending facilitation is complex with both inhibitory 
and facilitatory roles reported, depending on the receptor subtype activated 
at the spinal cord level (Bardin, 2011). The intrathecal ondansetron 
experiment carried out in chapter 4 suggests that as in other chronic pain 
models, the 5-HT₃ receptor has a pro-nociceptive role in the joint 
inflammation model. A limitation of this pilot study is the use of only one 
dose of drug, based on previous published work in which a single intrathecal 
injection of 10µg ondansetron was sufficient to fully reverse thermal 
hypersensitivity associated with plantar inflammation (LaGraize et al., 2010). 
However it is possible that the optimal dose may differ for the ankle joint 
model, and for the measurement of mechanical hypersensitivity. Future 
work could include a range of doses to generate a dose response curve 
specific to the joint inflammatory model of mechanical hypersensitivity. 
It is also important to note that we cannot rule out the involvement of other 
pro-nociceptive 5-HT receptors in mediating descending facilitation. Recent 
studies have shown that the 5-HT2A receptor may be involved in neuropathic  
pain, and this may warrant investigation in the joint inflammation model 
(Aira et al., 2012). However, it is also likely that parallel systems of 5-HT 
mediated inhibition and facilitation exist in chronic pain states, as has been 
suggested in a neuropathic model (Dogrul et al., 2009). Therefore it may be 
of interest to investigate if 5-HT plays a role in inhibition in the joint 
inflammation model.  
The microarray analysis carried out in this study has identified the CXC 
family of chemokines and receptor as a potential signalling pathway within 
the dorsal horn, regulated by descending facilitation. Our finding that 
CXCL10 is expressed within neurons of the dorsal horn, and CXCR3 is found 
in part on CGRP expressing primary afferent terminals, suggests a 
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mechanism by which primary afferent input could be modulated by this 
chemokine family. This is the first study to characterise protein expression of 
CXCL10 and CXCR3 in the dorsal horn however much work is required to 
determine if this receptor-ligand pair play a role in inflammatory joint pain, 
and projects are ongoing in our group to determine if this is the case. The 
first step is to determine if upregulation of protein occurs after the 7d time 
point. Future work could include inhibiting the receptor or the ligand within 
the dorsal horn by to determine if they play a role in nociception.  
Notably, the expression of CXCL9 and CXCL10 is increased in the joints of 
patients with rheumatoid arthritis (Laragione et al., 2011; Yoshida et al., 
2012) suggesting that these chemokines may contribute to the joint 
pathology associated with the disease. Furthermore a humanised anti-
CXCL10 antibody has been shown to be safe and effective in treating the 
pain in rheumatoid arthritis (Yellin et al., 2012). In animal models CXCR3 
receptor antagonists have also been shown to be effective in decreasing the 
pathogenesis of a model of rheumatoid arthritis (Jenh et al., 2012). 
Therefore safe and effective pharmacological tools exist to investigate the 
role of this chemokine pathway within the CNS in inflammatory pain states. 
If CXL10 to CXCR3 signalling is shown to be pronociceptive within the dorsal 
horn, this would provide further support for the use of such agents in the 
systemic treatment of joint pain states. 
7.4  Conclusion 
The data presented in this thesis demonstrates for the first that time that 
descending facilitation via the RVM contributes to behavioural 
hypersensitivity following joint inflammation. This suggests that in addition 
to targeting the underlying joint pathology, patients suffering from joint pain 
symptoms may benefit from treatments that reduce central sensitisation 
and descending facilitation.  
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Appendix 
A1. Solutions for immunohistochemistry 
Phosphate buffer (0.1M, pH7.4) 
190mM NaH₂PO₄ 
810mM Na₂H PO₄ 
Paraformaldehyde 
4% paraformaldehyde 
0.1M phosphate buffer 
Heparinised saline 
5IU/ml heparin 
0.9% NaCl 
Sucrose 
30% or 5% sucrose  
0.02% NaN₂ (Sigma) 
Blocking solution - fluorescence detection: 
0.1M PB 
3% normal serum (species dependent on host of secondary antibody) 
0.3% TritionX-100 
Blocking solution - chromogenic detection: 
0.1M PB 
3% normal serum (species dependent on host of secondary an 
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2% H₂O₂ to quench endogenous peroxidase activity 
0.3% TritonX-199 
TTBS (Tris-Triton buffered saline) 
0.05M Tris base 
0.3% TritonX-100 
0.9% NaCl 
Preparation of gelatinised slides 
2.5g gelatine in 500ml dH₂O, heat to < 50°C 
Add 0.5g chrome alum (chromic potassium sulphate, Sigma) 
Filter 
Dip twin-frost slides in solution for 30s 
Dry overnight 
A2. Solutions for western blot analysis 
RIPA 
100mM NaCl 
100mM NaF 
20mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) ph7.4 
5mM ethylenediametetraacetic acid (EDTA) 
1mM Na₂VO₄ 
1% v/v NP-40 
MOPS ph7.3 
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0.05M 3-(N-morpholino) propane sulphonic acid (MOPS) 
0.5M Tris base 
3.5mM SDS 
1mM EDTA 
Transfer buffer 
48mM Tris base 
39mM glycine 
0.037% SDS 
10% v/v methanol 
Tris-buffered saline 
0.05M Tris base 
0.9% NaCl 
PBS Tween 
0.1 M phosphate-buffered saline (Sigma-Aldrich) 
0.1 % v/v Tween 20 
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Appendix A3. Log2 transformation of von Frey hairs 
g log2 (g) 
0.07 -3.84 
0.16 -2.64 
0.4 -1.32 
0.6 -0.74 
1 0.00 
1.4 0.49 
2 1.00 
4 2.00 
6 2.58 
8 3.00 
10 3.32 
15 3.91 
26 4.70 
60 5.91 
 
 
 
